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ABSTRACT
Mercer, Carol A., Ph.D. Biomedical Sciences Ph.D. Program, Wright State
University, 2007. Structural and Signaling Elements Important for the Efficient
Degradation of BHMT through Macroautophagy

Healthy cells maintain a dynamic and responsive intracellular environment that is
marked by the synthesis and degradation of proteins, complex macromolecules and
organelles. Autophagy, literally ‘self-eating,’ is a mechanism that delivers cellular cargo
to the lytic compartment for digestion. Defects in the regulation of autophagy have been
implicated in pathologies such as cancer and neurodegenerative disease, making the study
of its regulation compelling. However, few studies have looked at the regulation of
mammalian autophagy as a function of a specific cargo protein. Previous studies had
indicated that the metabolic enzyme betaine homocysteine methyltransferase (BHMT) is
degraded through an autophagic mechanism. One aim of this study has centered on the
role of BHMT quaternary structure in determining the efficiency of autophagic
sequestration and degradation. In these studies, an oligomerization deficient form of
BHMT was used to show that modulation of the Class III PI3 kinase signaling pathway is
likely involved in discerning monomeric from multimeric BHMT and that this has a role
in the subsequent degradation of BHMT by autophagy.
The second aim has been to study to role of the nutrient-regulated mTOR pathway
in the autophagic degradation of BHMT. It has been proposed that mTOR-mediated
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inactivation of S6 kinase is required for induction of autophagy in mammals. However in
Drosophila melanogaster, S6 kinase activity has been shown to be essential for induction
of autophagy. The current study demonstrates that the inhibitory signal from mTOR to
autophagy does not go through S6 kinase or subsequent phosphorylation of the ribosomal
protein S6. The significance of these observations in terms of misfolded proteins,
neurodegenerative diseases and therapeutics is discussed.
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I. INTRODUCTION
1.1. Introduction
Healthy cells maintain a dynamic and responsive intracellular environment that is
marked by both the synthesis and degradation of proteins, complex macromolecules and
organelles. Autophagy, literally ‘self-eating,’ is a mechanism that delivers cellular cargo
to a lytic compartment for digestion. In basal conditions, this process removes cellular
‘garbage’ such as damaged or unwanted proteins, defective mitochondria, or excessive
internal membranes[1]. Autophagy also responds to conditions of cellular stress. When
nutrients are scarce, autophagy is induced to replenish the cell with essential building
blocks such as amino acids, lipids and nucleic acids that are needed to maintain cellular
processes necessary for survival. In metazoans, there are times in development when the
need for new synthesis for cellular growth and proliferation is predominant, and the need
for autophagy recedes[2]. Developmental periods of tissue remodeling tip the scales
toward more autophagy and less synthesis in the autophagic death and removal of
unwanted cells, as seen in Drosophila[3]. In the worm Caenorhabditis elegans,
autophagy is important for normal dauer formation, allowing survival during long periods
of limiting nutrients[4]. In mammals, the importance of autophagy to the whole
organism is apparent in the neonate. Shortly after birth, before suckling is able to
effectively provide nutrients, the newborn relies on autophagy, primarily of liver
glycogen, to maintain circulating glucose levels and for survival[5]. There is an
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increasing awareness of the significance of autophagy in human disease as defects in its
regulation have been shown to contribute to cancer, aging, cardiomyopathy, myopathy,
and neurodegenerative diseases[6, 7].
1.2. Types of autophagy
Autophagy is the lysosomal digestion of cytoplasmic cargo and occurs in all
eukaryotic cells. There are three main types of autophagy: macroautophagy, chaperonemediated autophagy (CMA) and microautophagy (Fig. 1). Macroautophagy is the most
common type of autophagy and the terms autophagy and macroautophagy are often used
synonymously. Distinct types of macroautophagy include the Cvt pathway (in yeast
only), pexophagy (degradation of peroxisomes), mitophagy (degradation of
mitochondria), and crinophagy (degradation of secretory vesicles)[6].
Macroautophagy and the yeast-specific Cvt pathway both require the formation of
an enclosed double-membrane vesicle to sequester cargo destined for the lytic
compartment. They share many of the same genes for the development of the
sequestering vesicle, but differ in select genes that are pathway specific, in vesicle size,
and in the nutrient conditions of activation. Macroautophagy is a non-specific
degradation pathway in all eukaryotic cells that is active when nutrients are limiting.
While non-lysosomal mechanisms exist for the degradation of protein, macroautophagy
is the only cellular pathway to remove organelles and macromolecular complexes such as
mitochondria and ribosomes respectively. The Cvt pathway is a biosynthetic pathway
specific to yeast that delivers the hydrolytic enzymes aminopeptidase 1 (Ape1) and αmannosidase to the vacuole. Ape1 is synthesized in the cytosol in an inactive form and
assembles into a large, multimeric complex which is recognized by Atg19 (Fig. 2).
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Figure 1. Schematic overview of macroautophagy, microautophagy, and chaperonemediated autophagy. Macroautophagy involves the formation of a double-membrane
autophagosome. Steps of macroautophagy include 1) induction at the preautophagosomal structure (PAS), 2) growth and elongation, 3) sequestration of cargo
within the autophagosome, 4) fusion with the lysosome/vacuole to create the
autolysosome, and 5) degradation of cargo. Microautophagy is the invagination of the
lysosomal membrane for the direct import of cargo. Chaperone-mediated autophagy
requires a KFERQ-like sequence on the substrate protein, recognition by hsc73, assembly
of the chaperone complex and binding to lysosome associated membrane protein 2a
(LAMP2a) at the lysosome. After the chaperone-mediated unfolding of the substrate
protein, it is threaded through the lysosome membrane, binds the lysosomal hsc73 protein
and is degraded.
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Figure 2. The Cvt pathway cargo recognition system. The Cvt pathway is a type of
specific autophagy. Aminopeptidase 1, a substrate of the Cvt pathway, is a dodecamer
which multimerizes into a larger Ape1 complex. The Ape1 complex is recognized by
Atg19, which in concert with Atg11 and perhaps Atg1, delivers it to the preautophagosomal structure (PAS), where it directly interacts with Atg8. After Ape1 is
delivered to the vacuole, it is proteolytically cleaved and becomes an active resident
hydrolase.
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Atg19 is an adapter protein that links the Ape1 dodecamer with Atg8 at the preautophagosomal membrane, in concert with Atg11 and other proteins that may include
Atg1. Once in the vacuole, cleavage of in inhibitory peptide converts Ape1 into an
active, resident enzyme. Phosphatidylinositol 3-phosphate (PI3P) is thought to be
important for the Cvt pathway because some of the Cvt-specific proteins contain FYVE
(first described in proteins Fab1, YOTB/ZK632.12, Vac1, and EEA1) or Phox homology
(PX) PI3P binding domains[8].
Microautophagy involves invagination and fission of the lysosome membrane to
create small intralysosomal vesicles. Little is know about this process in mammals, but
in yeast, membrane-associated complexes form and mediate this process. The EGO
complex, comprised of a Ras-related GTPase, Gtr2, Ego1 and Ego3, has been linked to
the target of rapamycin (TOR) kinase. Nutrient depletion or inhibition of TOR with the
drug rapamycin increases macroautophagy and the influx of membrane to the yeast
vacuole. When rapamycin is removed, microautophagy is activated in a TOR-dependent
manner to reduce the size of the vacuole[9]. It is not known if this type of TOR-mediated
mechanism for microautophagy exists in higher organisms.
Chaperone-mediated autophagy (CMA) is an autophagy pathway in mammalian
cells that responds to prolonged starvation. CMA is specific for proteins with a target
recognition sequence similar to the KFERQ sequence identified in RNase A, the first
known CMA substrate. Upon recognition of this motif by the heat shock cognate protein
hsc73, the substrate protein is surrounded by a chaperone complex, and delivered to the
lysosome. At the lysosome, the chaperone complex interacts specifically with lysosomal
associated membrane protein 2a (LAMP2a) and facilitates the unfolding of the substrate
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protein, allowing it to be threaded through the lysosome membrane to be degraded[10].
In CMA, proteins are imported and degraded one protein at a time. There are estimates
that up to 30% of cytosolic proteins are degraded by CMA, but significantly, the
LAMP2-/-/LAMP1-/- double knockout mouse shows no defect in total protein
degradation[11]. It may be that other autophagy pathways compensate for this defect as
the selective knockout of the LAMP2a isoform results in a compensatory increase in
macroautophagy[12].
1.3. The process of macroautophagy
Macroautophagy proceeds in a step-wise fashion that includes: 1) induction, 2)
growth and elongation of a pre-autophagosomal structure (PAS), 3) sequestration of
cargo within the double-membrane autophagosome, 4) fusion with the lytic compartment,
and 5) degradation[13]. Genetic studies in S. cerevisiae have identified specific genes
required for autophagy and for survival in nutrient-limiting conditions, leading to an
increase in an understanding of some of the interactions and mechanisms involved in the
autophagic process[14, 15]. A unified nomenclature system is now used that identifies
these genes as autophagy-related genes (Atg) 1-27 (Table 1)[16]. Many of these genes,
protein complexes and molecular mechanism are conserved in higher eukaryotes.
1.4. Molecular complexes in macroautopahgy
1.4.1. The ubiquitin-like conjugation systems
The formation of autophagosomes requires the function of two, novel, interrelated
ubiquitin-like conjugation systems (Fig. 3)[17]. Atg8 and Atg12 are ubiquitin-like
(UBL) modifiers which share the same E1-like activating enzyme Atg7. Atg8 and Atg12
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Figure 3. The Ubiquitin-like conjugation systems of macroautophagy. Ubiquitinlike proteins Atg8 and Atg12 are activated by the E1-like enzyme Atg7 and ATP,
transferred to their respective E2-like enzymes Atg3 and Atg10, and then conjugated to
their targets. Atg8 is covalently attached to phosphatidylethanolamine and Atg12 is
conjugated to Atg5. The Atg12-Atg5 heterodimer then forms a larger complex with
Atg16.
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are then conjugated to their respective targets through the action of their specific E2-like
enzymes, Atg3 and Atg10 respectively. Atg8 is translated in a pro-form that requires
cleavage by the protease Atg4 to reveal a carboxy-terminal glycine necessary for
conjugation. Atg8 is activated by Atg7 and ATP, transferred to Atg3, and then uniquely
conjugated to phosphatidylethanolamine (PE). Atg8-PE remains associated with both
inner and outer membranes of the expanding autophagosome, although Atg4-dependent
cleavage of some Atg8-PE from the outer membrane is required for fusion with the
vacuole (Fig. 3)[18]. In yeast, ∆atg8 mutants form aberrantly small autophagosomes
suggesting that Atg8 may be necessary for growth and elongation of the autophagosomes
membrane[19].
The Atg8 conjugation system is well conserved in higher eukaryotes. In
mammals, microtubule associating protein light chain (MAP-LC3) is the best known
ortholog of Atg8 and is often used as a specific marker of autophagosomes[20]. Three
isoforms of LC3 have been identified and are known as LC3A, LC3B and LC3C, with
some overlapping and some specific distribution among cell types[21]. In addition to the
LC3s, multiple other mammalian orthologs of Atg8 are known, although they are less
well characterized in terms of autophagy. These include Golgi-associated ATPase
enhancer of 16 kDa (GATE-16) and γ-aminobutyric acid receptor associated proteins
(GABARAP-I and GABARAP-II) and Atg8L[22, 23].
Atg12 is also activated by Atg7 and ATP, transferred to its own E2-like enzyme
Atg10, and conjugated to its only known target, Atg5[24]. The Atg5-Atg12 heterodimer
then assembles into a higher molecular weight complex through interaction with
Atg16[25]. The Atg5-Atg12 complex is found only on the outer, concave surface of the
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growing autophagosome and may have a structural role in the curvature of the membrane.
In addition, the Atg5-Atg12 complex may play a role in the recruitment and assembly of
the other Atg proteins at the PAS. The Atg12-Atg5-Atg16 complex does not remain with
the autophagosome but dissociates before fusion with the vacuole/lysosome.
The Atg12-Atg5 conjugation system is conserved in mammals[26]. Mice with
total disruption of either Atg5 or Atg7 develop normally but die within 24 hours of
birth[27, 28]. Early death is likely through a nutritional and energy collapse due to
defective glycogen autophagy. Gene disruption of either Atg5 or Atg7 in the central
nervous system results in a progressive, degenerative neurological phenotype causing
death before 28 weeks. Neurons in these targeted knock-out mice are characterized by
aggregates of poly-ubiquitinated protein and inclusion bodies[29, 30]. Protein
aggregates, inclusion bodies, and autophagosomes are often observed upon biopsy or
necroscopy of patients with neurodegenerative disease; however it had not been clear
whether they were a cause or effect of the neurodegenerative process. The Atg5 and
Atg7 targeted knock-out mice provide the first evidence that defects in autophagy can be
a cause rather than a consequence of neurodegeneration.
1.4.2. The Class III PI 3-Kinase and Atg6 complex
In yeast, Atg6 associates with Vps34, a Class III PI3-kinase that phosphorylates
the 3'-OH on the inositol ring of phosphatidylinositol to form phosphatidylinositol 3phosphate (PI3P)[31]. Vps34 associates with the serine kinase Vps15, which has a role
in the membrane localization and activation of Vps34 (Fig. 4). Vps34 activity or function
may also be regulated by complexes of associating proteins: Vsp34, Vsp15, Atg6 and
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Figure 4. The Vps34/Atg6 and Atg1 complexes in yeast. Class III PI 3-kinase Vps34
activity is controlled by its binding partners, Vps15, Atg6 and Atg14. Atg1 functions in
complex with multiple Atg proteins. Some of the Atg proteins in complex with Atg1 are
specific for the Cvt pathway, which has led to the proposal that the Atg1 complex acts as
a switch between the Cvt pathway and macroautophagy. When TOR and Atg1 are active,
the Cvt pathway is dominant, and when TOR is inactive, macroautophagy is preferred
over the Cvt pathway.
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Atg14 promote autophagy, and a modified complex with Vps38 in place of Atg14 favors
the Cvt pathway[32]. Atg6 and Vps34 localize to the trans-Golgi. The production of
PI3P may play a role in the recruitment of other Atg proteins to the pre-autophagosome
structure. Vps34 activity is thought to promote autophagy, and the activity of Class I PI3
kinases suppresses autophagy. This is based on several pieces of evidence. First, an
increase of PI3P increases degradation of long-lived protein, while the increase in
PI(3,4)P2 or PI(3,4,5)P3, products of the Class I PI3 kinases, inhibits degradation[33].
Second, injection of Vps34 antisense oligonucleotides inhibits autophagosome formation
in interphase cells[34]. And third, knockout mice for the myotubularin MTMR3, a
member of a large family of lipid phosphatases that specifically remove the 3′ phosphate
from PI3P, suffer from a large accumulation of autophagosomes in skeletal muscle,
resulting in a severe, progressive myopathy[35]. Contrary to this data, two recent studies
report that amino acids increase Vps34 activity which in turn activates the mTOR
signaling pathway[36, 37]. It may be that hVps34 activity, like yeast Vps34, is also
regulated by associating proteins. Wortmannin and 3-methyladenine (3MA) are
traditionally used as autophagy inhibitors, and their effectiveness is thought to be through
inhibition of Vps34 kinase activity[33].
Beclin1 is the mammalian ortholog of Atg6 and it has many of the same
characteristics of yeast Atg6: it forms a complex with hVps34 at the trans-Golgi and it
can complement autophagy in ∆atg6 mutant yeast[38, 39]. Beclin1, originally described
as a Bcl-2 binding protein[40], is the first autophagy protein whose disruption has been
implicated in cancer[41, 42]. Beclin1 is mono-allelically deleted in 40-70% of human
breast cancers, and its ectopic expression in MCF7 cells can induce autophagy and inhibit
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tumorigenicity[38]. Total disruption of beclin1 in mice is embryonic lethal, but
significantly, beclin1+/- mice have a high propensity to develop spontaneous tumors,
providing genetic evidence that Beclin1 may play a role in tumor suppression[19, 42].
The association between Beclin1 and Bcl-2 suggests a potential molecular link between
autophagy and apoptosis and a possible mechanism for the increased tumors in beclin1+/mice. In one model, there is a balance between free Beclin1, free Bcl-2, and the
Beclin1/Bcl-2 complex; increased free Beclin1 induces autophagy and inhibits tumors;
increased Bcl-2 inhibits autophagy and increases oncogenesis[43]. Although further
studies are needed to determine the accuracy of this model, it demonstrates the potential
relevance of Beclin1 and autophagy in human disease.
1.4.3. The Atg1 Complex
Atg1 was the first Atg gene identified in the genetic screens in S. cerevisiae and is
the only Atg gene that codes for a serine-threonine kinase[44]. In yeast, Atg1 is thought
to be downstream of the target of rapamycin TOR signaling pathway[45]. There are two
models of how TOR regulates Atg1 in yeast, and both place Atg1 within the context of a
complex of associating proteins (Fig. 4). In the first model, Atg1 activity is regulated by
its association with Atg13. When nutrients are plentiful and TOR signaling is active,
Atg13 is hyperphosphorylated and forms a loose complex with Atg1 that prevents its
activation. When nutrients are scarce and TOR signaling is off, the hypo-phosphorylated
Atg13 forms a tight complex with Atg1 that results in increased Atg1 activity and
autophagy[45]. In the second model, the Atg1 complex includes proteins that function in
only one of the autophagy pathways, Cvt or macroautophagy. This led to the hypothesis
that Atg1 activity is a switch that directs which pathway will be active. In the second
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model, Atg1 activity is important for the Cvt pathway but is dispensable for
autophagy[46]. The specific action or target of Atg1 activity is not known, however it
may have a role in the trafficking of the only Atg integral trans-membrane protein, Atg9,
between the PAS and autophagosome[47]. To date, no endogenous substrates of Atg1
catalytic activity are known.
Orthologs of Atg1 have been identified in many species from plants to humans
and all have been implicated in the autophagy process. Defects in autophagy have been
noted in Atg1 mutants in Dictyostelium dicoideum, C. elegans, and Drosophila
melanogaster[4, 48, 49]. Mammals have at least two orthologs of Atg1, unc-51 like
kinase 1 (hULK1) and hULK2[50, 51]. Consistent with the role of Atg1 in yeast, hULK1
is necessary for the localization of mAtg9 to LC3-marked membranes during autophagy
induction[52]. Unlike yeast, in higher organisms, the Atg1 orthologs have not yet been
shown to function downstream of TOR, nor has the connection between Atg1 and the
TOR pathway been unambiguously established.
1.5. Macroautophagy and the TOR pathway in higher eukaryotes
In the field of autophagy, there is general agreement that autophagy must be
tightly regulated because of the pathological consequences of deregulated autophagy.
The protein kinase mTOR plays a central role in the ability of cells to sense growth
signals, amino acid levels, and energy in order to make decisions that effect translation of
new proteins, cell growth and proliferation (Fig. 5)[53]. It is generally accepted that
mTOR also makes decisions that affect autophagy. If nutrients are readily available from
the extracellular milieu, mTOR signals for the cell to grow. But when extracellular
nutrients are scarce, mTOR signaling allows the cell to survive by increasing autophagy
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Figure 5. The mTOR pathway and autophagy in mammals. mTOR senses mitogen
signals through the PI3K/PKB pathway. Amino acids increase Vps34 activity and
increase the mTOR signaling pathway. mTOR is a negative regulator of autophagy.
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to degrade internal proteins for energy and raw materials necessary for survival.
In higher eukaryotes, the connection between mammalian mTOR and hULK1 is
not obvious. In mammalian cells, it has been proposed that the regulation of autophagy
involving mTOR may be through its downstream effector, p70S6 Kinase. mTOR
phosphorylates p70S6K on T389, which leads to p70S6K activation and the
phosphorylation of its downstream substrate, S6. Blommaart et al. (1995) demonstrated a
strong negative correlation between phospho-S6 and autophagy in rat hepatocytes and
proposed a model that the signal for autophagosome formation may be through
dephosphorylation of S6[54]. For many years, this data supported a role for mTOR,
p70S6K, and S6 in the regulation of autophagy. Although a recent paper suggests that
hAtg1 (hULK1) is a negative regulator of mTORs downstream effector, p70S6K, the
strongest data is based on ectopic expression of hAtg1[55]. Recently in Drosophila, it
was demonstrated that some p70S6K activity was required for maximum autophagic
activity[49]. The dilemma of an inactive mTOR and an active p70S6K is difficult to
resolve, but it is proposed to be a self-limiting mechanism for autophagy.
mTOR responds to signals from growth receptors through the Class I PI 3kinase/PKB pathway. Importantly, PTEN and TSC2 are two tumor suppressors on the
PI3K/PKB/mTOR pathway that are involved in the regulation of mTOR[56]. In both
mammals and Drosophila, positive signals through the PI3K/PKB pathway inhibit
autophagy and negative signals induce autophagy[57, 58]. Amino acid stimulation of
mTOR is independent of the PI3-kinase/PKB pathway[59]. It was recently shown by two
laboratories that the amino acid input to the mTOR pathway is through the Class III PI 3kinase Vps34[36, 37]. This interesting link between mTOR and Vps34 in the response to
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amino acids is unexpected, as Vps34 activity is also thought to regulate the induction of
autophagy[33]. However, as in yeast, it may be that the regulation of Vps34 occurs
through its association with different binding partners. The link between Vps34/Beclin1
and mTOR puts another tumor suppressor, Beclin1, upstream of mTOR in a potential
regulatory role. This brings one more layer of complexity and relevance to the pathways
regulating autophagy.
1.6. Significance of autophagy
The significance of autophagy in maintaining the health of not just the cell, but
the entire organism, is apparent in human disease. In cancer, the importance of
maintaining the balance in the mTOR pathway between synthesis and autophagy is
striking when one considers the tumor suppressors that keep this pathway in check. The
down-regulation of autophagy may be one way that tumor cells use to gain an advantage
in growth and proliferation. It suggests that negative regulators of the mTOR pathway
may be effective therapeutics for certain types of cancer, and indeed, rapamycin has
success in the treatment of renal cancer[60]. However, in certain cases, increased
autophagy may actually promote tumor survival in harsh, non-vascular, nutrient-limiting
conditions. It’s even thought that some tumors are resistant to cell-damaging agents
because of autophagy, underscoring the importance of understanding the regulation of
this process[61].
While decreased autophagy may tip the scales in favor of cancer in proliferating
cells, in differentiated cells, decreased autophagy may instead lead to degeneration and
cell death. The selective loss of the autophagy-related genes Atg7 and Atg5 in the
neurons of mice results in neurodegeneration with aging[29, 30]. Autophagy has long
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been suspected of being involved in degenerative diseases of both the neural and
muscular systems because of the appearance of autophagosomes in the post-mortem
tissue or biopsies of patients with diseases such as Alzheimer’s, Parkinson’s,
Huntington’s, Inclusion-body myositis, and X-linked myopathy with excessive
autophagy. These findings suggest that drugs which increase autophagy may be an
effective treatment for patients with neurodegenerative disease, and in support of this,
preliminary tests show that treatment with rapamycin can increase the autophagymediated removal of huntingtin aggregates[62].
Significantly, many of these diseases are associated with aging, and a decrease of
autophagic or lysosomal function is thought to be part of the aging process[63]. If true,
then more efficient autophagy should retard aging. This is supported by studies in
C.elegans where loss of signaling to TOR increased longevity, presumably by increasing
autophagy[4].
Autophagy can play a more acute role in human pathology by protecting cells
from invading intracellular pathogens. Autophagy has recently been described as
participating in the innate immune response to some bacteria and viruses. Autophagy can
be either friend or foe to microorganisms. Some, such as Coxiella burnetii use autophagy
to replicate while others such as Streptococcus pyogenes are removed from the cytoplasm
by autophagy and destroyed[64]. Understanding the difference is likely to be important
for therapeutics.
1.7. Thesis focus and significance
This research has focused on understanding the regulation and molecular
mechanisms of mammalian macroautophagy. To aid in this study, new methods were
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developed to unambiguously measure the induction and inhibition of autophagy. The
macroautophagy-specific degradation of BHMT was used to study the importance of
higher order structure on the efficiency of autophagic degradation. The data presented
here support a hypothesis that modulation of the Class III PI3-kinase pathway may lead
to the selective degradation of cargo based on quaternary structure. This is significant in
terms of understanding the mechanism that cells use to remove potentially damaging
protein aggregates by macroautophagy.
In addition, this study has sought to understand the relationship between mTOR,
p70S6 Kinase and macroautophagy. Using the methods developed in the course of this
study, the data show that the mTOR-dependent signal to autophagy does not go through
p70S6 Kinase or S6. The signal to macroautophagy through other downstream effectors
of mTOR is explored. Together, the data here confirm the importance of mTOR in the
induction of autophagy and offer new insights into how the modulation of the Class III
PI3-kinase and mTOR pathways may affect the clearance of cellular aggregates through
macroautophagy.
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II. MATERIALS AND METHODS
Cell lines and cell culture
HEK-293, T98G and A10 cells were purchased from ATCC. MCF7 cells were a
kind gift of the Moscat-Diaz laboratory at UC/GRI, C2C12, A2780, NIH-3T3 cells from
the Thomas-Kozma laboratory at UC/GRI, and H1299 cells from the Kadakia laboratory
at WSU. Cells were maintained in a custom-prepared DMEM media, supplemented with
4-6mM final concentration L-glutamine and either 10% fetal calf serum or 10% NuSerum I (BD), at 37°C in 5% CO2.
DMEM custom media (minus glucose, essential amino acids, L-glutamine, and
serum) was prepared as follows. For five liters of basic media, combine 1g CaCl2, 2g
KCl, 488.5mg MgSO4, 32g NaCl, 625mg NaH2PO4, 1ml of 0.5mg/ml Fe(NO3)3 stock,
5ml of 15mg/ml phenol red stock, 18.5gm NaHCO3, 50ml Pen/Strep 5,000 I.U.
Penicillin/5,000 µg/ml streptomycin (Cellgro/Mediatech: MT30-002-CI), 200ml MEM
Vitamins 100x solution (Cellgro/Mediatech: MT25-020-CI), 200ml MEM non-essential
amino acids (Cellgro/Mediatech: MT25-025-CI) in water, pH to 7.0, and sterile filter.
100mls of a 100x stock of either individual or 10 essential amino acids was prepared in
water with the following: 660mg L-phenylalanine, 840mg L-arginine, 952mg Lthreonine, 160mg L-tryptophan, 1462mg L-lysine, 300mg L-methionine, 420mg Lhistidine, 1050mg L-isoleucine, 940mg L-valine, 1050mg leucine. 50mls of a 200x stock
of tyrosine and cysteine was prepared in 1N HCl with 1040mg L-tyrosine and 630gm L-
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cystine. A 10x, 250mM glucose solution was prepared in water. All solutions were
sterile filtered.
Antibodies and reagents
The following antibodies were purchased from SantaCruz: GST (Z5), HA-probe
(Y-11) GFP (FL), p-p70 S6 Kinase (Thr389), Beclin1 (D-18). Antibodies purchased
from Cell Signaling include: Myc-Tag (9B11) LC3 (human) antibody (NB 100-2331)
was purchased from Novus Biologicals. Leupeptin (Bachem), E64d, chloroquine and
3MA were purchased from Sigma. PMSF (Acros) was purchased from Fisher Scientific.
SDS-PAGE, immunoprecipitation, pull-downs, and western blot
Cells to be extracted were washed with ice-cold PBS and scraped into extraction
buffer (EB)(50mM TRIS-HCl pH 8, 120mM NaCl, 5mM NaPPi, 10mM NaF, 30mM
paranitrophenylphosphate, 1mM benzamidine, 0.1% NP-40, 0.2mM PMSF). In most
cases, 1% Triton-X100 was added to the EB. Extracted cells were homogenized 10
strokes in a Dounce homogenizer and centrifuged to clear the supernatant of cellular
debris. Total protein of cell extracts was determined by Bradford method. For whole cell
extract (WCE) aliquots, SDS sample buffer was added and sample was boiled for 3
minutes before loading on SDS-PAGE gels. After SDS electrophoresis, protein was
electrophoretically transferred to PVDF membrane, blocked with 1% BSA in TBS/Tween
20, incubated with primary antibody diluted in 1% BSA in TBS/Tween 20 overnight at
4°C. Blots were then incubated with either a species-appropriate HRP-conjubated
secondary antibody, or with a species-appropriate biotin-conjugated second antibody
followed by a HRP-strepavidin conjugate.
Cell fractionation and Sucrose Gradient
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PBS-washed cells were scraped from a 10cm culture dish in 1ml of ice-cold PBS
and centrifuged at 1000xg for 5 minutes. All steps were carried out at 4°C. The cell
pellet was resuspended in 500ul homogenization buffer (HB) (10mM TRIS pH 7.5,
300mM sucrose, 0.2mM EDTA) and disrupted in a Dounce homogenizer with 10 strokes,
followed by centrifugation at 540xg to pellet the nucleus and large membrane pieces.
The supernatant was reserved in a separate 1.5ml eppendorf tube. The pellet was gently
resuspended in an additional 500ul HB, centrifuged at 540xg for 5 minutes, and the
supernatant combined with the reserved supernatant from the first spin. The combined
supernatant was centrifuged for 12,000xg for 20 minutes to pellet the light membrane
fraction (LMF). This pellet was then gently washed x3 with HB and centrifuged 5
minutes each at 12,000xg. The washed pellet was gently resuspended in 50 to 100ul HB
for analysis. In some cases, the protein of the LMF was determined by Bradford analysis
to normalize loading of sucrose gradients.
Percent sucrose solutions (60%, 45%, 35%, 27.5%, 20%, 15%) were prepared by
dissolving sucrose in HB. All preparation steps of gradients were performed with icecold solutions and tubes. Discontinuous sucrose gradients were prepared within an hour
of use by sequentially layering 1.8ml of 45% sucrose, 2.4ml of 35%, 1.6ml of 27.5%,
1.6ml of 20% and 2.4% of 15% in a 14 x 89mm polyallomer tube. Sample LMF in 1ml
of HB was gently layered on top of prepared gradient. Gradients were centrifuged at
200,000xg for 2 hours at 2°C in a Sorvall SV41 rotor. 1ml fractions were collected by
displacement, using 60% sucrose as the chase solution. Fractions were numbered with 1
being the top, least dense fraction and 10 the bottom, most dense fraction.
In-vitro Thrombin cleavage assay
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Thrombin Protease (Amersham Biosciences 27-0846-01) was diluted in cold PBS
to a concentration of 1 unit/ul. For on-bead cleavage, overexpressed GST-fusion protein
was pulled out of cell extracts with glutathione agarose beads. Beads were washed with
dilution buffer x1 and PBS x1, removing all excess PBS after final wash. 0.5ug of
thrombin in 15-20ul of PBS was added to beads and incubated for 2 hours at room
temperature. Reaction was stopped with SDS-sample buffer, boiled for 3 minutes and
run on SDS-PAGE.
Trypsin Protection Assay
In 10 mM TRIS-HCl pH 7.5, dilute Trypsin-TPCK (Worthington) to 1mg/ml,
Soybean Trypsin Inhibitor (STI) (Sigma T-9128) to 2mg/ml, and prepare a separate 1%
Triton X-100 solution. To digest extra-vesicular protein, add dilute trypsin to sucrose
fraction, incubate 5 minutes at 37°C, and stop with equal volume of STI and 0.1M PMSF.
Amount of trypsin was determined experimentally. For digestion of intra-vesicular
protein, add 1% Triton X-100 to a final concentration of 0.2%. Proceed as described
above. After reaction has been stopped, total protein can be TCA precipitated, or
individual tagged proteins can be isolated by affinity chromatography or
immunoprecipitation.
Quick-change mutagenesis
Method for mutagenesis was patterned from Stratagene’s QuikChange SiteDirected Mutagenesis Kit. Briefly, sense and antisense primers were designed to anneal
to the same sequence with the mutated codon in the middle of the primer. Primers were
between 25 and 45 bases in length, with a Tm greater than or equal to 78°
(Tm=81.5+0.41(%GC)-(675/N)-%mismatch). PCR was performed with primer in excess
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of plasmid template (125ng of each primer and 50ng of template) and with an annealing
temperature of 55°C or less for 18-24 cycles. DNA polymerases used successfully
include rTth DNA Polymerase XL (Applied Biosystems), Platinum Pfx DNA polymerase
(Invitrogen) and Deep Vent DNA polymerase (New England Biolabs (NEB)). Dpn1
restriction enzyme (NEB) was added to finished PCR reaction to digest template and the
mix was ethanol precipitated and reconstituted with sterile water. Successful production
of product was checked on an agarose gel before being transformed into either XL1-Blue
or DH5α competent cells.
TCA precipitation
Make a 100% solution of TCA (Fisher A322) in water. Add 100% TCA to dilute
protein to a final concentration of 15-20%. Use higher percentage of TCA for smaller
proteins. Mix and incubate on ice for a minimum of 2 hours. Centrifuge at 4°C at 1213,000 xg for 20 minutes to pellet protein. Carefully remove and discard supernatant.
Wash pellet x2 with ice-cold acetone. Allow pellet to air dry on ice and resuspend pellet
in 1x SDS sample buffer.
Kinase assay
Immunoprecipitated hULK1 was incubated with 5µg MBP, 10mM MgCl2, γ-32P
ATP, and reaction buffer (50mM Tris pH 7.5, 10mM NaCl, 1mM DTT, 10% glycerol) at
30º C for 30 min.
qPCR
Cells were detached by trypsin digestion and total RNA was extracted using the
NucleoSpin RNAII extraction kit according to manufacturer’s instructions. For RT-PCR
analysis, 500ng of total RNA was reverse transcribed using ABgene Reverse-IT 1st
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Strand Synthesis Kit using random hexamer primers according to manufacturer’s
recommendation. Conditions of RT-PCR: 70ºC for 5 min; put on ice; add Reverse-IT
enzyme; 47ºC 60 min; 75ºC 10min. Final product was diluted 1:10 with nuclease-free
water for qPCR. Primer sets for qPCR were purchased from Qiagen. Target genes were
normalized to Actin or 18S.
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III. RESULTS
3.1. Autophagy Assay Development
3.1.1. Autophagy Conjugation Systems
3.1.1.1. Atg12-Atg5 conjugation
Autophagosome formation requires the recruitment and assembly of autophagyspecific proteins to a pre-existing, or de-novo membrane structure that elongates and
eventually fuses to form an enclosed, double-membrane autophagosome. hAtg12 and
hAtg5 are covalently linked in an ubiquitin-like posttranslational modification, and then
assembled with hAtg16 in a large multimeric complex that coats the convex side of
developing autophagosomes. Like the ubiquitin conjugation system, the Atg12-Atg5
system requires the activity of E1- and E2-like enzymes, hAtg7 and hAtg10, which might
be regulated by conditions known to induce autophagy[26].
One of the goals of this research project was to develop novel ways to study
autophagy, and the hAtg12-hAtg5 conjugate was an attractive target because it was both
specific and required for autophagosome formation. Conceptually, it was not unlike
another specific marker of autophagosomes, LC3-II, whose levels were already being
used to measure autophagy. At the time of this study, there were no reports in the
literature on how an increase in autophagy might affect levels or regulation of the
hAtg12-hAtg5 conjugate, but it seemed likely that a demand for new autophagosomes
might require increased levels of conjugated hAtg12-hAtg5.
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Because commercial antibodies were not available for either endogenous hAtg12
or hAtg5, both genes were cloned from a human B-cell cDNA library and subcloned into
mammalian expression vectors downstream of the respective epitope tags HA and GST,
for which antibodies were readily available. In a subcloning strategy that will be used for
multiple reporters in this study, heamagglutinin (HA) epitope-tagged hAtg12 was placed
in a bicistronic vector upstream of green fluorescent protein (GFP) under the translational
control of an internal ribosome entry site (IRES). In this background, expression of GFP
can be used for independent normalization of the upstream reporter gene (Fig. 6A).
HA-hAtg12IRESGFP and GST-hAtg5 were co-transfected in HEK293 and
maintained for 36 hours to allow for expression of the reporter genes. Cells were placed
in either complete media, or media from which essential amino acids and serum had been
removed for 4 hours, after which the cells were harvested. Aliquots of cell extract,
normalized for protein, were immunoprecipitated with 12CA5 antibody to the HA
epitope tag that was fused to HA-hAtg12IRESGFP. Protein G purified antibody and
attached protein were processed for western blotting with antibodies against GST or HA.
Whole cell extracts (WCE) from these samples were processed for western blot and
probed with an antibody against GFP. In a separate set of cell extracts, glutathione
agarose beads were added to affinity purify GST-Atg5. These pulldowns were prepared
for western blotting as above, and probed with antibody against GST.
A band of approximately 100 kDa was observed in the samples that were
immunoprecipitated for HA-Atg12, and probed with antibody to GST-Atg5 (Fig. 6B, left,
top panel). The 100 kDa band was slightly higher than the 85 kDa predicted molecular
weight of the covalently linked fusion-proteins, but is not inconsistent with what is likely
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Figure 6. Conjugation of GST-Atg5 and HA-Atg12. A. Schematic of epitope tagged
HA-Atg12IRESGFP and GST-Atg5. GFP under the translational control of an IRES has
been placed downstream of HA-Atg12 to allow for normalization of transfection
efficiency. B. Western blot of HEK293 cells co-expressing HA-Atg12 and GST-Atg5.
Cells represented in left panel were immunoprecipitated with 12CA5 (anti-HA) and
probed with antibody against GST (top) or HA (middle) showing conjugate and
unconjugated Atg12. Expression of GFP is in bottom panel. Cells in the right panel were
pulled down with glutathione agarose and probed with antibody against GST showing
conjugate and unconjugated GST-Atg5.
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the slightly retarded migration of two covalently linked proteins. In support of this, a
similar 100 kDa band was seen by western blot in the matched sets of 12CA5 IP samples
probed with an antibody against HA for HA-Atg12. A second band at 22 kDa was
observed on the blot probed with anti-HA that was likely unconjugated HA-Atg12 (Fig.
6B, left, middle panel). In the samples pulled down with glutathione and probed with
antibody toward GST, two bands, one at 100 kDa and one at 65 kDa were found that
were consistent with the GST-Atg5/HA-Atg12 conjugate (100 kDa) and with
unconjugated GST-Ag5 (65 kDa) (Fig. 6B, right panel). These data show that the
epitope-tagged proteins HA-Atg12 and GST-Atg5 were expressed as individual proteins
and were competent for the conjugation reaction to form a covalent linkage.
Levels of the 100 kDa conjugated hAtg12-hAtg5 complex did not change when
HEK293 cells were starved of essential amino acids and serum, compared to cells in
compete media (Fig. 6B, left and right panels). Expression levels of free GST-Atg5 also
showed little change in starvation conditions (Fig. 6B, right panel) However, levels of
unconjugated HA-hAtg12 dropped significantly with amino acid starvation (Fig.6B, left
middle panel). This was not due to differences in transfection efficiency, as expression
levels of GFP, the second protein in the bicistronic message of HA-hAtg12IRESGFP, were
unchanged (Fig. 6B, bottom panel).
Under conditions of amino acid starvation, there is a general arrest of new protein
synthesis. In the absence of newly translated protein, there are two possible explanations
for the short half-life of unconjugated HA-Atg12. First, it could be conjugated into the
covalent complex and consumed in the process of making new autophagosomes, or
second, Atg12 may be degraded by another mechanism. Discriminating between the two
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was important, because if unconjugated HA-Atg12 decreased due to consumption by the
autophagosome-forming process, then HA-Atg12 levels could potentially be used to
measure changes in autophagy. Cycloheximide was used to distinguish between the two
possibilities because it serves two purposes; cycloheximide inhibits translation like amino
acid starvation, and it inhibits autophagy. If decreased levels of Atg12 are due to
autophagic consumption, then cycloheximide should protect levels of HA-Atg12 in
starved cells. However, if Atg12 is degraded by another mechanism, cycloheximide
should not protect levels of Atg12 levels.
HEK293 cells were co-transfected with HA-hAtg12IRESGFP and GST-hAtg5.
After allowing sufficient time for expression, control cells were incubated in either
complete media or starvation media for 4 hours. Cycloheximide was added to a matched
set of non-starved and starved cells for the duration of the 4 hour incubation. After
harvesting, cell extracts were immunoprecipitated with anti-HA antibody 12CA5, run on
SDS-PAGE and processed for western blotting as before. Consistent with previous
observations, levels of unconjugated Atg12 were significantly decreased in the amino
acid starved control cells (Fig. 7, lane 2). In the cycloheximide-treated cells, levels of
HA-Atg12 were not protected in the starved cells and were also significantly decreased in
cells maintained in complete media (Fig. 7, lanes 3 and 4). The cycloheximide results
suggest that decreased levels of Atg12 in starved cells are not due to autophagic
consumption and that degradation of Atg12 is not regulated by nutrients or mitogens.
The cycloheximide result supports the second explanation that Atg12 is likely
degraded by another mechanism. Proteasome degradation is a major route for the
removal and degradation of proteins. To test if Atg12 is degraded by the proteasome,
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Figure 7. Levels of unconjugated HA-Atg12 in amino acid starved HEK293 cells.
Western blot: HEK293 cells co-expressing HA-Atg12IRESGFP and GST-Atg5 in
complete media (lane 1), starvation media (land 2), and complete and starvation media
with cycloheximide (lanes 3 & 4). Levels of unconjugated HA-Atg12 are not protected
by cycloheximide. Conjugate levels do not change.
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Figure 8. Unconjugated HA-Atg12 is degraded by the proteasome. Western blot:
HEK293 cells co-expressing HA-Atg12IRESGFP and GST-Atg5 were treated to
conditions of complete media (lane 1), starvation media (lane 2), and starvation media
with the proteosome inhibitor 20µm MG132 (lane 3). Levels of free Atg12 are protected
in starved cells treated with MG132, suggesting degradation of Atg12 is proteasomal.
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HEK293 cells expressing both HA-Atg12IRESGFP and GST-Atg5 were treated to
conditions of complete media, amino acid and serum-depleted media, or starvation media
with the proteasome inhibitor MG132. Levels of HA-Atg12 were completely protected
by MG132 in starved cells (Fig. 8), confirming that levels of unconjugated HA-Atg12 are
due to proteasome degradation and not consumption by the autophagic machinery. In all
of these conditions, levels of the hAtg12-hAtg5 conjugate did not change (Figs. 7 & 8).
These results demonstrate that levels of the hAtg12-hAtg5 conjugate or of
unconjugated HA-hAtg12 are not suitable readouts for the induction of autophagy.
However, the stability of the hAtg12-hAtg5 complex in all conditions tested, the short
half life of unconjugated hAtg12, and the potential role of the proteasome in regulating
hAtg12 cytoplasmic levels are findings that may have physiological relevance.
3.1.1.2. LC3 conjugation
LC3-II has been extensively used as a marker of autophagosomes, both by
western blotting and by fluorescent microscopy with a GFP-tagged LC3 reporter[20].
The specificity of the LC3 assay makes it a valuable tool to verify autophagosome
formation and to validate that the lysosomal degradation pathway is macroautophagy.
At the beginning of this study, antibodies for endogenous LC3 were not yet
available, and in a strategy similar to the one used for hAtg12, LC3 was cloned from a
human B-cell cDNA library and subcloned into a mammalian expression vector with HA
and myc epitope tags at the amino and carboxy termini respectively. The myc epitope tag
at the carboxy-terminus of LC3 was added to slow the electrophoretic mobility of the
proform of LC3 on SDS-PAGE to allow for better separation from LC3-I. A similar
strategy had been successfully used with rat LC3, one of the first mammalian Atg8
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orthologs identified[20]. It was expected that three forms of human LC3 would be seen
on SDS-PAGE similar to rat LC3: the slowest migrating proform, the middle cleaved
form, LC3-I, and the fastest migrating form with conjugated lipid, LC3-II. A year after
LC3 was cloned, a study would report that humans have at least three different isoforms
of LC3: LC3A, LC3B and LC3C. The LC3 in the tagged reporter was determined to be
LC3B.
HA-LC3B-myc was transfected into HEK293 cells which were maintained for
approximately 36 hours to allow for expression. Cells were washed into either fresh
complete media or media deficient in essential amino acids and serum and incubated for
four hours to induce autophagy. After harvesting, aliquots of cell extracts were
normalized for equal protein, immunoprecipitated with an antibody to the HA epitope
tag, and processed for western blotting with an antibody against HA. Three forms of
LC3B, pro-LC3B, LC3B-I and the lipidated LC3B-II, were seen by western blot analysis
(Fig. 9A). However, in contrast to the three bands seen with epitope tagged-LC3B and
rat LC3, published immunoblots of human and mouse LC3 usually showed LC3-I and
LC3-II, but not pro-LC3. Sequence analysis of the B-cell cloned LC3B reporter revealed
two abnormalities. Specifically, an arginine was deleted from the central region of LC3B
(∆R) and an additional nine amino acids were inserted at the carboxy-terminus (+9aa)
after the conserved TFG-glycine necessary for lipid conjugation (Fig. 9A).
The mutant HA-LC3B-myc reporter was tested for its response to known
inhibitors of macroautophagy, 3MA and chloroquine (see Table 2). The autophagy and
PI3K inhibitor 3MA is thought to block macroautophagy early in the formation of
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Figure 9. Mutant HA-LC3B-myc reporter. A. The mutant HA-LC3B-myc reporter
has an additional nine amino acids near the carboxy-terminus (in red), and a deletion of
three nucleotides that code for an arginine (∆R), also in red. Western blot is shown of
mutant LC3B reporter in plus and minus amino acid conditions. B. The mutant LC3B
reporter is shown in minus amino acid conditions (lane 1), and with autophagy inhibitors
10mM 3MA (lane 2) and 100µM chloroquine (lane 3). C. Restoration of the deleted
arginine (R68/R69) of LCB3, with the ‘+9aa’ insertion intact, yields a reporter that
processes LC3B to LC3B-I and LC3B-II in a manner like endogenous or HA-tagged wild
type LC3B (western blot)
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autophagosomes, although the exact mechanism is not known. Chloroquine blocks
macroautophagy by preventing acidification of the lysosome and fusion, while allowing
for the formation of autophagosomes. Large numbers of autophagosomes have been
observed to accumulate with the use of chloroquine. After sufficient time to allow for
expression, HEK293 cells transiently transfected with mutant HA-LC3B-myc were
treated for four hours with complete media, starvation media, and starvation media with
either 10mM 3MA or 100µM chloroquine. After harvesting, aliquots of cell extracts
were immunoprecipitated with anti-HA antibody and processed for western blotting as
before. The cells starved for amino acids and treated with 100µM chloroquine showed a
strong accumulation of LC3B-II was seen as expected (Fig. 9B, lane 3). Interestingly,
3MA treatment resulted in a significant increase in the proform of LC3B (Fig. 9B, lane
2), suggesting that 3MA affected early LC3B processing.
The effect of 3MA on LC3B proform processing led to the investigation of which
mutation, the ∆R deletion or the nine amino acid insertion, was responsible for the
delayed cleavage. The abundance of the pro-form in the mutant LC3B suggests that its
cleavage by Atg4B is impaired, although not completely inhibited. It was reasoned that
the ∆R deletion (of R68 or R69) might affect cleavage by Atg4B because of its proximity
to phenylalanine 80 (F77 in yeast), an amino acid essential for Atg4 binding and activity
in yeast[65]. The R68 and R69 residues are highly conserved between Atg8 orthologs
and species, making the importance of this region likely (Table 3). Alternatively, the
proximity of the nine amino acid (+9aa) insertion to the glycine where Atg4B-mediated
cleavage must occur might partially inhibit the activity of the protease. In order to
determine which mutation was affecting LC3B processing, the mutant LC3B reporter was
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repaired in a way that reinserted the arginine but left the ‘+9aa’ insertion intact, so that
the newly created HA-LC3B+9aamyc mutant could be tested for expression by western
blotting. HA-LC3B+9aamyc was transiently transfected in HEK293 cells, and after
sufficient time to allow for expression, washed into either complete or starvation media
for four hours. Cell extracts normalized for equal protein were prepared for western
blotting as described. Only the processed forms of the HA-LC3B+9aamyc mutant, LC3B-I
and LC3B-II, were observed by western blot, similar to other published reports of human
LC3 (Fig. 9C). Although only a wild type or endogenous LC3 will be used in subsequent
studies, the mutant LC3B construct is a unique reporter that may prove useful in future
studies involving the early processing steps of LC3B.
To facilitate studies which utilize the HA-LC3B-myc reporter, an HA epitopetagged wild-type LC3B-myc allele was made and stably integrated into HEK293 cells.
Expression levels of the stable LC3B reporter are lower than the transiently overexpressed LC3B reporter, and were later found to be roughly equal to that of endogenous
LC3 (data not shown). HA-LC3Bwtmyc4.1H stably expressed in HEK293 cells has the
benefit of an epitope tag without issues of variable transfection efficiency. HEK293 cells
stably expressing HA-LC3Bwtmyc4.1H were tested with either complete or starvation
media for 4-5 hours. Cell extracts were collected and processed for western blot as
before. The stably expressing HA-LC3B demonstrated increased LC3B-II levels with
amino acid and serum starvation (Fig. 10A). However, unlike the transient reporter,
levels of LC3B-I decreased in cells starved of amino acids. The decrease in LC3B-I is
consistent with published reports of endogenous LC3-I and with early interpretations of
the LC3 assay that rely on ratios of LC3-II/LC3-I to measure autophagy.
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Figure 10. MG132 partially protects levels of LC3B-I in starvation conditions. A.
HEK293 cells stably expressing HA-tagged wild-type LC3B-myc in complete media
(lane 1) and starvation media (lane 2). B. HA-LC3Bwtmyc4.1H stable cells in complete
media (lane 1), starvation media (lane 2) and with the proteosome inhibitor MG132
(20µM) (lanes 3&4).

49

50

Concerning the use of ratios, to interpret results from the LC3B assay, both a
decrease in LC3B-I and an increase in LC3B-II are considered. This makes a starvation
induced decrease in LC3B-I an important aspect of the LC3B assay. Although not
generally accepted, some researchers have even interpreted decreased LC3-I levels alone
as evidence of increased autophagy[66]. There are two possible interpretations to explain
why LC3B-I levels decrease with starvation. The first, and most obvious, is that in the
absence of new protein synthesis, LC3B-I levels drop as it is processed to LC3B-II when
cells need more autophagosomes. The second is that LC3B-I, like unconjugated HAAtg12, may be proteasomally degraded independent of conversion to LC3B-II. To test
the latter, HEK293 cells stably expressing HA-LC3Bwtmyc4.1H were incubated in
complete or starvation media for four hours, either with or without the proteasome
inhibitor MG132. Unexpectedly, levels of LC3B-I in starved cells were partially
protected by MG132. In contrast, MG132 had no effect on LC3B-I in full media, and did
not change levels of LC3B-II in either plus or minus amino acid media (Fig. 10B). This
indicates that little LC3B-I was degraded proteasomally in conditions of complete media,
and that LC3B-II was also not degraded proteasomally, as one might predict for a protein
attached to a membrane degraded in the lysosome. However, the MG132 data showing
protection of LC3B-I in minus amino acid media reveal that at a percentage of LC3B-I
may be degraded proteasomally under autophagy-inducing conditions. Therefore,
decreased levels of LC3B-I do not necessarily reflect conversion to LC3B-II and must be
used cautiously in conjunction with LC3B-II to interpret levels of autophagy.
The stably expressing HA-LC3B-myc4.1H was tested under conditions known to
inhibit autophagosome degradation. Chloroquine and bafilomycin A1 both inhibit
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autophagy by increasing lysosomal pH to block fusion of lysosomes with
autophagosomes. The block of fusion causes an accumulation of autophagosomes and an
increase in LC3B-II levels. HEK293 cells stably expressing the HA-LC3B-myc reporter
were starved of essential amino acids for 5 hours, with or without 100µM chloroquine or
100nM bafilomycin A1. After extraction, aliquots of cell extracts were normalized for
protein concentration, immunoprecipitated with antibody to HA, and processed for
western blotting. In the chloroquine and bafilomycin A1 treated cells, the accumulation
of LC3B-II was much greater than that of control cells (Fig. 11), which was expected
with strong lysosomal inhibition. However levels of accumulated LC3B-II in the
inhibitor-treated cells were essentially the same in complete media as in media depleted
of essential amino acids and serum (Fig. 11). The accumulation of LC3B-II in complete
media was surprising because one would expect that more LC3B-II would accumulate in
starved cells. In control cells, the increase of LC3B-II in starvation media was slight.
The data show that LC3B-II levels reach a limit where no more is produced under plus
amino acid and minus amino acid conditions. Without the lysosomal inhibitors, the
accumulation of LC3B-II is largely determined by its rate of degradation. And
surprisingly, LC3B-II is actively produced and degraded in the presence of amino acids
and serum.
These finding raise questions about the induction of autophagosome formation.
Does amino acid and serum starvation cause an actual increase in the rate of LC3B-II
production? And is there a way to inhibit the lysosome to give optimal accumulation of
LC3B-II when under starvation conditions? Since blocking lysosomal proteolysis and
autophagosome fusion causes an accumulation of LC3B-II, it should be possible to see
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Figure 11. LC3B-II with lysosome inhibitors. HEK293 cells stably expressing HALC3Bwtmyc4.1H were incubated in complete and starvation media (lanes 1 & 2) with
100µM chloroquine (lanes 3 & 4) or 100nM bafilomycin A1 (5 & 6). LC3B-II levels in
complete media approaches or reaches levels in starvation media, as seen by western
blotting.
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differences in rates of LC3B-II accumulation at early time points of lysosomal inhibition.
To test this, HEK293 cells stably expressing the HA-LC3B-myc construct were prestrong lysosomal block, and subsequently extracted at time points ranging from zero to
starved for sixty minutes without inhibitors, then treated with 100µM chloroquine for a
four hours. LC3B-II levels accumulated faster in starved cells compared to cells cultured
in full media, consistent with amino acid and serum starvation inducing the synthesis of
LC3B-II (Fig. 12A). The early time points of 20 and 40 minutes provided the most
sensitive window to differentiate between LC3B-II levels in plus vs. minus amino acid
conditions. Beyond that time, the difference between complete media and starvation
media rapidly narrowed until LC3B-II levels reached a plateau with no detectable
difference between the two treatments, consistent with the previous result (Fig. 11). The
reason for this plateau effect is not known, but could be explained by a self-limiting
mechanism that prevents excessive autophagosome formation. From this data, starvation
induced increases in LC3B-II can be seen only at early time points under conditions of
strong lysosomal inhibition.
Although a chloroquine time course was helpful in visualizing changes in
autophagic induction, the window of differentiation was small in that the accumulated
LC3B-II rapidly reached maximum levels with or without amino acids. In order to see
changes in autophagy at long time points, it was tested whether partial inhibition of
lysosomal degradation would allow for the accumulation of LC3B-II while still allowing
its breakdown. In this way, a stronger LC3B-II signal could be observed while
maintaining the ability to see regulation of LC3B-II at short and long time points. To test
this, HEK293 cells stably expressing the HA-LC3B reporter were treated with decreasing
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Figure 12. Lysosome inhibitors can validate LC3B-II induction and flux. A. Time
course experiment of LC3B-II accumulation with 100µM chloroquine. At 120 minutes,
levels of LC3B-II in plus and minus amino acid media are equal. B. Chloroquine dose
response experiment. At lower doses, chloroquine controls autophagosome flux and
increases the sensitivity of the LC3B-assay at longer time points. (western blot)

56

57

conditions. At lower doses of 10µM and 25µM chloroquine, differences in LC3B-II
levels between the two conditions were apparent (Fig. 12B). In principle, weak
lysosomal inhibition enhances the sensitivity of the LC3B assay, without sacrificing the
ability to see regulation by amino acid availability.
While chloroquine was useful, its potency occasionally made it difficult to
correctly dose without reaching maximum LC3B-II accumulation. Chloroquine raises
lysosomal pH, affecting many lysosomal hydrolases. Specific protease inhibitors may be
less severe but still give the required result. E64d, combined with either leupeptin or
pepstatin A, has been used in the literature as an effective inhibitor of lysosomal
cathepsins. HEK293 cells stably expressing the HA-LC3Bwtmyc4.1H reporter were treated
with leupeptin and E64d, or pepstatin A and E64d, in either complete or starvation media
for 5 hours. Control cells stably expressing HA-LC3B were incubated in either plus or
minus amino acid media without inhibitors. HA-LC3B was immunoprecipitated from
cell extracts and prepared for western blotting. Both leupeptin/E64d and pepstatin
A/E64d were successful in increasing the window of sensitivity of the LC3B assay
compared to control cells (Fig. 13) without the problem of maximal accumulation. This
demonstrates that protease inhibitors can be successfully used for long time periods to
control autophagosome flux and increase the sensitivity of the LC3B assay.
The experiments presented here emphasize some of the advantages and
disadvantages of using a midpoint assay. In light of the current knowledge of LC3, LC3II unquestionably has value for its specificity for autophagosomes. However, the
transient nature of autophagosomes and the lack of specific knowledge of regulation of
events at either formation or degradation, make correct interpretation difficult.
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Figure 13. Protease inhibitors can control LC3B-II flux. HEK293 cells stably
expressing HA-LC3B-myc were treated with leupeptin (10.0µM) + E64d (5.8µM) or
pepstatin A (14.6 µM)+ E64d (29.2 µM) for five hours. This increases sensitivity of
LC3B-II assay to flux. (western blot)
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3.1.2. The BHMT assay
3.1.2.1. Assay development and pharmacological validation
Macroautophagy is a multi-step, biological process. The LC3 assay and electron
microscopy (EM) are both valuable tools to semi-quantitatively assess levels of
autophagosomes, but alone, they are inadequate to determine rate or level of autophagy.
Optimally, one must consider delivery of cargo to the lysosome and its subsequent
degradation. The importance of the lysosomal endpoint is widely acknowledged, and
researchers in mammalian autophagy have developed biochemical methods to measure
the degradation of long-lived proteins as a group[67]. However, these methods are
neither sensitive nor specific for macroautophagy. One goal of this research was to
develop and validate a functional, biochemical endpoint assay that would be
reproducible, specific, and sensitive for macroautophagy. Ideally, this assay would
measure the vesicular uptake, delivery and lysosomal degradation of cytoplasmic cargo.
In a literature search to find proteins that might be useful in an autophagy endpoint assay,
betaine homocysteine methyltransferase (BHMT) emerged as a promising candidate.
BHMT, a metabolic, cytosolic enzyme in high abundance in liver and kidney, was
identified by mass spectrometry as a protein that associated with purified autolysosomes
in rat liver [68]. Although the authors were searching for autophagosome-specific
membrane proteins, its presence in autolysosomes was likely due to engulfment as
autophagosome cargo. In support of this, a specific carboxy-terminal degradation
fragment of BHMT was found only within the lumen of leupeptin-treated rat
autolysosomes. The authors concluded that a leupeptin-resistant cathepsin was able to
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cleave BHMT to produce a discrete, 32kDa, lumenal fragment that could be visualized on
SDS-PAGE.
Based on these observations, a BHMT plasmid-based autophagy reporter assay
was developed for use in cell culture. In concept, the assay would measure levels of a
BHMT lysosomal fragment similar to the one found in rat autolysosomes. In addition, if
autophagic flux was high, levels of full-length BHMT might also be expected to decrease
with increased autolysosomal consumption. The BHMT reporter was created using a
subcloning strategy that fused a slightly truncated human BHMT cDNA downstream of a
glutathione S-transferase (GST) epitope tag and upstream of a small epitope myc tag
(Fig. 14A). This allowed for easy enrichment of full-length GST-BHMT and GST-fused
fragments with glutathione agarose. Since commercial antibodies to the GST epitope tag
were readily available, GST-BHMT and GST-fused fragments of BHMT could then be
easily visualized on a western blot.
To determine if the chimeric GST-BHMT-myc would be a suitable reporter, it
was necessary to 1) determine if GST-BHMT-myc, like rat BHMT, had a leupeptininsensitive proteolytic cleavage site that could be seen by western blotting, and 2) test if
degradation could be induced under conditions known to initiate macroautophagy. The
GST-BHMT-myc reporter was transiently transfected into HEK293 cells and maintained
in culture for 24-48 hours to allow for expression. HEK293 cells expressing GSTBHMT-myc were incubated for five hours under various media conditions previously
shown to induce autophagy, such as amino acid deprivation and/or serum starvation.
Aliquots of cell extracts, normalized for total protein, were incubated at 4ºC with
glutathione agarose to purify and enrich GST-tagged BHMT and BHMT fragments
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Figure 14. Leupeptin-dependent generation of GST-BHMT fragments. A.
Schematic of the plasmid-based BHMT reporter, with a glutathione S-transferase (GST)
epitope tag at the amino-terminus and a myc epitope tag at the carboxy-terminus. B.
GST-BHMT fragmentation requires the protease inhibitors leupeptin (10ug/ml) and E64d
(2ug/ml) (lanes 5-8 vs. 1-4). Levels of BHMT fragments increase in media depleted of
12 essential amino acids (lanes 7 and 8). Serum starvation does not increase levels of
fragment 1 (lane 6 compared to lane 5, and lane 8 compared to lane 7). All data shown is
obtained by glutathione pulldown and western blotting.
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which were run on SDS-PAGE and probed with an antibody to GST. To test for GSTBHMT fragmentation, half of the cells received the protease inhibitors leupeptin and
E64d. Leupeptin and E64d were chosen because they were both used to observe
accumulation of BHMT fragmentation in the original study by Ueno et al[68]. In
addition, the leupeptin/E64d cocktail has already been shown to have a modest,
controlled effect on LC3B processing and thus on macroautophagy in the current study
(see Fig. 13). It was expected that the proteases would slow the autophagic process to a
rate that would allow the accumulation of partial degradation products within the
autolysosome. If human GST-BHMT was proteolytically cut in a region similar to rat
BHMT, generation of a fragment of approximately 35 kDa on SDS-PAGE was expected.
Consistent with these expectations, a fragment of approximately 35 kDa, labeled
fragment 1, was observed on western blot in the leupeptin/E64d treated cells that was not
seen in cells without protease inhibitors (Fig. 14B, lanes 5-8 compared to lanes 1-4). A
second fragment, labeled fragment 2, was noted at 25 kDa which was the approximate
size of either endogenous GST or of the epitope GST tag. Significantly, accumulation of
the 35 kDa fragment increased in the absence of essential amino acids (Fig. 14B, lanes
7&8). Serum starvation alone, or in combination with essential amino acid starvation,
did not alter the accumulation of fragment 1 (Fig. 14B, compare lanes 5 and 6, and lanes
7 and 8). These data show that BHMT fragmentation occurs in response to the specific
removal of amino acids rather than serum. To see changes in the GST-BHMT fragments,
it is necessary to partially inhibit macroautophagy with protease inhibitors. In all
subsequent BHMT experiments, unless otherwise noted, leupeptin and E64d have been
added to the media to visualize fragmentation. In addition, although serum deprivation
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had no effect on induction of macroautophagy, the starvation media used to induce
autophagy is generally deficient in both amino acids and serum for experimental
convenience.
Expression of GST-BHMT requires the transient transfection of the expression
plasmid. To compare levels of BHMT fragments between experimental conditions, it is
necessary to normalize for differences of transfection efficiency. Normalization to the
expression of the full length GST-BHMT-myc protein is not preferred because of its
degradation during active autophagy. To address the issues of transfection efficiency and
independent normalization of GST-BHMT, a bicistronic message under the control of a
single CMV promoter was created by placing GFP downstream of GST-BHMT under the
translation control of an IRES (Fig. 15A).
To validate that the generation of GST-BHMT fragments was due to
macroautophagy, HEK293 cells were transiently transfected with the GSTBHMTIRESGFP construct, and 48 hours later starved from serum and essential amino
acids in the presence or absence of a panel of inhibitors known to inhibit
macroautophagy; 3MA, wortmannin, bafilomycin A1, and puromycin. Wortmannin and
3-methyladenine (3MA) are PI3 Kinase inhibitors that are thought to inhibit autophagy
through their inhibition of the Class III PI3 Kinase, Vps34. Bafilomycin A1, a potent
inhibitor of the vacuolar H+ ATPase (V-ATPase), prevents acidification of the lysosome
and lysosome-fused vesicles. Puromycin, like cycloheximide, is an inhibitor of
translation and autophagy. To exclude a role of the proteasome in the fragmentation of
BHMT, the proteasome inhibitor MG132 was included in the panel of inhibitors. Each of
the autophagy inhibitors prevented the accumulation of BHMT fragment 1 and fragment
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Figure 15. The original BHMT assay with pharmacological inhibitors. A.
Schematic of the GST-BHMT-IRESGFP reporter plasmid. Placement of an IRES-GFP
downstream of GST-BHMT in a bicistronic message allows for independent
normalization of transfection efficiency. B. The BHMT assay. Fragmentation of GSTBHMT increases with amino acid and serum starvation and is inhibited with the
macroautophagy inhibitors, 10mM 3MA, 100nM wortmannin, 100nM bafilomycin A1,
and 50µM puromycin. The proteosome inhibitor MG132 does not effect fragmentation.
All data shown is obtained by glutathione pulldown and western blotting.
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2. As expected, the proteasomal inhibitor MG132 had no effect (Fig. 15B, lanes 3 to 7).
These data provide pharmacological validation that the GST-BHMT proteolytic
fragments are generated through macroautophagic delivery of GST-BHMT to the
lysosome.
Although levels of BHMT fragment 1 were consistently increased in conditions of
autophagy induction and inhibited by autophagy inhibitors, fragment 2 was occasionally
problematic; it was not always induced by amino acid starvation and did not always
appear to be due to macroautophagy. If the cleavage sites responsible for the generation
of fragment 1 and fragment 2 could be identified, then it might be possible to produce a
more reliable readout for the induction and inhibition of autophagy. The initial rationale
to test human BHMT as an autophagy reporter was based on the association of rat BHMT
with autolysosomes[68]. Human BHMT and rat BHMT are 92% conserved at the amino
acid level, making it likely that the cleavage site responsible for cleavage of human
BHMT is at or near the cleavage site predicted by Ueno et al. in rat BHMT[68]. In
support of this, the calculated molecular weight of the GST protein plus the first amino
acids of BHMT up to the predicted cleavage site in BHMT is 35 kDa which corresponds
well with the molecular weight estimated on SDS-PAGE for fragment 1.
In the crystal structure of rat BHMT, loop L2, which connects β2 and α2 of the (α/β)8
barrel, is not visible on electron density maps due to a high degree of mobility[69]. The
cleavage site described by Ueno et al. is within this disordered, flexible loop region, L2,
of BHMT (Fig. 16A). Proteolytic cleavage of human BHMT to generate fragment 1
might also occur somewhere in this flexible, exposed loop, potentially at the same E92
site described by Ueno et al[68].
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Figure 16. BHMT fragment 1 cleavage site maps to loop 2 (L2). A. Crystal structure
of overlapping subunits of rat BHMT, as published by Gonzalez et al[69]. The L2 loop is
disordered and not visible on the electron density maps. Sequence of the L2 loop is
conserved in human BHMT; ^ marks the only residue that is different between rat and
human. Site of cleavage to generate peptide in Ueno paper is marked with an arrow.
Sites considered as contenders for fragment 1 generation are similarly indicated.
Engineered thrombin recognition site is noted, with mutations marked in red. B. Western
blot of control and ‘L2Thr’ mutant. Starvation of the ‘L2Thr’ mutant generates two closely
related fragments in lane 4. In-vitro thrombin cleavage assay has no effect on control but
efficiently cleaves the ‘L2Thr’ mutant (lanes 7-8) to produce a band consistent with the
upper band of the doublet.
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While examining the L2 and surrounding regions of BHMT for potential protease
recognition sites, it was noticed that L2 contained a sequence similar to a thrombin
recognition site. The BHMT sequence LENRGN was different from a thrombin
recognition site, LVPRGS, by just three amino acids, and was slightly upstream of the
predicted E92 site (Fig. 16A). In an attempt to map the autophagy specific cleavage site
in human BHMT, a strategy was designed to mutate the three amino acids necessary to
introduce a thrombin cleavage site in the L2 loop of BHMT. If fragment 1 was produced
by cleavage at E92 or somewhere downstream, and if the engineered thrombin site was
not itself cleaved in vivo, then an in-vitro thrombin-generated fragment could be easily
analyzed by mass spectrometry to obtain information on the precise cleavage site.
However, it was possible that lysosomal thrombin-like proteases might cleave the
introduced thrombin site either preferentially or in addition to the original cleavage site.
In fact, the latter proved correct, as amino acid starvation of the GST-BHMT L2thr mutant
resulted in the production of two, very closely associated fragments on SDS-PAGE (Fig.
16B, lane 4). The newly generated fragment seen in lane 4 migrated slightly slower on
SDS-PAGE than control fragment 1, suggesting that the cleavage site for fragment 1 was
not downstream as supposed, but rather was upstream of the engineered thrombin
cleavage site.
To verify that the thrombin cleavage site was functional and that the upper band
in lane four was generated by cleavage at the introduced thrombin recognition site,
glutathione Sepharose pull-downs from control and GST-BHMT L2thr mutant cell
extracts were treated with thrombin protease in-vitro and prepared for western blotting.
Thrombin cleavage of the BHMT L2Thr mutant generated a band on SDS-PAGE identical
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in size to the upper band of the doublet (Fig. 16B, lanes 7 and 8). In-vitro thrombin had
no effect on GST-BHMT from control cells as expected (Fig. 16B, lanes 5 and 6). The
results of the in-vitro thrombin cleavage assay confirm that the upper band was generated
from the introduced site.
In an attempt to more closely map the fragment 1 cleavage site, mutations were
made in the acidic and basic residues upstream of the thrombin cleavage site, E80A,
D81A, K82Q, but they did not disrupt the production of fragment 1 (data not shown). To
date, the exact proteolytic site responsible for fragment 1 is not known, although it is
thought to be within a few amino acids upstream of the terminal amino acid, R86
produced by thrombin cleavage.
The inconsistencies that were observed in the generation of fragment 2 raised
concerns that its cleavage was not entirely due to lysosomal proteases. Changes in levels
of fragment 2 were not easily explained and distracted from the consistent, autophagyrelated changes observed in levels of fragment 1. The goal of the BHMT assay was to
create a clean and unambiguous reporter for macroautophagy, so it was necessary to
make changes in the reporter that would preserve fragment 1, but eliminate fragmentation
that generated fragment 2. If the site or region responsible for the generation of fragment
2 could be identified, then it might be possible to change it by mutation or deletion to
make it a less favored substrate for its specific protease. Since the molecular weight of
fragment 2 was very near the predicted molecular weight of GST alone (predicted to be
27 kDa), the linker region between GST and BHMT was examined for potential
proteolytic sites. Sequence analysis of the GST-BHMT construct revealed a thrombin
recognition site near the 3’end of the GST epitope tag (Fig. 17A in bold).
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Figure 17. Mapping the major cleavage site responsible for fragment 2. A.
Sequence analysis of the carboxy-terminal region of GST revealed a thrombin
recognition sequence (bold and underlined). The twelve amino acids that were removed
to make the BHMT∆T reporter are bracketed between the arrows. B. An in-vitro
thrombin cleavage assay was performed with the original BHMT reporter to validate that
the thrombin cleavage site was functional and capable of producing a fragment near the
size of fragment 2. All data shown is by glutathione pull-down and western blotting.
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The GST fused to BHMT was originally subcloned from the PGEX -2T cloning
vector (accession number U13850). All PGEX vector GST sequences are identical from
the amino-terminus through FDHPPKSD (Fig. 17A), but vary in the protease recognition
sites and sequences that follow. The thrombin recognition site in the original vector was
designed to allow cleavage and release of protein fused to GST for purification purposes.
Thrombin cleavage of the GST-BHMT reporter could be useful in narrowing the region
of the proteolytic site responsible for the generation of fragment 2, by generating a
defined fragment that could be compared to the size of fragment 2. It was also possible
that the thrombin cleavage site itself might be responsible for generation of fragment 2 as
was observed with the L2Thr form of BHMT. Since thrombin-like proteases exist in both
the cytoplasm and the lysosome, cleavage at this site would explain why fragment 2
appeared to be of lysosomal origin in some experiments, but not others.
An in-vitro thrombin cleavage assay was performed to determine the size of a
thrombin-released GST-BHMT fragment on SDS-PAGE compared to fragment 2.
HEK293 cells were transiently transfected with the GST-BHMT-myc reporter construct
and extracted after 48 hours. GST-BHMT-myc was affinity-purified on glutathione
Sepharose beads from 300µg of cell extracts. PBS-washed glutathione beads with bound
GST-BHMT were incubated at room temperature for 2 hours in 20µl of PBS with 0.5µg
thrombin. A negative control was processed in the same manner without thrombin.
Samples were prepared for western blotting with an antibody against GST. Independent
glutathione pull-down was included as a control for the size of fragment 2 (Fig. 17B, lane
1). Negative thrombin assay control is shown in Fig. 17B, lane 2. The fragment released
by in-vitro thrombin cleavage ran on SDS-PAGE at a molecular weight equal to that of
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fragment 2 (Fig. 17B, lane 3 compared to lane 1). It seemed likely that the thrombin
recognition site was responsible for the generation of fragment 2 in-vivo.
The amino acids in the carboxy-terminal region of the GST tags vary between the
different PGEX vectors, and are likely not essential for glutathione interaction or
antibody recognition. Therefore, a PCR strategy was used to remove the thrombin
recognition site plus six additional amino acids from the linker region between the GST
tag and BHMT to create a new reporter called GST∆TBHMT myc (Fig. 17A).
The new GST∆TBHMTmyc reporter was tested to determine if it retained the
ability to generate fragment 1 in conditions known to induce and inhibit macroautophagy,
and to see if deletion of the thrombin cleavage site had removed the cleavage site
responsible for the generation of fragment 2. HEK293 cells were transiently transfected
with GST-BHMT-myc as a control and the GST∆TBHMTmyc construct. After allowing
sufficient time to allow for expression, the cells were starved from serum and essential
amino acids in the presence or absence of a panel of macroautophagy inhibitors: 3MA,
wortmannin, chloroquine, and bafilomycin A1. The proteasome inhibitor MG132 was
included as before. Glutathione pull-downs were performed from cell extracts and
prepared for western blotting. The GST∆TBHMT reporter was as fully responsive to
induction of autophagy by amino acid starvation and to the effects of macroautophagy
pharmacological inhibitors in the generation of fragment 1 as the original reporter (Fig.
18B). GST∆TBHMT fragment 1 migrated slightly faster on SDS-PAGE as expected due
to the deletions in the GST linker regions. Although the ∆T modification seemed to
reduce the level of fragment 2, it did not completely eliminate generation of a second
fragment (Fig. 18B, lane 2 compared to lane 1). On closer examination, the original
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Figure 18. The GST-BHMT∆T assay. A. Schematic of the GST-BHMT∆T reporter
construct. B. GST-BHMT∆T produces two consistently lysosomal fragments with amino
acid and serum starvation. BHMT fragmentation is inhibited by the autophagy inhibitors,
10mM 3MA, 100nM wortmannin, 100µM chloroquine, or 100nM bafilomycin A1. GSTBHMT∆T fragmentation was not inhibited by the proteasome inhibitor MG132. All data
shown is obtained by glutathione pull-down and western blotting.
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GST-BHMT-myc reporter fragment 2 is actually a doublet. The larger, slower migrating
fragment was eliminated in the BHMT∆T background, but the smaller fragment remained.
Unlike the original fragment 2, generation of the smaller fragment, called fragment 2′ in
the ∆T background, correlated well with fragment 1 under conditions of autophagic
induction and inhibition.
Although both fragments 1 and 2′ were now consistent in their response to
autophagic induction and inhibition, it was possible that the overall signal observed in the
generation of fragment 1 might be diluted by subsequent cleavage to fragment 2′. If this
were true, the elimination of the fragment 2′ cleavage site might increase the generation
of fragment 1 and the overall signal strength. To do this, two things were considered.
First, it was assumed that either the same or a similar lysosomal cathepsin was
responsible for the generation of both fragment 1 and the remaining 2′, since both
fragments were generated in the presence of the protease inhibitors leupeptin and E64d.
Second, the size of fragment 2′ again suggested that the cleavage site must be near the
end of GST. Ueno et al. indicated the intralysosomal carboxy-terminal fragment of rat
BHMT was cleaved between glutamate E92and lysine K93 to produce the carboxyterminal peptide identified by mass spectrometry[68]. With this information, point
mutations were made in the carboxy-terminal region of GST that changed two aspartates
to glycines (D214G, D220G), and a lysine to a glutamine (K218Q) (Fig. 19A).
While making these modifications, an additional mutation was made in GST to
address a potential KFERQ-like chaperone-mediated autophagy (CMA) site. Although it
seemed unlikely that GST-BHMT was imported via CMA, Majeski and Dice reported
that glutathione GST was a known CMA substrate[10]. The identified site, NKKFE was
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found in the GST fused to BHMT, so a N43A mutation was introduced that was known
to destroy substrate recognition by the CMA complex (Fig. 19A).
The new GSTmodBHMT construct was subcloned as before to create a bicistronic
message with a downstream IRES-GFP (Fig. 19A). HEK293 cells were transiently
transfected with GSTmodBHMTIRESGFP and maintained in culture for 36 hours to allow
for expression of the reporter and GFP. GFP expression on western blot is shown for
normalization (Fig. 19B, bottom panel). Cells were treated for five hours with or without
leupeptin (10ug/ml) and E64d (2ug/ml), which was essential to observe fragment 1 at a
molecular weight of approximately 35 kDa by western blotting (Fig. 19B, lanes 5-8
compared to lanes 1-4). Serum starvation of cells with the full cocktail of essential amino
acids was not sufficient to induce an increase in fragment 1 (Fig. 19B, lanes 5 vs. lane 6).
Depletion of essential amino acids was sufficient to increase levels of fragment 1, with
the presence of dialyzed serum having no effect (Fig. 19B, lanes 7 and 8). The deletions
and mutations in the GSTmodBHMT reporter did not prevent the starvation-induced
generation of fragment 1. Protease inhibitors were still necessary to see fragment 1,
which was now the only fragment observed.
The deletions and mutations in the GSTmodBHMT reporter had successfully
eliminated the generation of fragment 2 and it seemed prudent to verify that the extensive
modifications had not affected the generation of fragment 1 with autophagy inhibitors.
The GSTmodBHMT reporter was transiently transfected into HEK293 cells and treated for
5 hours with complete media and starvation media with the panel of macroautophagy
inhibitors as before, including wortmannin, 3MA, bafilomycin A1, chloroquine, and
puromycin. Aliquots of cell extracts were pulled down with glutathione Sepharose and
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Figure 19. Leupeptin-dependent generation of GSTmodBHMT fragment 1. A.
Schematic of the GSTmodBHMTIRESGFPmyc reporter; the thrombin recognition site has
been removed and N43A, D214G, K218Q, and D220G mutations have been made in
GST. B. GSTmodBHMT fragmentation requires the protease inhibitors leupeptin
(10ug/ml) and E64d (2ug/ml). Levels of BHMT fragment 1, but not fragment 2, increase
in media depleted of 12 essential amino acids (lanes 7 and 8). All data shown is obtained
by glutathione pulldown and western blotting.
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prepared for western blotting. GSTmodBHMT demonstrated increased fragment 1
accumulation with amino acid starvation that was effectively blocked with the panel of
autophagy inhibitors (Fig. 20). Increased fragmentation of this reporter was also
observed in cells treated with 40nM rapamycin, an agent reported to induce
macroautophagy in the presence of full amino acids[54], providing further evidence that
GSTmodBHMT was a reporter for macroautophagy (Fig. 20 lane 3). A band near the
molecular weight of fragment 2 was observed, but is likely endogenous GST, as it was
also observed in extracts from untransfected cells (data not shown).
Recently, it was reported that intact microtubules were necessary for
macroautophagy in hepatocytes and that their disruption with the drug vinblastine
allowed and potentiated autophagosome formation, but inhibited the vesicular trafficking
necessary for fusion with lysosomes[70]. Vinblastine was also recently tested for its
effects on chaperone-mediated autophagy (CMA) by Finn et al., who showed that
vinblastine did not inhibit CMA in IMR90 cells[71]. For further validation that BHMT
fragmentation was the result of macroautophagy and not CMA, the BHMT assay was
tested with the pharmacological agent vinblastine. HEK293 cells stably expressing
GSTmodBHMTmyc were starved of essential amino acids and serum for 5 hours. Cells
were treated with decreasing doses of vinblastine from 50µM to 5µM, with 100µM
chloroquine as a positive control for maximum lysosomal inhibition. Amino acid starved
cells served as a control for generation of fragment 1. After the cells were harvested,
glutathione pull-downs from cell extracts were processed for western blotting. The
starvation-induced generation of fragment 1, seen in lane 1, was inhibited by chloroquine,
seen in lane 2, as expected (Fig. 21). Generation of BHMT fragment 1 was inhibited by
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Figure 20. The BHMT assay with GSTmodBHMTIRESGFPmyc. Western blot of
modified BHMT reporter in plus and minus amino acid media and with a panel of
pharmacological agents: 40nM rapamycin, 100nM wortmannin, 10mM 3MA, 100n
bafilomycin A1, 100µM chloroquine, 50µM puromycin. The band marked with an * is
not specific for cells expressing the GST-BHMT constructs and is most likely
endogenous GST.

85

86

Figure 21. Validation of the BHMT assay with vinblastine. Western blot of HEK293
cells stably expressing GSTmodBHMT-myc. Amino acid starved cells represented in
lanes 3-6 were treated with 50µM, 25µM, 10µM and 5µM vinblastine repectively. Lane
1 represents cells in starvation media, and lane 2, starvation media with 100 µM
chloroquine as a control for a block of lysosomal degradation. Western blot of
endogenous LC3 is shown in the bottom panel. BHMT fragmentation and LC3-II are
inversely related in amino acid starved cells with chloroquine or higher doses of
vinblastine.
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vinblastine in a dose dependent manner, and at 50 µM was as effective as chloroquine at
inhibiting BHMT fragmentation (Fig. 21, lanes 3-6). Western blot of endogenous hLC3
shows an inverse correlation between levels of LC3-II and BHMT fragment 1,
confirming that vinblastine blocks macroautophagy at a late stage, causing an
accumulation of autophagosomes. The vinblastine data provide additional
pharmacological validation that the BHMT assay does not measure chaperone-mediated
autophagy, but is specific for macroautophagy.
The pharmacological inhibitors of BHMT fragmentation strongly argue that the
BHMT assay specifically measures macroautophagy. The lysosome inhibitors
convincingly demonstrate that BHMT fragmentation is lysosomal and the
macroautophagy inhibitors wortmannin and 3MA, and vinblastine suggest it is not due
chaperone-mediated autophagy (CMA). However, the effects of any of these inhibitors
on microautophagy are not known, and therefore the pharmacological data cannot rule
out microautophagy as a mechanism of BHMT lysosomal import.
3.1.2.2. Validation of the BHMT assay by modulating levels of known autophagy genes.
Silencing of a macroautophagy-specific gene by short-interfering RNA (siRNA)
would unambiguously validate that BHMT is delivered to the lysosome by
macroautophagy. Beclin1, the human ortholog of yeast Atg6, was chosen as one target
for siRNA. The expression of Beclin1 is thought to promote autophagy through its
interaction with the Class III PI3 Kinase, Vps34[72]. Over-expression of Beclin1
increases macroautophagy in MCF7 cells and monoallelic deletion of Beclin1 promotes
tumorigenesis in part due to suppressed macroautophagic activity[38]. pSilencer DNA
plasmid vectors (Ambion), designed with a short hairpin (sh) insert, were used to express
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target-specific sequences to be processed into siRNA that would silence certain Atg
genes. In a manner similar to the HA-LC3B-myc reporter, the GSTmodBHMTmyc
reporter was stably integrated into HEK293 cells. This eliminated issues related to the
co-transfection of shRNA plasmids with a BHMT reporter plasmid, especially when
multiple transfections were required for efficient gene silencing. HEK293 cells that
stably expressed GSTmodBHMT were transfected twice with pSilencer plasmids to
achieve a transfection efficiency of approximately 90%. Three different shRNA
sequences targeting Beclin1 successfully lowered Beclin1 expression by approximately
60% (Fig. 22). Significantly, in the cells with shRNA targeting Beclin1, generation of
BHMT fragment 1 in amino acid and serum starved cells was decreased by
approximately 60% (Fig. 22). This provides the first direct evidence that an autophagy
specific gene is necessary for the BHMT assay to generate fragment 1 and that the
BHMT assay is measuring the process of macroautophagy.
A second gene of interest in macroautophagy is human unc 51-like kinase 1
(hULK1). hULK1 is an ortholog of yeast Atg1, the only protein kinase identified in the
initial genetic screens in S. cerevisiae[44]. In yeast, one model suggests that Atg1
activity increases with autophagy induction in response to the decreased phosphorylation
of Atg13, an associating protein in complex with Atg1[45]. The phosphorylation of
Atg13 is downstream of the target of rapamycin (TOR). Inhibition of yeast TOR by
nitrogen starvation or by its inhibitor rapamycin decreases phosphorylation of Atg13 and
increases the activity of Atg1. However, this model is not universally accepted, as
Abeliovich et al. reports that Atg1 activity is not required for macroautophagy, although
it is required for the Cvt pathway[46]. Although hULK1 was first described in 1998 as
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Figure 22. Validation of the BHMT assay by silencing Beclin1 with shRNA.
Plasmid vectors with three different short hairpin inserts designed to target Beclin1
mRNA with siRNA were transfected twice in HEK293 cells stably expressing
GSTmodBHMT-myc. Cells were treated to conditions of plus and minus amino acid
media. Levels of BHMT fragment 1 are decreased in cells with decreased levels of
Beclin1. Western blot for Beclin1 verifies that levels of endogenous Beclin1 decreased
with each shRNA targeting Beclin1.
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an Atg1 ortholog, data that suggests a role in autophagy has only recently been published.
It was shown that shuttling of the mammalian autophagy-related protein mAtg9 between
the trans-Golgi and autophagosomes is inhibited in cells in which hULK1 transcript
levels are decreased by shRNA, providing the first evidence that human hULK1 plays a
role in mammalian macroautophagy[52].
Because hULK1 is a kinase, it seemed likely that conditions known to induce or
inhibit autophagy might change its specific activity. This is supported by data in S.
cerevisiae that Atg1 activity increases in conditions known to induce autophagy[45]. To
test this, it was necessary to create and express an epitope-tagged hULK1 because
hULK1 antibodies that were commercially available were not sensitive enough for
immunoprecipitation or western blotting of the endogenous protein. hULK1 was cloned
from a human cDNA library and subcloned into a mammalian expression vector with an
HA epitope tag at the amino-terminus and a myc tag at the carboxy-terminus. To make a
catalytically inactive allele of hULK1, the invariant lysine in subdomain two of the
catalytic domain, known to disrupt ATP binding in other kinases, was mutated to a
glutamine (K39Q) by site directed mutagenesis. The HA-tagged hULK1KD mutant
migrated faster on SDS-PAGE than HA-ULK1-myc, in a band shift consistent with loss
of phosphorylation (Fig. 23A). To test the activity of HA-hULK1-myc and HAhULK1KD, the two kinases were tested in an in-vitro kinase assay with myelin basic
protein (MBP) as a generic substrate. In the conditions tested, HA-ULK1-myc was
catalytically active toward MBP and was able to autophosphorylate as expected. The KD
mutant was not active toward MBP and did not autophosphorylate (Fig. 23B).
To test the specific activity of hULK1, HEK293 cells expressing HA-ULK1-myc
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Figure 23. Expression and activity of HA-hULK1-myc and HA-hULK1KDmyc. A.
Western blot of HA-tagged hULK1 and the slower-migrating HA-tagged kinase dead
hULK1KD. B. In-vitro kinase assay: The epitope-tagged wild type hULK1 can
autophosphorylate and phorphorylate MBP in vitro. HA-hULK1KDmyc shows no
evidence of catalytic activity.
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Figure 24. Specific activity of HA-hULK1-myc in conditions known to induce or
inhibit macroautophagy. HEK293 cells expressing HA-hULK1-myc were treated to
conditions known to induce autophagy, such as minus essential amino acids and
rapamycin treatment, or to conditions known to inhibit autophagy, such as 10mM 3MA,
100nM wortmannin, and 100µM chloroquine. Top panel shows expression of HAhULK1-myc by western blotting. Middle and bottom panels are autorads showing
autophosphorylation of HA-hULK1-myc and phosphorylation of the generic substrate,
myelin basic protein (MBP).
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were tested under conditions known to induce autophagy such as amino acid starvation or
treatment with 40nM rapamycin, as well as conditions that inhibit autophagy such as
treatment with 100nM wortmannin, 10mM 3MA or 100µm chloroquine. After four hour
treatment and extraction, HA-ULK1-myc was immunoprecipitated from cells extracts
and tested for activity toward MBP in an in-vitro kinase assay. As a control of
expression, a western blot of HA-hULK1-myc in crude extracts is shown in the top panel
(Fig. 24). Autophosphorylation of hULK1 and phosphorylated MBP are shown in the
bottom two panels of Figure 24. Unlike in yeast, the specific activity of HA-hULK1-myc
did not change in starvation conditions, with rapamycin treatment, or in any of the other
conditions tested.
Protein kinase function can be regulated by mechanisms other than changes in
specific activity. Expression levels regulate the function of some kinases and could be a
mechanism of regulation for hULK1. Although endogenous hULK1 cannot be seen by
western blotting with the available antibodies, qPCR is a testable method to determine if
amino acid starvation affects levels of hULK1 mRNA. Total RNA was extracted from
HEK293 cells that were maintained in either complete or starvation media for
approximately 7 hours. Each condition was repeated in triplicate. After reverse
transcription to cDNA with random primers, qPCR was performed on each sample, in
duplicate, with primers specific to hULK1 and its isoform hULK2. Quantitation is
expressed as fold change, normalized to two housekeeping genes, actin and 18S (Fig. 25).
Amino acid starvation did not significantly change levels of either hULK1 or hULK2
mRNA, compared to cells in complete media. Regulation of hULK1 does not seem to
occur at the transcriptional level.
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Figure 25. hULK1 and hULK2 transcript levels are unchanged in amino acid
starved cells. T98G cells were maintained in complete media or media depleted of
essential amino acids and serum for 6 hours. After extraction of total RNA and RT-PCR,
qPCR was performed with primers to either hULK1 or hULK2. Relative levels of
hULK1 and hULK2 mRNA in amino acid starved cells are compared to cells in complete
media. Fold change is normalized to two housekeeping genes: actin and ribosomal 18S.
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Figure 26. HA-hULK1KDmyc inhibits starvation-induced BHMT fragmentation.
HEK293 cells were cotransfected with GSTmodBHMTIRESGFP and either HAhULK1KDmyc or empty plasmid. Generation of fragment 1 is inhibited in cells
expression HA-hULK1KDmyc. Expression levels of GFP and hULK1 by western blotting
are shown in the bottom two panels.
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Although the specific activity of hULK1 did not change observably under
conditions that modulate autophagy, it was tested how disruption of hULK1 signaling
might affect autophagy as judged by BHMT fragmentation. One easy way to test this is
to use the kinase dead allele of hULK1 as a dominant interfering mutant. The
catalytically inactive HA-hULK1KD allele was co-expressed in HEK293 cells with the
BHMT reporter. After sufficient time to allow for expression, the cells were starved of
essential amino acids and serum for approximately 5 hours and extracted. Expression of
the catalytically inactive hULK1KD mutant consistently inhibited the generation of
BHMT fragment 1 in starved cells (Fig. 26). The dominant interfering effect of the
hULK1KD mutant on the assay suggests that ULK1 activity may be important for
autophagy.
There is a caveat to the use of a dominant-interfering allele. The effects of its
over-expression can occur through sequestration of either downstream effectors or
upstream regulatory proteins. Therefore, the dominant-interfering effect of hULK1KD on
the BHMT assay might not be specific for ULK1 alone. To address this caveat, a
strategy was implemented to decrease the expression of endogenous hULK1 by shRNA.
hULK1 mRNA levels were measured by qPCR to assess the effectiveness of silencing.
Two shRNAs were designed to target the three prime untranslated region (3′ UTR) of
hULK1. hULK1 sh3′12 and sh3′13 were the most effective in decreasing hULK1
message by approximately 90% and 80% respectively, as measured by qPCR (Fig. 27A).
Significantly, when transfected into HEK293 cells stable expressing GSTmodBHMT, each
of these hULK1 shRNAs inhibited the ability of BHMT to generate fragment 1 in amino
acid starvation conditions (Fig. 27B). Therefore, the effectiveness of hULK1 silencing
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Figure 27. shRNA-targeted depletion of hULK1 inhibits BHMT fragmentation. A.
Plasmid vectors with two different short hairpin inserts designed to target hULK1 mRNA
with siRNA were transfected twice in HEK293 cells stably expressing GSTmodBHMTmyc. Cells were treated to conditions of plus and minus amino acid media. qPCR
derived from cells expressing sh3′12 and sh3′13 shows significant knockdown of hULK1
mRNA to 90% and 80% of normal levels. Fold change is normalized to the
housekeeping gene, ribosomal subunit L32. This is typical of three independent
experiments. B. The BHMT assay is shown in HEK293 cells stabling expressing
GSTmodBHMT, with a non-specific shNC or the two shRNA hairpins targeting hULK1.
Generation of fragment 1 is inhibited in cells expressing the shULK1 3′12 and 3′13.
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on BHMT fragmentation provides further validation of the BHMT assay by targeting a
second autophagy specific gene, and also demonstrates with an endpoint assay that loss
of ULK1 alone is sufficient to inhibit autophagy.
3.1.2.3. Sensitivity of the BHMT assay to amino acids
In the development and validation of the BHMT assay, essential amino acid
starvation was the predominant condition used to induce macroautophagy in cell culture.
For starvation experiments, cells were maintained in culture media that lacked the twelve
essential amino acids but contained levels of glutamine and non-essential amino acids
normal for Dulbeccos’s modified essential media (DMEM). Except for the harsh nutrient
deprivation seen in ischemia, cells in a physiological setting are rarely forced to respond
to total starvation. However, circulating levels of amino acids are known to fluctuate:
being lower during fasting, in the perinatal period, and in times of poor nutrition; and
higher after the ingestion of a protein-rich meal. To test the response of the BHMT assay
to changes in levels of available essential amino acids, HEK293 cells expressing the
GSTmodBHMTIRESGFP reporter were incubated in culture with steadily decreasing
concentrations of the essential amino acids for six hours. Aliquots of cell extract
normalized for total protein were pulled down with glutathione agarose and prepared for
western blotting. Expression of GFP in WCE is shown on western blot as a
normalization control for the BHMT reporter (Fig. 28). It was expected that cells might
respond to changes in amino acid levels in a linear fashion and that this would be
reflected in increasing levels of BHMT fragment 1. However, only minor increases in
fragment 1 were seen in the range of amino acid concentrations between 100% and 20%
(Fig. 28A). The major increase in levels of BHMT fragment 1 was found only after the
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Figure 28. The BHMT assay is sensitive to physiologic levels of essential amino
acids. A. HEK293 cells expressing GSTmodBHMTIRESGFP were maintained in media
containing decreasing concentrations of 12 essential amino acids for 6 hours. Essential
amino acids in this experiment are listed in Table 4. Significant increase of BHMT
fragmentation is seen at levels less than 20%. B. The experiment describe in A was
repeated with the same conditions, except with titration points in the lower concentration
range. Concentration of essential amino acids must be less than 10% of normal DMEM
media to generate significant levels of BHMT fragmentation. All data shown is by
western blotting.
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concentration of essential amino acids had decreased by more than 80% of normal culture
conditions.
To further define the percentage of essential amino acids required for BHMT
fragmentation, HEK293 cells expressing the GSTmodBHMTIRESGFP reporter were tested
in conditions as before, but with a titration of essential amino acids more specific for the
ranges between 25% and 0%. Significant accumulation of BHMT fragment 1 was noted
only when essential amino acids fell below 10% (Fig. 28B). Expression of endogenous
LC3 at each of the titration points correlate well with the BHMT assay (Fig. 28B bottom
panel). On careful examination of the amino acid composition in DMEM, it was noted
that for cultured cells, amino acid levels in DMEM are up to 6 times greater than the
mean reference values for circulating amino acids in human plasma (Table 4). Therefore,
the window of response noted with the BHMT assay is likely within the physiological
range.
Some of the essential amino acids play a regulatory role in macroautophagy,
based on inhibition of intracellular proteolysis. In rat hepatocytes cultured from fetal,
suckling or weaned animals, Bloomaart et al. showed that intracellular levels of leucine,
isoleucine, lysine, phenylalanine and tyrosine increased in linear fashion in response to
extracellular levels of the same[73]. Amino acids within this group effectively decreased
proteolysis independent of hormonal levels. These experiments are difficult to perform
and are not necessarily specific for macroautophagy. The BHMT assay provides an
excellent means to test the effects of these and the other essential amino acids on the
induction of macroautophagy. To test the response of the BHMT assay to small changes
in the amino acid content of the media, cultured cells expressing GSTmodBHMTIRESGFP
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were deprived of select essential amino acids, while all other amino acids were
maintained at DMEM levels. Removal of either leucine or arginine alone was able to
moderately induce autophagy, while loss of isoleucine, valine, lysine, methionine,
phenylalanine or tryptophan caused only a mild increase in fragmentation (Fig. 29). The
removal of the three branched-chain amino acids as a group induced autophagy to levels
approaching the loss of all essential amino acids. No change was noted with the removal
of histidine or threonine (Fig. 29). Levels of LC3-I and LC3-II in the selectively-starved
extracts are shown by western blotting with antibody against endogenous LC3, showing
some response to the loss of individual amino acids, although with less sensitivity (Fig.
29). A caveat that must be considered in the interpretation of these results is that
although amino acid depletion was presumed, intracellular levels of amino acids were not
measured in this experiment. However, it has been shown that intracellular levels of free
branched chain amino acids decrease 90% with a 30 minute starvation period in HEK293
cells[74]. The data from this experiment suggest that full induction of macroautophagy
needs the additive effects of a small number of essential amino acids, particularly the
branched chain amino acids. The BHMT assay provides a degree of sensitivity to look at
small changes in macroautophagy not possible with the LC3 assay. Future experiments
using the BHMT assay will be able to determine what combination of essential amino
acids is sufficient to induce a full macroautophagy response.
3.1.2.4. The BHMT assay is functional in multiple cell lines
The BHMT assay depends on the activity of a lysosomal cathepsin to cleave
BHMT in a specific region of the protein to generate fragment 1. Multiple isoforms of
cathepsins are expressed to varying degrees in different cell types[75]. To determine if
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Figure 29. Sensitivity of the BHMT assay to single essential amino acids. HEK293
cells expressing GSTmodBHMTIRESGFP were incubated in specially prepared DMEM
media missing one or more essential amino acids for 6 hours. A. The BHMT assay was
tested for sensitivity to the loss of leucine, isoleucine, and valine individually and in
combination. B. The BHMT assay was tested for sensitivity to the loss of each of the
following essential amino acids: arginine, histidine, lysine, methionine, phenylalanine,
threonine, and tryptophan. A.and B. Western blot of GFP is shown as a control of
reporter expression in middle panel. Bottom panel is a western blot with antibody against
endogenous LC3 from same samples that were starved for individual amino acids.
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the BHMT assay was cell type specific or capable of functioning in a broad range of
cells, the GSTmodBHMTIRESGFP reporter was transiently transfected into an array of cells
from human, mouse, and rat (Fig. 30 and data not shown). Cells were starved of essential
amino acids and serum for 6 hours to induce autophagy, and the autophagy inhibitors
3MA and chloroquine were added to starved cells to validate that fragmentation was due
to macroautophagy. After treatment, cells were harvested and WCE and glutathione pulldowns were prepared for western blotting as before. The expression of GFP by western
blotting is shown as a control for transfection of the BHMT reporter (Fig. 30, second row
of panels from the top). Western blot with antibody against endogenous LC3 is included
for comparison and for validation of chloroquine dosage (Fig. 30, third row of panels
from top). Cancer cells were chosen with known mutations or deficiencies that have
been reported to effect macroautophagy. Immortal, but not transformed cells of mouse
origin, NIH3T3 and C2C12, were included to test the efficacy of the BHMT assay in a
non-tumor cell setting. Starvation induced BHMT fragmentation was observed in all of
the cell lines selected (Fig. 30 top panels). However, the degree of increase over basal
varied between cell lines. In each case, BHMT fragmentation was sensitive to 3MA and
chloroquine, indicating that accumulation of fragment it was due to an induction of
autophagy.
In summary, the BHMT assay is effective in transformed and non-transformed
cells of varying species. In the present form, its usefulness is limited to cells in culture
that can be transfected to a level of efficiency that allows sufficient expression of the
reporter. Fragmentation of BHMT accurately reflects the state of macroautophagy when
LC3-II levels alone are ambiguous.
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Figure 30. The BHMT assay is functional in multiple cell lines.
GSTmodBHMTIRESGFP was transiently transfected into T98G cells, MCF7 cells, H1299
cells, NIH3T3 cells, and C2C12 cells, which were tested under conditions known to
induce and inhibit macroautophagy for 6 hours. Levels of BHMT fragment 1 increased
in all cells with amino acid starvation and were inhibited by the autophagy inhibitors
10mM 3MA and 100µM chloroquine. Western blot of GFP is shown as a control for
transfection efficiency between conditions. Western blot for endogenous LC3 is shown
in the bottom panel for comparison.
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3.1.2.5. Example of the BHMT and LC3 assays with W7
Ultimately, the value of the BHMT assay lies in its ability to provide an endpoint
assessment of autophagy. Its use is not mutually exclusive with the LC3 assay which is
valued for its specificity in autophagosome formation, but complements the LC3 assay by
providing a read-out for the autolysosomal completion of autophagy. By using these two
assays together, one can gain insight into how a signaling pathway or experimental
condition affects the autophagic pathway. To demonstrate the value of using both an
endpoint assay and a midpoint assay to assess regulation of autophagy, examples in the
literature were sought for which the BHMT assay would bring clarification.
The role of Ca2+/calmodulin-dependent protein kinases in the regulation of
autophagy is ambiguous, at least in part due to the difficulties of measuring autophagy.
Early in the study of autophagy, one method loaded cells with [3H]raffinose and
measured the sedimentable [3H]raffinose to assess autophagic sequestration. With this
method, a study in 1992 reported that Ca2+/CamK-II activity inhibited autophagy, and
that autophagy was restored by the use of the calmodulin inhibitor W-7[76]. Later, the
same group published that W-7 had little or no effect on autophagy[77]. Various other
studies have suggested a role for the Ca2+/calmodulin dependent kinase, DeathAssociated Protein kinase (DAPk) and the Ca2+/calmodulin-dependent protein kinase,
elongation factor 2-kinase (EF2-Kinase) in the induction of autophagy[78, 79]. Methods
used to monitor autophagy in these studies included electron microscopy,
monodansylcadaverin (a marker of acidic vesicles), and LC3. The conflicts in the
conclusions of these studies and the ambiguities of the methods used to measure protein
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autophagy raise questions about the role of calcium and the Ca2+/calmodulin-dependent
kinases in autophagy.
Based on what has been reported, the calmodulin inhibitor W-7 could inhibit,
increase, or have no effect on autophagy. The BHMT assay in conjunction with the LC3
assay may be able to resolve whether Ca2+/calmodulin-dependent protein kinases are
necessary for the induction of autophagy. W-7 was chosen for this experiment because
its effect on EF2 can be easily assessed by western blotting. During amino acid
starvation, EF2 Kinase activity increases in a Ca2+/calmodulin dependent manner, and
increases the phosphorylation of EF2. The activity of EF2 Kinase and the effectiveness
of W-7 can be determined by the use of a phospho-specific antibody that recognizes EF2
(Fig. 31, bottom panel). To test the effects of W-7 on autophagy, W-7 was added to
HEK293 cells stably expressing either GST-BHMT or HA-LC3B reporter and
maintained in either complete media or starvation media for six hours. Normalized
aliquots of cell extracts were pulled down with either glutathione agarose of antibody to
HA and prepared for western blotting. In the extracts from HA-LC3B cells, LC3B-II
levels were the same between the control and W-7 treated cells (Fig. 31, second panel
from the top). Based on the LC3B assay alone, W-7 appears to have no effect on
autophagy. In contrast, W-7 strongly blocked the generation of BHMT fragment 1 in
starvation conditions (Fig. 31). The BHMT assay unambiguously demonstrates that W-7
inhibits autophagy. Together, the results show that the inhibitory effects of W-7 on
autophagy do not interfere with the early steps of LC3 processing and autophagosome
formation, but appear to be at a later step,
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Figure 31. Example of BHMT and LC3B assays with the calmodulin inhibitor W7.
HEK293 cells stably expressing either GSTmodBHMTmyc4.1 or HA-LC3B-myc were
treated for 6 hours in complete or starvation media, with the calmodulin inhibitor W7
(1µM). Cell extracts were pulled down with glutathione agarose or antibody to HA and
prepared for western blotting. A. Western blot in top panel shows BHMT fragmentation
upon amino acid starvation (lane 2) which is inhibited by W7 (lane 4). Western blot
showing LC3B is in bottom panel. LC3B-II levels increase with starvation in control and
W7-treated cells in a similar manner. B. Western blot of cell extracts from
GSTmodBHMTmyc4.1 and HA-LC3B-myc cell extracts with a phospho-specific antibody
that recognizes phosphorylated eEF2. Phosphorylation of EF2 is decreased in cells
treated with W7.
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In conclusion, the BHMT assay is a novel endpoint assay for macroautophagy,
whose specificity has been validated pharmacologically and by shRNA targeting known
autophagy genes. Its effectiveness has been demonstrated in multiple cell lines. The
BHMT assay alone, or in combination with the LC3 assay, provides a unique method to
study macroautophagy in cell culture.
3.2. The BHMT assay and higher order structure
3.2.1. The carboxy terminus of BHMT is important for generation of fragment 1
In the process of developing the BHMT assay, it was evident that the generation
of fragment 1 was lost with severe modification or truncation of the carboxy-terminus. It
was originally expected that a carboxy-terminal fragment might be generated from a
BHMT reporter, similar to the peptide of rat BHMT originally identified by mass
spectrometry. To help capture what was expected to be the carboxy-terminal fragment,
constructs were made that fused a GST epitope tag to the carboxy-terminus of BHMT,
with a variety of amino-terminus epitope tags. Two examples are shown (Fig. 32A). No
fragmentation of the HA-BHMT-GST reporter was observed in any of three experimental
conditions: incubation in complete media, starvation media, or complete media with
rapamycin (Fig. 32B, lanes 4-6). When the amino-terminal GST-tagged BHMT reporter
was fused to a second carboxy-terminal GST tag to create a GST-BHMT-GST reporter,
the presence of a carboxy-terminal GST was detrimental to generation of the observed
fragment 1, even though the fusion protein expressed at approximately the same level as
GST-BHMT-myc (Fig. 32, lanes7-9). The data led to a hypothesis that a functional
carboxy-terminus was important for generation of GST-BHMT fragment 1.
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Figure 32. Carboxy-terminus of BHMT is important for generation of fragment 1.
A. Schematic of three early BHMT reporters: GST-BHMT-myc, HA-BHMT-GST and
GST-BHMT-GST. B. Each reporter was expressed in HEK293 cells and incubated in
complete media, media starved of essential amino acids and serum, or media with 40nM
rapamycin for 5 hours. Western blot of glutathione agarose pull-downs shows that
fragment 1 only accumulated in cells transfected with the GST-BHMT-myc reporter
(lanes 1-3). Cells transfected with a GST epitope tag at the carboxy-terminus did not
generate observable fragmentation with either amino acid and serum starvation or with
rapamycin (lanes 4-9).
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The original GST-BHMTwt is in fact a 9 amino acid truncation mutant that could
correctly be designated ∆C9. It seemed likely that if the carboxy-terminus was
important, restoring the carboxy terminus to full length might make BHMT a better
reporter. Conversely, it was predicted that a more severe carboxy-terminal truncation of
BHMT might make a poorer reporter. To test this, truncated GST-BHMT∆C142 was made
that deleted 142 amino acids from the carboxy-terminus. This construct did not produce
fragments with amino acid starvation and expressed poorly, most likely due to instability
(data not shown). Separately, a GST-BHMT full length reporter was made that restored
the nine carboxy-terminal amino acids that had been truncated in the original reporter.
The full length reporter produced fragments 1 and 2 in a manner identical to the original
reporter, suggesting that the moderate ∆C9 truncation of the original reporter was
tolerated without adversely affecting the readout (Fig. 33). For the remainder of this
document, the term full length, original, or GST-BHMTwt will refer to the original ∆C9
construct.
The above data raised questions about the nature of the carboxy-terminal and its
role in the generation of GST-BHMT fragment 1. How much of the carboxy-terminus
could be truncated without losing the ability to generate fragment 1? To answer this
question, a number of progressive carboxy-terminus truncation mutants of BHMT were
produced. Each mutant was compared to the original GST-BHMTwt construct in the
ability to generate fragment 1 when expressed in cells starved of essential amino acids.
The autophagy inhibitors 3MA and bafilomycin A1 were tested with each mutant to
validate that any fragment generated from the truncation mutants was due to
macroautophagy. GST-BHMT∆C24 generated fragment 1 in a manner identical to the
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Figure 33. BHMT assay with full length GST-BHMT. HEK293 cells were
transfected with either the original BHMT reporter (∆C9) or with a carboxy-terminal
restored full length GST-BHMT. After starvation of essential amino acids and serum,
cell extracts were pulled down with glutathione and prepared for western blotting. Both
BHMT reporters generated fragment 1 upon amino acid starvation in a similar manner.
Minor truncation of original reporter is not detrimental to fragment formation.
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Figure 34. The BHMT assay with truncation mutants: ∆C24 and ∆C51. Truncation
mutants of BHMT were created with a PCR and sub-cloning strategy to remove either 24
or 51 amino acids from the carboxy-terminus. BHMT and the truncation mutants were
transfected into HEK293 cells and treated with starvation media to induce autophagy or
starvation media with the autophagy inhibitors 10mM 3MA or 100nM bafilomycin A1.
Compared to control BHMT, truncation of 24 amino acids from the carboxy-terminus of
BHMT does not prevent generation of fragment 1 with starvation (lanes 3-6), but
fragment 1 does not accumulate in starved cells expressing ∆C51 (lanes 7-9).
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control (Fig. 34, lanes 3-6). However, deletion of an additional 27 amino acids in GSTBHMT∆C51 created a truncation mutant that failed to generate fragment 1 under amino
acid starvation conditions, in spite of the fact that its expression and stability was equal to
either control or ∆C24 (Fig. 34, lanes 7-9). Further truncations (∆C92 and ∆C115)
produced proteins that expressed poorly and were likely unstable and degraded (data not
shown). The data confirm that the carboxy terminus of BHMT is important in the
generation of fragment 1.
Rat BHMT exists as a homo-tetramer. Each subunit is an (α/β)8 barrel with an
extended dimerization arm, a hook region, and a linker region leading to a long alphahelix at the carboxy-terminus (Fig. 35). The carboxy-terminus of BHMT is important for
the interaction between subunits, and oligomerization is essential for enzymatic activity
of the endogenous enzyme[80]. The two subunits that form a dimer interact with each
other through both the dimerization arm, which extends from one subunit and imbeds in
the structure of its dimer partner, and the hook, a region of intertwining complementary
strands between the two subunits. The long carboxy-terminal alpha-helix of each subunit
interacts with a subunit of the second dimer pair, linking the two dimers to form the
complete tetramer. It is likely that truncation of the BHMT carboxy-terminus, or fusion
of bulky epitope tags to the carboxy end, might disrupt the ability of the subunits to
interact.
This raised a question about whether it was catalytic activity or oligomerization of
BHMT that might be important to be recognized as a substrate for the autophagy. If
activity was important, then a catalytically inactive BHMT mutant should not generate
fragment 1 in starvation conditions. BHMT is a metabolic enzyme that transfers one
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Figure 35. BHMT structure. BHMT structure is shown with interaction of 3 of the 4
subunits. BHMT is a dimer of dimers. Two subunits interact with each other through the
dimerization arm (as labeled) and hook regions (shown in enlarged box). The carboxyterminal alpha-helix of each subunit then interacts with a subunit of the other dimer to
form a tetramer. Oligomerization of subunits is required for an active enzyme. The
truncations that affect the original BHMT reporter (∆C9) and the ∆C24 mutant are in the
carboxy-terminal alpha helix as labeled on the dark blue subunit. The ∆C51 truncation
and the W352A mutation are in the hook region of the dimerization arm as labeled. The
region of the disordered L2 loop that is likely cleaved to generate fragment 1 is labeled in
red.
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methyl group from betaine to homocysteine to generate methionine. It contains a Zn2+
ion, coordinated by three cysteine residues (C217, C299 and C300) which are necessary
for its activity[81]. To test whether catalytic activity of BHMT effected its ability to be
processed by macroautophagy, a mutation reported to kill catalytic activity, C217A[81],
was introduced by site directed mutagenesis. HEK293 cells transiently transfected with
GST-BHMT-myc and the mutant GST-BHMTC217Amyc were incubated for 4 hours in
complete media, starvation media, or starvation media with the autophagy inhibitor 3MA.
After the cells were harvested, glutathione pull downs of cell extracts were processed for
western blotting. Both control and GST-BHMTC217A reporters generated similar levels of
starvation induced fragment 1 that was inhibited by the autophagy inhibitor 3MA (Fig.
36). These data suggest that catalytic activity of BHMT does not play a role in its ability
to generate fragment 1 in starved cells.
It appeared there was correlation between the ability to generate fraction 1 and the
ability to form multimers. The results obtained with the ∆C51 truncation of BHMT
initiated a search for a single mutation that would affect oligomerization without
truncating large regions of the protein. A study by Szegedi and Garrow found that
mutation of a tryptophan in the dimerization arm of BHMT, W352A, impaired the
stability of subunit dimerization[80]. The W352A point mutation was made in the
original GST-BHMT reporter so that oligomerization would be disrupted. The W352A
mutant was expressed at levels identical to control GST-BHMT, and cells were cultured
under the same conditions described in Figure 34. Like the ∆C51 truncation mutant, the
W352A point mutant did not generate fragment 1 under starvation conditions (Fig. 37).
These data show that the predicted ability of BHMT to oligomerize correlates with the
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Figure 36. Catalytic activity of BHMT is not required for fragmentation. The
C217A mutation in BHMT is known to kill enzymatic activity, and was introduced in
BHMT by site directed mutagenesis. HEK293 cells were transfected with either control
BHMT or BHMTC217A and treated with starvation media to induce autophagy or
starvation media with 10mM 3MA to inhibit autophagy for 6 hours. Cells were extracted
and prepared for western blotting as previously described. The control and C217A
mutant BHMTs both generated fragment 1 in starvation conditions that was inhibited by
3MA.
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Figure 37. The BHMTW352A point mutant in the BHMT assay. A mutation, W352A,
was introduced into BHMT by site directed mutagenesis that was reported to prevent
oligomerization and activity. HEK293 cells were transfected with either control or GSTBHMTW352A mutant and treated to conditions identical to the previous experiment with
the truncation mutants (Fig. 34). Cells were extracted and prepared for western blotting
as previously described. Fragment 1 did not accumulate in the BHMTW352A mutant
extracted from amino acid starved cells.
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ability to generate intralysosomal fragment 1.
It was necessary to determine if the GST-tagged BHMT mutants could or could
not oligomerize as predicted. To do so, the original BHMT cDNA was sub-cloned
downstream of a HA epitope tag and co-expressed in HEK293 cells with each of the
GST-tagged BHMT constructs. To demonstrate interaction, glutathione beads were
added to cell extracts to pull out the GST-BHMT mutants, and the beads were gently
washed so as not to disrupt interacting proteins. The purified GST-BHMT complex was
then run on SDS-PAGE, transferred to PVDF membrane, and probed with an antibody to
the HA epitope tag. Expression levels of the GST and HA tagged proteins show that all
expressed at equivalent levels (Fig. 38, bottom two panels). As expected, the two
mutants that were able to generate fragment 1, GST-BHMTwt and GST-BHMT∆C24, were
able to pull down HA-BHMTwt, indicating multimerization (Fig. 38, lanes 1 and 2). In
contrast, the two mutants that disrupted the hook region of the dimerization arm by either
truncation (GST-BHMT∆C51) or mutation (GST-BHMTW352A) were either unable to pull
down HA-BHMTwt in the case of the former, or pulled down very small amounts of HABHMTwt in the case of GST-BHMTW352A (Fig. 38, lanes 3 and 4). The ability of GSTBHMTW352A to pull down a small amount of HA-BHMTwt is consistent with the
published report that the W352A mutant is able to form dimers, but in complexes that are
less stable than wild-type BHMT.
The data above demonstrate that the ability of the BHMT mutants to assemble
inversely correlates with the ability to generate fragment 1 with starvation. How does
oligomerization affect the ability of BHMT to generate fraction 1 with starvation? Two
possibilities are likely: 1) Quaternary structure of BHMT is required for the lysosomal
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Figure 38. The carboxy-terminal of BHMT is important for oligomerization.
HEK293 cells were co-transfected with HA-BHMT and each of the GST-tagged BHMT
mutants: wt, ∆C24, ∆C51, and W352A. After allowing time for expression, cells were
harvested and cell extracts were processed for glutathione pull-down and western blot.
Membrane was probed with antibody against HA to demonstrate interaction between
subunits. Interacting subunits were demonstrated between HA-BHMT and GST-BHMT
(lane 1) and HA-BHMT and GST-∆C24 (lane 2). No interaction was found between HABHMT and GST-∆C51 (lane 3). A small amount of GST-W352A associated with HABHMT, consistent with the ability of this mutant to form unstable dimers (lane 4). Each
mutant expressed to equivalent levels as shown in the bottom two panels.
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cathepsin to bind, recognize and cut the L2 region to generate fragment 1, or 2)
Quaternary structure of BHMT is important to be recognized by the autophagic
machinery and for import into autophagosomes.
3.2.2. BHMT∆C51 is in autophagosomes
To distinguish between these two possibilities, an assay was designed that would
test for the presence of BHMT within autolysosomes/autophagosomes. If both
BHMTwt and BHMT∆C51 trafficked inside of autolysosomes, then the first explanation
would be favored. However, if BHMT∆C51 was not found in autolysosomes, then the data
would suggest that quaternary structure was important for cargo selection. The
accomplishment of this aim would require two steps. First, a population of intact
autophagosomes would be fractionated from cultured cells expressing either GSTBHMTwt or GST-BHMT∆C51. Second, autophagosome/autolysosome associating proteins
such as BHMT would be digested with a protease, with or without a membranedisrupting detergent. This protection assay would determine if ∆C51 was enclosed
within a membrane compartment (Fig. 40A). Resistance to proteolytic digestion in the
absence of a detergent would indicate the target protein is enclosed and protected in a
membrane structure.
The isolation and enrichment of intact autolysosomes was challenging due to their
transient nature, low abundance, and high rate of turnover within the cell. To increase the
abundance of autophagosomes and autolysosomes, cells were starved of essential amino
acids for 12 hours with protease inhibitors leupeptin and E64d to slow lysosomal
proteolysis and turnover of the autolysosomal population. GST-BHMT and HA-LC3Bexpressing HEK293 cells treated in this manner were collected, disrupted by dounce
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Figure 39. BHMT on a Sucrose gradient. A. Schematic of the sucrose gradient
protocol. Transfected HEK293 cells are extracted and processed by differential
centrifugation to isolate the light membrane fraction (LMF). The LMF is then loaded on
a discontinuous sucrose gradient for ultra-centrifugation. Fractions are collected by
upward displacement, numbered 1 at the top to 11 at the bottom of the gradient.
Fractions are then analyzed by either glutathione pull-down, immunoprecipitation, or
TCA precipitation. B. BHMT fragment 1 co-fractionates with the lysosomal marker
LAMP1 in fractions 6 and 8. LC3B peaks in fraction 5.
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Figure 40. Protection assay. A. Schematic of the protection assay protocol. Briefly,
sucrose gradient fractions are prepared and incubated for 5 minutes with trypsin to digest
outer membrane proteins, and with trypsin and Triton X-100 to digest protein both inside
and outside of the enclosed membrane space. B. Validation of conditions for protection
assay. Left panel shows total trypsin digest of BHMT in cytosolic fraction. Pooled
fractions 5 and 6 are digested with trypsin, with and without the detergent Triton X-100.
Full length BHMT, fragment 1 and LC3B-II that remain in the presence of trypsin are
within membrane-enclosed vesicles.
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homogenization and gently centrifuged to remove intact nuclei and large membrane
remnants. The post-nuclear supernatant (PNS) was collected and centrifuged at high
speed to pellet the light membrane fraction (LMF), consisting of autophagosomes,
autolysosomes, lysosomes, mitochondria and other small organelles or microsomes. The
LMF pellet was washed to remove excess cytoplasmic protein, gently resuspended in the
homogenization buffer, and loaded on a prepared discontinuous sucrose gradient. After 2
hours of ultra-centrifugation at 2º C to separate the subcellular organelles by density, 1 ml
fractions were collected by upward displacement. The first fraction collected from the
top of the gradient was labeled fraction 1 and the densest fraction from the bottom was
labeled fraction 11 (Fig. 39A).
Aliquots of fractions from the sucrose gradient were then analyzed for the
presence of autolysosomes. Figure 39B is representative of fractions 5 through 8 from
cells starved of essential amino acids. LC3B-II, a marker of both autophagosomes and
newly fused autolysosomes, accumulated only in cells starved for essential amino acids,
with the highest levels in fraction 5. GST-BHMT fragment 1 also accumulated as
expected in fractions collected from amino acid starved cells (Fig. 39B). BHMT
fragmentation was first observed in fraction 5, and peaked in fractions 6 and 8. A
western blot for an endogenous lysosomal membrane protein, lysosome-associated
membrane protein 1 (LAMP1), demonstrates that BHMT fragment 1 and LAMP1 cofractionate and peak in identical fractions, validating that BHMT fragmentation is
lysosomal.
Although fragment 1 of GSTmodBHMTwt co-fractionated with autolysosomes, full
length BHMT could be found in every fraction of the gradient. This could be due to the

145

abundance of an over-expressed protein that is known to oligomerize and associate with
the cytoskeleton. GSTmodBHMTwt elutes from a gel filtration column over a broad range
of molecular weight fractions, suggesting the propensity of this protein to form higher
order complexes (data not shown). Having established that autophagosomes and
autolysosomes could be tracked on a sucrose gradient, LC3B-II marked fractions
enriched in these vesicles were pooled to test if GSTmodBHMTwt was sequestered within
vesicles. The post-LMF supernatant, which contained GSTmodBHMTwt but was expected
to be devoid of vesicular structures, was used as a negative control. In the post-LMF
supernatant, trypsin alone was able to fully degrade full-length GSTmodBHMTwt (Fig.
40B, left panel). At the end of the 5 minute trypsin digest, all that remained was a
fragment approximately the size of GST. Aliquots of pooled fractions 5 and 6 were
digested with trypsin alone, or with trypsin plus 0.2% Triton X-100. After the reaction
was stopped with soybean trypsin inhibitor (STI), GSTmodBHMTwt and HA-LC3B were
pulled down with glutathione or HA-antibody attached to Sepharose beads, and run on
SDS-PAGE. Approximately half of LC3B-II and full length BHMT, and most of BHMT
fragment 1 remained after the trypsin digest (Fig. 40B, right panel). However, LC3B-II,
full length BHMT, and BHMT fragment 1 were completely degraded when identical
aliquots were digested with trypsin 0.2% TritonX-100 under the same conditions (Fig.
40B, right panel). This assay demonstrates that in fractions 5 and 6, but not in the postLMF supernatant, some of BHMT and fragment 1 and approximately half of LC3B-II
were within intact vesicles, likely autolysosomes and autophagosomes. It is likely that
not all vesicles were intact, as a portion of fragment 1 was digested with trypsin alone.
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With evidence that the protection assay was functional, sucrose gradients were
prepared from the LMF of cells expressing GSTmodBHMTwt or GST-BHMT∆C51. To
enrich the LMF with autophagosomes, the HEK293 cells were starved of essential amino
acids and serum for 12 hours with the autophagy inhibitor chloroquine (100µM).
Prolonged treatment with chloroquine was used to inhibit fusion of autophagosomes and
lysosomes, causing an accumulation of autophagosomes loaded with undegraded cargo.
After differential centrifugation, the LMF was loaded on discontinuous sucrose gradients
and fractions were collected as before. Levels of LC3-II peaked in fractions 5 and 6 and
were more broadly distributed throughout the gradient, indicating that the chloroquineinduced block of fusion had created a more heterogeneous population of autophagosomes
(Fig. 41A). Aliquots of fractions from each gradient, one from cells expressing
GSTmodBHMTwt and one from cells expressing GST-BHMT∆C51, were digested with
trypsin as before. Both GSTmodBHMTwt and GST-BHMT∆C51 were protected from the
action of trypsin (Fig. 41B) and levels of sequestered protein correlated well with LC3-II.
The data show that 1) BHMT∆C51, like GSTmodBHMTwt, is sequestered into
autophagosomes and 2) the carboxy terminus and/or quaternary structure of BHMT is
important for lysosomal cathepsin cleavage to generate fragment 1, but may not play a
role in autophagosomal delivery.
3.2.3. BHMT∆C51 and 3MA
The above data show that BHMT∆C51 is within autophagosomes and by inference,
likely within autolysosomes. A second experiment was designed to validate
the actual degradation of ∆C51 in autolysosomes. The above data showed that the
carboxy-terminus is important for lysosomal cleavage of “modified” GSTmodBHMTwt in
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Figure 41. Protection assay with GST-BHMT and GST-BHMT∆C51. A. HEK293
cells expressing GST-BHMT or GST-BHMT∆C51 were incubated for 6 hours in media
from which essential amino acids and serum had been removed and with 100µM
chloroquine to enrich fractions in autophagosomes. Sucrose gradient fractions were
prepared as described. A. Equal aliquots of each gradient fraction were precipitated with
TCA and prepared for western blotting with antibody against endogenous LC3. With
chloroquine, LC3-II is found in multiple lower fractions. LAMP1 is found only in
fractions 5 and 6. B. Protection assay was performed in conditions described on each
fraction from GST-BHMT and GST-BHMT∆C51 expressing cells. BHMT and BHMT∆C51
are both protected from the protease action of trypsin in fractions corresponding well
with LC3, suggesting that both BHMT and BHMT∆C51 are enclosed within
autophagosomes.
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the L2 loop, but the “no thrombin” GST∆TBHMT has a lysosomal cleavage site outside
BHMT that may not be dependent on the carboxy-terminus. The GST∆TBHMT reporter
generated two fragments, fragment 1 and fragment 2′ (Fig. 18). Unlike the original
reporter, both fragments of GST∆TBHMT were invariantly lysosomal. Quaternary
structure might not be important for cleavage of GST in this linker region to generate
fragment 2′. If this prediction was correct, then fusion of GST∆T to BHMT∆C51 should
make a ∆C51 reporter capable of generating fragment 2′ in a manner similar to
GST∆TBHMT.
To test this, ∆C51 was sub-cloned into the GST∆T background to match
GST∆TBHMT. The GST∆T versions of BHMT and ∆C51 were expressed in HEK293
cells and tested under conditions of amino acid starvation to induce autophagy, and
treated with 3MA and wortmannin to inhibit autophagy as before. Both fragments 1 and
2′ in the control GST∆TBHMT were generated be amino acid starvation and were
completely sensitive to 3MA and wortmannin (Fig. 42, left panel). The accumulation of
fragment 2′ also increased in the ∆C51 mutant with amino acid starvation, consistent with
an autophagic response. However, while completely sensitive to wortmannin, ∆C51
fragment 2′ was partially resistant to the effects of 3MA (Fig. 42, right panel). This was
surprising because it suggested that there was a difference between the processing of
∆C51 and full length BHMT.
The sucrose gradient provides a level of resolution between light and dense
autolysosomes that might be useful in determining how ∆C51 differs from BHMT.
HEK293 cells expressing GST∆TBHMT or GST∆TBHMT∆C51 were starved of essential
amino acids and serum to induce macroautophagy. The LMF fractions from cells
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Figure 42. GST∆TBHMT∆C51 generates fragment 2′ under starvation conditions.
The ∆C51 mutant was sub-cloned into the BHMT∆T background to see if it would
generate fragment 2′. HEK293 cells expressing either GST∆TBHMT or GST∆TBHMT∆C51
were starved of essential amino acids and serum to induce autophagy and treated with
starvation media with 10mM 3MA or 100nM wortmannin to inhibit autophagy. Cell
extracts were prepared for western blot as previously described. In control BHMT cells,
fragments 1 and 2′ accumulate under starvation conditions and are inhibited by 3MA and
wortmannin (left panel). In starvation conditions, GST∆TBHMT∆C51 generated increased
levels of fragment 2′. GST∆TBHMT∆C51 fragment 2′ levels were inhibited by
wortmannin, but were 50% resistant to 3MA (right panel).
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Figure 43. GST∆TBHMT∆C51 fragment 2′ co-fractionates with LAMP1 in sucrose
gradient fractions. HEK293 cells expressing cells expressing GST∆TBHMT or
GST∆TBHMT∆C51 were starved of essential amino acids and serum to induce autophagy
or GST∆TBHMT∆C51 were starved of essential amino acids and serum to induce
autophagy. After 6 hours, the LMF of cell extracts were prepared and separated by
density on a sucrose gradient as described. Glutathione extracts and WCE were prepared
for western blotting as described. BHMT fragments 1 and 2′, ∆C51 fragment 2′, and
LAMP1 cofractionate and peak in fractions 6 and 8. Lower right panel shows
distribution of LAMP1-marked vesicles in gradients prepared from 3MA-treated
HEK293 cells. Note that in fractions from 3MA-treated cells, distribution of LAMP1
shifts to the lighter fraction.
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expressing each BHMT mutant were isolated by differential centrifugation and loaded on
sucrose gradients as before. Glutathione pulldowns from gradient fractions were
analyzed for GST-tagged proteins and peptides by western blotting. Under amino acid
starvation conditions, GST∆T BHMT generated fragment 1 and 2′ as expected. GST∆T
BHMT∆C51 generated fragment 2′ that co-fractionated perfectly with BHMT fragments 1
and 2′ and with LAMP1 (Fig. 43). This was consistent with the presence of
autolysosomes in fractions 6 and 8.
To determine the effect that 3MA might have on the two autolysosome fractions,
sucrose gradient fractions were prepared from the LMF of HEK293 cells which were
starved of essential amino acids and serum as before, but in the presence of 10mM 3MA.
TCA precipitation and western blot analysis of the 3MA-treated fraction, prepared as
before, showed decreased LAMP1 staining in the denser fraction 8 (Fig. 43, lower right
panel). This is consistent with previous reports that 3MA changes the distribution of
lysosome-type vesicles on density gradients[82]. It suggests that 3MA may prevent the
formation of denser autolysosomes or other amphisomes.
The resolution provided by the sucrose gradients was used to examine the
fractionation pattern of GST∆TBHMT or GST∆TBHMT∆C51 in the presence or absence of
3MA. HEK293 cells expressing either GST∆TBHMT or GST∆TBHMT∆C51 were starved
of essential amino acids and serum as before, with or without 10mM 3MA. After
extraction, the LMFs from each treatment and BHMT reporter were isolated by
differential centrifugation and loaded on discontinuous sucrose gradients to resolve
autolysosomes by density as before. GST∆TBHMT fragments 1 and 2′ were observed in
fractions 5-10, peaking in fraction 9. Both fragments were completely sensitive to the
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effects of 3MA (Fig. 44). As before, GST∆TBHMT∆C51 generated fragment 2′ which cofractionated with the two fragments of GST∆TBHMT. However, although fragment 2′
was as sensitive to 3MA in fractions 7 to 10 as control, it was completely resistant in
fractions 5 and 6 (Fig. 44). Western blot analysis with antibody against endogenous LC3
showed that LC3-II co-fractionated with BHMT fragments, and like GST∆TBHMT∆C51
was resistant to 3MA only in the middle fractions (Fig. 44). In this experiment, 3MA
effectively prevented fragmentation of GST∆TBHMT in all fractions, but prevented
fragmentation of GST∆TBHMT∆C51 only in the denser fractions. What types of vesicles
are in these fractions of different densities?
The LAMP1 data show that 3MA affects the distribution of LAMP1 in the dense
fraction of the sucrose gradient. LAMP1 is a membrane-spanning protein found
predominantly on lysosomes, but can also be found on some autolysosomes,
amphisomes, and late endosomes. To further characterize the nature of the vesicles in the
light and dense fractions of the sucrose gradient, a lysosomal disrupting agent, glycyl-Lphenylalanine 2-naphthylamide (GPN) was used. GPN is hydrolyzed by the lysosomal
cathepsin C, producing an intralysosomal accumulation of product that osmotically
ruptures the lysosomal membrane. GPN is most effective in small mature lysosomes, and
is less effective in larger digestive bodies such as autolysosomes and amphisomes where
it must compete with other substrates. It does not disrupt intact autophagosomes[83].
Two sets of HEK293 cells, starved of essential amino acids and serum, were collected
and gently disrupted by dounce homogenization. One set was incubated for 6 minutes at
37º with the lysosome disrupter GPN, after which both sets were processed as described
to separate the LMFs by density on matched sucrose gradients. Fractions 6 -9 were
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Figure 44. GST∆TBHMT∆C51 fragment 2′ is resistant to 10mM 3MA in the lighter
sucrose gradient fractions. HEK293 cells expressing GST∆TBHMT or
GST∆TBHMT∆C51 were starved of essential amino acids and serum to induce autophagy
or were treated under starvation media with 10mM 3MA. The LMF of each sample was
prepared and fractionated by density on a sucrose gradient. Western blots of glutathione
pull-downs and TCA precipitation samples were prepared as before. Top panel shows
fractions from cells expressing GST∆TBHMT. Fragments 1 and 2′ show good sensitivity
to 3MA. Middle panel shows fractions from cells expressing GST∆TBHMT∆C51.
Fragment 2′ is sensitive to 3MA in the denser fractions, 7-10, but is completely resistant
to 3MA in fractions 5 and 6. Bottom panel: Like ∆C51, endogenous LC3 is also
resistant to 3MA in fractions 5 and6, and sensitive to 3MA in fractions 7-9 (no LC3 is
seen in fraction 10).
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Figure 45. Characterization of sucrose gradient fractions with GPN. HEK293 cells
were extracted in PBS and gently dounced to rupture the plasma membrane. One set was
exposed to the lysosome disrupter GPN. Cells were then processed as before to obtain
the LMF, which was processed on prepared sucrose gradients. Gradient fractions were
precipitated with TCA and prepared for western blotting with an antibody against
LAMP1. In the GPN-treated samples, LAMP1 was decreased in fraction 6 compared to
control. In fraction 8, LAMP1 levels were equivalent between the GPN-treated and
control samples. GPN is a more effective inhibitor of cathepsin C in mature lysosomes,
which predicts that fraction 6 contains mature lysosomes and that fraction 8 is
predominantly amphisomes and autolysosomes.
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probed for LAMP1. LAMP1 in the denser fraction was not affected by GPN, while
levels of LAMP1 in fraction 6 were reduced, suggesting that in HEK293 cells, mature
lysosomes are in the lighter fractions (Fig. 45). The combined data of the previous
experiments suggest answers to the following questions:
What type of vesicles are in the light and dense sucrose gradient fractions (See
Table 5)? 1) Mature lysosomes are in fractions 5/6 and are not in fractions 8/9. This is
supported by the GPN data and LAMP1 antibody staining by western blotting. It is also
supported by previous data with chloroquine, which prevents lysosomal fusion. With
chloroquine, LAMP1 is only seen in the lighter fractions. 2) Autophagosomes are likely
in fractions 5/6. This is supported by the LC3 data and by previous gradient data of
amino acid starved cells with the HA-LC3B reporter. 3) Autolysosomes are in fractions
5/6. These fractions are marked by both LAMP1 and LC3-II. BHMT fragment 1 and 2′
demonstrates the presence of functional autolysosomes. 4) Autolysosomes are in
fractions 8/9. This is supported by the western blot data of LAMP1 and LC3-II. BHMT
fragment 1 and 2′ in the dense fractions supports the presence of functional
autolysosomes. 5) Autophagosomes may be in fraction 8/9. The denser fractions are
more likely to be digestive organelles, however the data cannot rule out denser
autophagosomes. The chloroquine data suggest that dense autophagosomes can form if
lysosomal fusion is inhibited.
What is 3MA doing? 1) 3MA quantitatively decreases LAMP1, LC3-II and
BHMT fragmentation of either mutant in dense fractions. Therefore, 3MA likely inhibits
the formation of dense autolysosomes and perhaps dense autophagosomes. 2) 3MA
inhibits the generation of GST∆TBHMT fragment 1 and 2′ in fractions 5/6. 3) 3MA does
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not inhibit fragmentation of GST∆TBHMT∆C51 in fractions 5/6. 4) LC3-II levels are not
affected by 3MA in fractions 5/6. This raises the following question:
Does the 3MA-resistant generation of GST∆TBHMT∆C51 fragment 2′ occur in
autolysosomes or lysosomes? 1) The protection assay data validate that
GST∆TBHMT∆C51 is normally sequestered in autophagosomes, however it does not rule
out a compensatory mechanism of lysosomal import of the ∆C51 mutant by 3MA or
microautophagy. 2) The co-fractionation of LAMP1 and LC3-II in the presence of 3MA
supports a hypothesis of autolysosomal degradation, but it too does not rule out a
lysosomal-only mechanism.
The persistence of LC3-II in fractions 5/6 is surprising, because 3MA is thought
to block autophagosome formation by inhibiting the Class III PI 3-kinase, Vps34.
However, the sucrose data suggest that LC3-II vesicles are formed in the presence of
3MA To determine what affect 3MA might have on the production and turnover of
LC3, HEK293 cells stably expressing HA-LC3B-myc were used to test the effects of
3MA on LC3B-II flux in either complete or starvation media. 3MA treatment caused a
slight increase in levels of LC3B-II compared to control cells, which suggested that 3MA
was not inhibiting LC3B-II formation, but was likely inhibiting LC3B-II flux, similar to
the effects of leupeptin and pepstatin A.
If 3MA treatment was in fact revealing LC3B-II flux, than inhibition of the
lysosome in 3MA-treated cells should cause an accumulation of LC3B-II. To test this,
the HEK293 cells stably expressing HA-LC3B-myc were treated with or without 3MA as
before, but with the additional treatment of 25µM chloroquine. The accumulation of
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Figure 46. Lysosomal flux of LC3B-II in cells treated with 3MA. HEK293 cells
stably expressing HA-LC3B-myc were treated to complete or starvation media for 4
hours, with and without 10mM 3MA, extracted and prepared for western blotting as
before. LC3B-II levels in 3MA treated cells were slightly increased compared to control
cells (lanes 3 and 4, compared to lanes 1 and 2). A second set of HA-LC3B-myc stable
cells were treated under the same condition, except with added 25µM chloroquine for a
stronger inhibition of lysosomal turnover. Surprisingly, LC3B-II levels in the 3MA and
chloroquine-treated cells were increased almost to the level of the control cells (lanes 7
and 8, compared to 5 and 6). This suggests that LC3B-II continues to be made and
degraded in the presence of 3MA.
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LC3B-II levels in cells treated with 3MA plus chloroquine was significant, reaching
levels approximately half of that found in control cells (Fig. 46, lanes 7 and 8, compared
to lanes 5 an 6). This demonstrates that in the presence of 3MA, LC3B-II continues to be
made and that it is degraded in the lysosome. The surprising conclusion is that LC3B-II,
and presumably LC3B-II decorated vesicles, are made and degraded by the lysosome in
the presence of 3MA. Quantitatively, LC3B-II turnover in the presence of 3MA is
decreased, but is still significant compared to control.
These data support the hypothesis that the fragmentation of GST∆TBHMT∆C51
occurs in autolysosomes in the presence of 3MA, even though GST∆TBHMT degradation
has been inhibited. This result is surprising. The autophagy field defines
macroautophagy almost exclusively in terms of sensitivity to 3MA. The data suggest that
there is a 3MA sensitive and a 3MA insensitive macroautophagy. GST-BHMT is
processed by the former and ∆C51 by the latter. This is important because 3MA inhibits
a signaling molecule, VPS34. It suggests that production of new PI3P is important for the
autophagic machinery to recognize BHMT, but is either not necessary or lower levels are
necessary for macroautophagy-related degradation of ∆C51. The ability of the BHMT
mutants to form higher order structure suggests how these two types of macroautophagy
are different. (See discussion).
3.3. Regulation of autophagy: S6 Kinase and mTOR
mTOR is well known for its role in responding to changes in nutrients, mitogens,
and ATP to regulate cell growth. In times of stress such as amino acid starvation, mTOR
signaling is down-regulated and its downstream effectors p70S6K and 4E-BP1 are
hypophosphorylated. This results in reduced translation and increased autophagy. Other
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stressors such as hypoxia are well known inhibitors of the mTOR pathway and not
surprisingly, there are suggestions in the literature that hypoxia and ischemia induce
autophagy. Hypoxia-ischemia creates a severe energy crisis in cells that are deprived of
nutrients and the oxygen necessary for energy production, and generally results in cell
death. In a physiological context, normal cells exposed to conditions of ischemia after
arterial occlusion normally die by apoptosis, although in some models, the mechanism of
cell death is proposed to be through excessive autophagy. Evidence in support of the
latter includes TEM showing extensive vacuolization and decreased LC3-I levels in
damaged tissue compared to control[66]. The question that arises from this data is
whether these cells would have sufficient ATP to activate and sustain autophagy under
ischemic conditions. Multiple steps of the autophagic process require ATP and even
small changes of ATP levels have been shown to slow autophagic proteolysis[84]. It is
likely that decreased ATP negatively affects the ATP-dependent steps of LC3
conjugation, lysosome acidification, and vesicle fusion.
Experimental conditions of hypoxia-ischemia can be tested in cell culture and the
BHMT and LC3B assays can both be used to measure the effects at two different stages
of the autophagic process. HEK293 cells stably expressing either GSTmodBHMTmyc or
HA-LC3B-myc were used for these experiments to eliminate potential effects of
transfection reagents. The two cells lines were maintained in either complete or
starvation media, with or without glucose. One set was maintained at normoxia (37ºC,
5% CO2 and 21% O2), and a matched set was incubated at hypoxia (37ºC, 5% CO2, and
1% O2). The duration of the experiment was approximately five hours. In normoxia,
BHMT fragment 1 accumulated normally in conditions of amino acid and serum
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starvation. Glucose starvation slightly decreased the level of fragmentation (Fig. 47,
lanes 3&4 compared to lanes 1&2). LC3B-II levels were in agreement with BHMT
fragmentation, showing induction with amino acid and serum starvation and slightly less
LC3B-II with glucose deprivation (Fig. 47, lanes 1-4, second panel from the top). At 1%
O2 with full glucose, autophagy by both BHMT and LC3B assays was not impaired,
compared to control (Fig. 47, lanes 6 & 7 compared to lanes 1 & 2). However, in the
experimental condition of ischemia, defined as loss of amino aids, serum, and glucose at
1% O2, LC3B-II levels were severely decreased and accumulation of amino acid
starvation-induced BHMT fragment 1 was significantly less than control (Fig. 47, lanes 7
and 8). In this experiment, BHMT fragmentation and LC3B-II levels both suggest that
autophagy is inhibited in these conditions of ischemia.
However, even with impaired LC3B processing, there was a small amino acid
starvation-induced increase of BHMT fragmentation in ischemia. Some turnover of
autophagic cargo did occur in ischemia. It suggests that in ischemia, as amino acid,
glucose, O2 and ATP levels fall, mTOR is down-regulated, and an attempt is made to
activate an autophagic response. However, as the ischemic-induced energy crisis
continues, the cell utilizes and exhausts the limited resources of LC3-II and ATP in
response to the loss of amino acids and autophagy is inhibited. Understanding how cells
respond to ischemic conditions has physiological relevance in tumor biology as well as in
pathological infarct.
The BHMT assay for autophagy is a good tool to look at the signaling pathways
involving mTOR and p70S6K, and phosphorylated S6. Amino acid starvation inactivates
the mTOR pathway, which inactivates p70S6K and results in the dephosphorylation of
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Figure 47. The BHMT and LC3B assays in a cell culture model of ischemia.
HEK293 cells stably expressing either GSTmodBHMTmyc4.1 or HA-LC3B-myc were
incubated for 5 hours in complete media with and without glucose, or in media deficient
in essential amino acids and serum, with and without glucose. One set was maintained in
conditions of normoxia (37ºC, 5% CO2 and 21% O2) and another set was maintained in
hypoxia (37ºC, 5% CO2, and 1% O2). The cellular condition of ischemia is mimicked in
the cells deprived of amino acids, serum, glucose and oxygen (lane 8). Amino acid
starvation induced the accumulation of BHMT fragment 1 in both normoxia and hypoxia.
No significant increase in fragment 1 was noted with glucose starvation in either
normoxia or hypoxia. The combined effects of experimental ischemia inhibited BHMT
fragmentation, although a slight increase in fragment 1 is noted in lane 8 compared to
lane 7. LC3B-II production was significantly decreased in the absence of glucose and
oxygen. Autophagy, by both the BHMT and LC3B assays, was inhibited in conditions
of ischemia.
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S6[85]. This has led to the suggestion that inactivation of S6K and dephosphorylation of
S6 are important events in the induction of autophagy[54]. In order to test if starvation
induced S6 dephosphorylation is necessary for the induction of autophagy, a
constitutively active allele of S6K was used that is known to be active in the absence of
amino acids. HEK293 cells were co-transfected with GSTmodBHMTIRESGFP and the
constitutively activate allele of p70S6K, p70S6KT389E,D3E, or vector control. After
allowing sufficient time for expression, the cells were treated in complete media or media
deficient in essential amino acids and serum with protease inhibitors, to induce
autophagy. After 6 hours, cells were harvested and cells extracts were prepared for
glutathione pulldown and western blotting. Expression of GFP is shown as a control of
GSTmodBHMTIRESGFP transfection efficiency. Western blotting with anti-myc antibody
is shown to verify expression of the p70S6K allele. As expected, amino acid starvation
significantly increased BHMT fragmentation in the control (Fig. 48, lane 2).
Surprisingly, expression of the constitutively active allele of p70S6KT389E,D3E did not
inhibit BHMT fragmentation, but rather appeared to slightly increase the accumulation of
BHMT fragment 1 in both basal and starvation conditions (Fig. 48, lanes 3 and 4)). The
expression p70S6KT389E,D3E is expected to send a positive signal to S6, the downstream
substrate of p70S6K. WCE aliquots were prepared for western blotting with an antibody
against phospho-S6. In control cells, S6 was dephosphorylated during the 6 hour
starvation period, but remained phosphorylated in the presence of the p70S6KT389E,D3E
allele as expected (Fig. 49, lanes 2 and 4). Expression levels of total S6 protein are
shown in the bottom panel (Fig. 49).
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Figure 48. Active p70S6KT389E,D3E does not inhibit autophagy; over-expression of
RHEB inhibits autophagy. HEK293 cells expressing GSTmodBHMTIRESGFP were
transfected with an activated allele of p70S6KT389E,D3E or with mycRHEB. After
allowing time for expression, the transfected cells were treated with complete media or
were treated under amino acid starvation conditions for 6 hours to induce autophagy.
Cell extracts were prepared as previously described for western blotting. In control cells
and cells expression the active S6K, levels of BHMT fragment 1 increased in starvation
conditions (lanes 1-4). Active S6K was not sufficient to inhibit autophagy, and levels of
fragment 1 were actually a little greater than control. In the cells expressing the upstream
activator or mTOR, BHMT fragmentation and autophagy were inhibited in starved cells.
Controls of expression of the BHMT reporter, RHEB and S6K are shown in panels 2-4.
The bottom panel is a western blot of endogenous LC3 from each sample. Neither S6K
nor RHEB affect the accumulation of LC3-II levels.
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Figure 49. S6 phosphorylation in cells with activated p70S6KT389E,D3E and
mycRHEB. Western blot of cell extracts from BHMT experiment in Figure 48 with a
phospho-specific antibody against S6. Total S6 is shown in bottom panel as a control of
expression. As expected, phosphorylation of S6 is decreased in cells starved of essential
amino acids, compared to cells in complete media (lane 2 compared to lane 1).
Phosphorylation of S6 is protected in cells starved from amino acids that over-express
activated p70S6KT389E,D3E or mycRHEB.
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Figure 50. 4E-BP1 phosphorylation in cells with activated p70S6KT389E,D3E and
mycRHEB. Western blot of cell extracts from BHMT experiment as in Figure 48 with a
rapamycin control for each condition. Top panel is western blot with a phospho-specific
antibody against 4E-BP1. Total 4E-BP1 is shown in bottom panel as a control of
expression. In control cells, amino acid starvation causes a band-shift collapse.
Rapamycin also causes a slight band shift down of 4E-BP1. Phosphorylation and total
levels of 4E-BP1 are equivalent between cells expressing active S6K and control cells in
each condition tested. In last four lanes, over-expression of RHEB protects phospho-4EBP1 in starved cells, but not in rapamycin-treated cells. Note that expression levels of
total 4E-BP1 are decreased in cells with over-expressed RHEB. This is most evident in
the starved, rapamycin-treated cells (lanes 12).
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If the amino acid signal for autophagy is through mTOR, then activation of
mTOR should inhibit autophagy. Although there are no activated alleles of mTOR, overexpression of its upstream activator RHEB has been shown to activate mTOR in the
absence of amino acids. To test the role of mTOR on autophagy, HEK293 cells were cotransfected with GSTmodBHMTIRESGFP and mycRHEB or vector control and treated
under plus and minus amino acid media conditions as before. Over-expression of
mycRHEB completely inhibited the induction of autophagy as judged by the
accumulation of BHMT fragment 1 in amino acid starved cells (Fig. 48, lanes 5 and 6).
The RHEB data support a hypothesis that the signal to autophagy goes through mTOR
and that activation of mTOR is sufficient to inhibit autophagy. Ectopic expression of
either p70S6KT389E,D3E or RHEB did not effect levels of LC3-II, shown in the bottom
panel of Figure 48.
Like activated S6K, mycRHEB should also send a positive signal to S6. WCE
aliquots of samples were prepared for western blotting with an antibody against phophoS6. In control cells, amino acid and serum starvation inhibited the phosphorylation of S6.
In cells expressing the mycRHEB allele, phosphorylation of S6 was retained in minus as
well as plus amino acid conditions. Western blot with antibody against total S6 is shown
as a control of expression. This suggests that phosphorylation of S6 does not inhibit
autophagy and supports the hypothesis that the signal to autophagy does not go through
p70S6K or S6.
The RHEB and p70S6K data suggest that the signal to autophagy goes through
mTOR but is not through p70S6K. The small increase that was observed in BHMT
fragment 1 in cells transfected with activated p70S6KT389E,D3E could suggest that the
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over-expressed allele was interfering with a mTOR-dependent pathway parallel to
p70S6K. Another well-known effector of mTOR signaling is 4E-BP1, a negative
regulator of the translation initiation factor, eIF-4E. To test the effects of RHEB and
p70S6KT389E,D3E on 4E-BP1 phosphorylation, an experiment identical to the one in Figure
48 was performed with the addition of a rapamycin control for each condition tested. A
western blot was prepared from whole cell extracts with antibody against phosphorylated
4E-BP1. Levels of total 4E-BP1 are shown in the bottom panel as a control (Fig.50). In
control and p70S6KT389E,D3E cells, 4E-BP1 was phosphorylated in plus amino acid media,
but phosphorylation was inhibited in cells that were starved of amino acids (Fig. 50, lanes
1 and 5, compared to 3 and 7). 4E-BP1 in rapamycin-treated cells shows a slight bandshift down, which can be seen with both phospho and total 4E-BP1 antibodies (lanes 2
and 6). In starved cells expressing the p70S6KT389E,D3E mutant, little change in 4E-BP1
phosphorylation was noted compared to control cells. S6K does not appear to have
dominant interfering effect. Expression of ectopic RHEB increased the phosphorylation
of 4E-BP1 in either plus or minus amino acid conditions, and rapamycin was effective in
blocking the phosphorylation (Fig. 50, lanes 9-12). Surprisingly, the expression of total
4E-BP1 was slightly decreased in the RHEB samples compared to control or
p70S6KT389E,D3E (Fig. 50, lane 12). The band-shift pattern of 4E-BP1 makes
interpretation of expression difficult in some instances, but rapamycin is effective in
collapsing the band-shift, making the decrease in expression more obvious in the
rapamycin-treated sample. Sustained mTOR signaling, through the over-expression of
RHEB, increased phosphorylation of 4E-BP1 and decreased the expression of the protein.
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While the mechanism through which mTOR signals to autophagy is still not
known, the 4E-BP1 data suggest that a possible mechanism may involve signaling
through 4E-BP1 and the initiation of translation. The potential link between 4E-BP1,
translation, and autophagy is consistent with other studies that link autophagy and
translation initiation through eIF-2alpha kinase. (See discussion.)
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IV. DISCUSSION
4.1 Development of Autophagy Assays
The study of mammalian autophagy has been hindered by the complexity of the
process. It requires the coordinate assembly of autophagy-specific proteins to build an
autophagosome, an intact cytoskeletal network for trafficking, and a functional lysosome
to degrade both the autophagosome and its cargo. Much of the study of autophagy has
centered on the autophagosome itself and on the Atg proteins that assemble it. Two of
the most commonly used methods to study autophagy involve electron microscopy and
LC3. Both are based on the identification and quantification of autophagosomes.
Although autophagosome formation is of fundamental importance, its degradation must
be considered to understand and study the complete process of autophagy. An ideal
assay would measure both sequestration and delivery to the lysosome. One goal of this
study was to identify a substrate for macroautophagy that could be used to study the
entire process, from engulfment through to lysosomal degradation.
4.1.1. Atg12 and Atg5 Conjugation
Much of what is known about the molecular mechanism of autophagosome
formation originated from genetic studies in S. cerevisiae mutants that were defective in
autophagy. Among the autophagy-specific genes identified by this approach were Atg12,
Atg5, Atg7, and Atg10. Together, the proteins coded by these genes function in one of
two novel ubiquitin-like conjugations systems required for the maturation of the

181

autophagosome membrane[26]. Atg12 is a ubiquitin-like modifier that is activated in an
ATP dependent step by the E1-like enzyme Atg7, transferred to the E2-like enzyme
Atg10, and finally conjugated to Atg5 through the formation of an isopeptide
bond, linking the carboxy-terminal glycine of Atg12 to the ε-amino group of lysine 149
of Atg5. The linked Atg12-Atg5 proteins then form a larger complex with Atg16[26].
This large complex can be found on the convex side of a forming autophagosome and
may function as a coating complex to help in the curvature of the forming membrane.
The Atg12-Atg5 conjugation system is fully conserved in higher organisms, underscoring
the importance not only of this mechanism, but of autophagy itself. In Atg5-/- mouse
embryonic fibroblasts (MEFs), autophagosomes do not form, and surprisingly, LC3-I is
not conjugated to LC3-II, suggesting functional interaction between the two conjugation
systems[27]. If Atg5K130R, an Atg5 mutant that cannot link to Atg12, is expressed in
Atg5-/- MEFs, Atg5K130R and Atg16 associate with small vesicles in the absence of Atg12,
however the small vesicles do not grow[27]. Recent studies have shown that calpainmediated cleavage of Atg5 produces an Atg5 fragment that induces apoptosis[86],
however there is no known function for unconjugated Atg12.
At the beginning of this study, it seemed likely that the formation of new
autophagosomes might require the assembly of more Atg12-Atg5 based complexes to
coat the newly generated membrane. Changes in levels of either the complex or the
individual conjugate partners would then be a novel way to assess the cells demand for
new autophagosomes The data demonstrate that levels of the Atg12-Atg5 conjugate are
exceedingly stable and do not appear to be regulated by amino acid starvation, inhibition
of autophagy, or by levels of new protein synthesis. The conjugation occurs without

182

autophagy stimulus and appears to be irreversible. It is now known that there is a large
cytoplasmic pool of the Atg12-Atg5-Atg16 complex and only a small percentage is
associated with autophagosomal membranes[87]. Apparently, the Atg12-Atg5 complex
exists in excess to meet cellular demand. The Atg12-Ag5-Atg16 complex does not stay
associated with autophagosomes after formation is complete, and it is likely that the cell
recycles and reuses the complex, keeping a stable pool available at all times. This makes
the Atg5-Atg12 conjugate unsuitable as a measure of autophagy.
Unlike the conjugate, levels of Atg12 dropped significantly with amino acid
starvation. This suggested two possible explanations. Either more Atg12 was recruited
to the covalent complex during starvation, or it was degraded by another mechanism.
Since conjugate levels were unchanged, the latter explanation was more likely.
Cycloheximide provided an elegant way to discriminate between the two possibilities.
As an autophagy inhibitor, it should protect levels of Atg12 if Atg12 levels are turned
over by autophagy. As a translation inhibitor, it should cause levels of Atg12 to drop if
Atg12 is degraded through another mechanism. The data support the latter.
Cycloheximide also did not protect Atg12 levels during nutrient rich conditions,
suggesting that Atg12 stability is not significantly regulated by the nutrient conditions of
the cell. A major non-lysosomal mechanism for protein degradation in the cytoplasm is
the protesome and data with the proteasome inhibitor MG132 confirm that unconjugated
Atg12 was likely degraded by this mechanism.
Unlike ubiquitin, which has many targets, Atg12 is only known to have one,
Atg5. Levels of unconjugated Atg12 and Atg5 are thought to be very low. It could be
that the only cellular function of Atg12 is to post-translationally modify Atg5. Although
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there is one report that suggests that unconjugated murine Atg12 facilitates LC3
processing, the data is based on overexpression and the authors clearly state that there is
no evidence of unconjugated, endogeonous Atg12[88]. It is possible that unconjugated
Atg12 may be either unnecessary or deleterious to the cell, making quick elimination in
the best interest of the cell. Atg8 (LC3), the second ubiquitin-like modifier in
autophagy, shares the same E1 enzyme, Atg7, with Atg12 in the conjugation process. In
murine cells, Atg12 is the preferred substrate for Atg7, over LC3 and the other murine
Atg8 orthologs[89]. This suggests that the Atg12-Atg5 conjugation takes preference over
LC3 modification, and supports the idea that free unconjugated Atg12 is undesirable. It
is also possible that the preference of Atg7 for Atg12 is to keep an excess supply of
Atg12-Ag5 complex.
In conclusion, neither the Atg12-Atg5 conjugation system nor changing Atg12
levels proved suitable for the measurement of autophagy. The stability of the Atg12Atg5 complex is an interesting observation that may be useful to validate knock-down of
conjugation-specific ATG genes. HA-Atg12 and GST-Atg5 not only conjugate to each
other, but they form conjugates with their endogenous partners as well (data not shown).
The stability of the conjugate in normal cells allows for reliable interpretation of
decreases induced by siRNA to Atg7 or Atg10 in future studies. The limited stability of
unconjugated Atg12 is an interesting observation which may have physiological
relevance.
4.1.2. LC3 conjugation and autophagy
LC3, the mammalian ortholog of Atg8, is a ubiquitin-like modifier in the second
UBL conjugation system in autophagy. Pro-LC3 is translated in a form that requires
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proteolytic cleavage by Atg4B to expose the carboxy-terminal glycine required for
conjugation. It shares the E1-like enzyme Atg7 with the Atg12, but has its own E2-like
enzyme, Atg3. Unlike any of the other known UBLs, LC3 does not modify another
protein, but is conjugated to a lipid, most likely phosphatidylethanolamine, which
anchors LC3-II to the autophagosome membrane[90]. LC3 is one of at least seven Atg8
orthologs in mammals, including GATE-16, GABARAP-I, GABARAP-II, and hAtg8L,
LC3A, LC3B, and LC3C[23, 90]. All have been reported to associate with
autophagosomes, though other functions are likely. LC3-II is the first, reported protein to
specifically associate with autophagosomes, making it a valuable tool to identify these
structures.
LC3 processing has been embraced by much of the research community as an
assay to measure autophagosomes by both biochemical and fluorescent assays[20, 91].
The later relies on the localization of a chimeric LC3 fused to a fluorescent protein,
normally green fluorescent protein (GFP). Cytoplasmic, punctate structures containing
GFP-LC3 are thought to represent autophagosomes and autolysosomes. GFP- and RFPLC3 reporters have been developed in the context of this study and punctate structures
can be observed and compared between individual cells (data not shown). However,
populations of each are found in both well-fed and starved cells making reproducible and
sensitive counting of punctate structures problematic.
The biochemical LC3 assay has been heavily used in the study autophagy,
sometimes in conjunction with the fluorescent assay. The lipid attached to LC3-II
changes its electrophoretic mobility to create a faster migrating band that can be easily
separated from LC3-I by SDS-PAGE. Changes in either levels of LC3-II or in ratios of
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LC3-II/LC3-I are often used to assess autophagy[20]. In rare cases when LC3-II cannot
be seen, decreased levels of LC3-I have been interpreted as increased autophagy[66].
Recently in the literature, issues concerning interpretations of the LC3 assay were raised
by one the original investigators who introduced it[92]. Autophagosomes are not a
product of autophagy and therefore, levels of autophagosomes do not always directly or
linearly correlate with autophagy. They are intermediate structures in flux, and levels of
LC3-II only measure how much is present at a given moment. High rates of autophagy
can result in decreased LC3-II and low turnover at the lysosome can increase LC3-II.
Both the fluorescent and biochemical LC3 assays have a high potential for false positive
and false negative interpretations. However, if carefully used and interpreted, the LC3
assay maintains its value of specificity. For this reason, the biochemical LC3 assay was
developed and carefully assessed in this study to provide a tool to independently confirm
published findings and to compare autophagosome and autolysosome accumulation with
an endpoint assay
During the subcloning of LC3, a mutant with the deletion of a conserved arginine
(R68 or R69) in LC3 was discovered that retarded cleavage of pro-LC3 so that all three
forms of LC3 were seen on SDS-PAGE. An additional insertion of nine amino acids
between the conserved glycine and the translational stop also occurred during subcloning
but was found not to affect cleavage. The region of LC3 affected by the deleted arginine
is in a stretch of residues that is highly conserved in all the isoforms and orthologs of
Atg8 from human to yeast. R68 in particular is 100% conserved in all species examined,
with the exception of the plant Arabidopsis (Table 3). These residues are very near to a
region containing two residues (F77 and F79 in yeast Atg8, F80 and L82 in human LC3)
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that in yeast are important for the binding of Atg8 to the protease Atg4[65]. In the
structure analysis of human Atg4B, the active site of Atg4B is occupied and inhibited by
an autoinhibitory loop[93]. The core region of LC3, potentially involving F80 and L82,
binds Atg4B, causing a conformational change to release the autoinhibitory loop and
open the active site so that the carboxy-terminal tail of LC3 can bind the open cleft of the
protease and be cleaved. Large bulky proteins fused to the carboxy-terminus of LC3 do
not affect the ability of Atg4B to cleave LC3 efficiently in an in-vitro cleavage assay,
supporting the conclusion that the additional 9 amino acids at the carboxy-terminal of the
mutant LC3 reporter did not contribute to the delayed processing[94]. In one study of
yeast Atg8, an alanine mutation was made in K66 (comparable to R69 in LC3) and tested
for the ability to rescue autophagy in ∆atg8 cells. No defect was found in the K66A
mutant within the limitations of their assay[65]. With the data from the mutant LC3 of
this study, it is likely that the K66A mutation would be functional, though delayed in
processing.
The mutant LC3 reporter was tested for its response to two classic autophagy
inhibitors: chloroquine and 3MA. Chloroquine enters the lysosome and acts as a proton
sink, increasing the lysosomal pH and inhibiting lysosomal function and fusion with
other vesicles. As expected, levels of LC3-II accumulate in the presence of 100µM
chloroquine. 3MA inhibits the Class III PI3K, Vps34. The product of Vps34 activity is
phosphatidylinositol 3-phosphate (PI3P) which is found on cytoplasmic vesicles and is
thought to be required for autophagy. Although the mechanism is not clear, it is thought
that PI3P is necessary for the assembly of Atg proteins at the newly forming
autophagosome. One Atg protein that interacts with and possibly regulates Vsp34 is
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Beclin1. Some studies have shown that decreased Beclin1 effects LC3-processing, so
3MA effects on LC3 are likely due to inhibition of Vps34[72]. Inhibition by 3MA causes
an increase in the proform of LC3 in the mutant reporter, but does not affect
accumulation of LC3-II. It is likely that the 3MA-mediated increase in the proform of
LC3 is the result of a defect in the recruitment and colocalization of the substrate proLC3
with the Atg4B enzyme. Proteins that bind PI3P do so through FYVE or PX domains,
neither of which is found in LC3 or Atg4B. Although interaction of proLC3 and Atg4B
may be limited, the data show that LC3-II is still processed in the presence of 3MA. If
PI3P is specifically responsible for Atg4B localization to the autophagosome, then in the
presence of 3MA, less Atg4B would be available for both the cleavage of proLC3 and the
de-lipidating activity or LC3-II necessary for vesicle fusion, thereby affecting autophagy
in at least two distinct steps of the process. In the latter scenario, LC3-II levels would be
frozen with no new production and no degradation. The mutant LC3 reporter may be
useful for future studies on the early processing steps of LC3 processing.
The stable expression of HA-LC3-myc in HEK293 cells was a useful way to
study the behavior of LC3 under various conditions. Four conclusions can be drawn
from data generated by this reporter. First because some LC3-I may be degraded
proteasomally under starvation conditions, LC3-I levels do not necessarily represent
changes in autophagy. This is important because decreased levels of LC3-I have been
used to invoke increased autophagy in the use of LC3-II to LC3-I ratios and occasionally
as a stand-alone marker. It is possible that not all LC3-I observed by western blotting is
newly synthesized and modified. Some LC3-II at the autophagosome membrane must be
cleaved and removed by Atg4B before vesicle fusion can occur. The electrophoretic
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mobility of the released LC3-I would likely be the same as newly modified LC3-I. It has
been suggested that released yeast Atg8-I is reused, however the data does not describe
the exact site of the second cleavage[95]. Although some deubiquitinating (DUB)
enzymes cleave the functionally-related ubiquitin from small adducts, the structure of
human Atg4 is most similar to the UBP family of DUB enzymes which cleave the
ubiquitin molecule from proteins[93]. Cleavage of LC3 at a peptide bond to remove PE
would also remove the carboxy-terminal glycine, making it incompetent for a new round
conjugation. If correct, it is conceivable that a pool of incompetent LC3 would be
proteasomally degraded during starvation. It also explains why LC3-I levels are not
proteasomally degraded in nutrient rich conditions, as this pool of LC3-I is likely newly
processed from proLC3.
The second conclusion that was apparent from the LC3 data is that levels of LC3II do not directly correlate with autophagy and can easily be misinterpreted.
Autophagosomes are intermediate, transient vesicles in a constant state of flux and LC3II levels are ‘snapshots’ that reflect the balance between synthesis and degradation at a
specific moment in the process. Degradation is an important part of the regulatory
process and LC3-II levels can increase, decrease, or not change under starvation
conditions. The data show that inhibition of lysosome degradation can be used as a tool
to demonstrate LC3-II flux at short and long time points, dependent on the strength of the
inhibition. The data in this study are consistent with recently published data that
lysosomal protease inhibitors are necessary to properly interpret LC3-II levels[92].
Strong lysosomal inhibition shows that a significant amount of LC3-II turns over
in nutrient rich conditions. This observation is supported by data published by Kochl et
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al. that examined the effect of microtubule disrupting agents on macroautophagy in both
full and minimal media[70]. It suggests a significant degree of autophagosome
membrane flux during nutrient rich conditions and raises a question about whether amino
acid starvation increases LC3-II processing. The chloroquine time course data from this
study show that levels of LC3-II accumulate faster under starvation conditions, consistent
with an interpretation that LC3-II is processed at a faster rate under starvation conditions.
Conceptually however, the unexpected level of LC3-II flux in complete media is not
inconsistent with a form of a mammalian Cvt-like pathway or of a cytoplasmic version of
pinocytosis, with constant internal LC3-II-marked membrane flux through the lysosome.
Interestingly, LC3-II levels appear to be self-limiting. The limiting factor does not appear
to be LC3-I, because in nutrient rich media, levels of LC3-I are maintained and still
available. It has been suggested that the E1-like conjugating enzyme Atg7 may be
limiting[88]. However, overexpression of Atg3, Atg7, or Atg4B does not appear to
promote LC3-II processing or autophagy (data not shown). The exact nature of this
feedback is not yet known.
The ultimate conclusion of the data generated from the study of LC3 is that LC3-I
and LC3-II data must be interpreted cautiously. There is a growing acknowledgement in
the field that LC3-II levels alone are not sufficient to measure autophagy. To address
this, some studies interpret LC3-II levels only in conjunction with measurement of the
degradation of long-lived proteins. Unfortunately, these methods are neither sensitive
nor specific for macroautophagy. An ideal assay would measure a product of autophagy
at completion, after specific cargo has been sequestered, delivered to the lysosome and
degraded.
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4.1.3. The BHMT assay
There is a need in the field of mammalian autophagy for an assay that would
specifically and sensitively measure the lysosomal degradation of an autophagy cargo
protein. This need led to the development of the BHMT assay. Highlights of the
discussion will focus on three topics. Why choose BHMT? Is the BHMT measuring
macroautophagy? What is the sensitivity and linearity of the BHMT assay?
The decision to turn a metabolic enzyme, betaine homocysteine methyltransferase
(BHMT) into a reporter for autophagy began with a published report that rat BHMT
associates with purified autolysosomes[96]. One specific proteolytic fragment of rat
BHMT was found only on the inside of autolysosomes of rats that were administered the
protease inhibitor leupeptin, suggesting that there was a leupeptin-resistant cathepsin
specific for a particular site in BHMT[96]. Despite the fact that the authors of a followup paper suggested their attempts to create an exogenous BHMT reporter for autophagy
had been unsuccessful[68], BHMT was chosen as one of several promising candidates for
a plasmid-based reporter assay for autophagy in cell culture.
It was assumed that if proteolytic fragments of BHMT were generated
lysosomally, they would not be abundant. However, creation of an epitope-tagged
BHMT fusion protein would allow for purification and enrichment of rarified fragments.
After several unsuccessful attempts to fuse BHMT to GST, HA or myc epitope tags in an
assortment of different combinations, a successful combination was found that fused GST
to the amino terminus of BHMT and myc to the carboxy terminus. In conditions known
to induce macroautophagy, a leupeptin-resistant GST-fused fragment, termed fragment 1,
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of the expected size accumulates quantitatively. Attempts to isolate a carboxy fragment
with antibody to myc were not successful (data not shown).
Multiple forms of the BHMT reporter were generated in the course of this study.
Each reporter consistently generated fragment(s) in conditions known to induce
autophagy, such as starvation from essential amino acids, and to a lesser degree,
rapamycin treatment. The starvation-induced generation BHMT fragment(s) was
inhibited by every macroautophagy inhibitor tested: 3MA, wortmannin, chloroquine,
bafiolomycin A1, puromycin, cycloheximide, and vinblastine. Further validation of the
lysosomal nature of the fragments generated from BHMT is found in the co-fractionation
of BHMT fragments with the lysosomal marker, LAMP1, in fractions collected from the
LMF compartment of cells separated by density on sucrose gradients.
Although the pharmacological data with the BHMT assay suggest that lysosomal
import occurs through macroautophagy, other mechanisms of autophagy must be
eliminated as either primary or alternative routes to the lysosome for GST-BHMT. One
mechanism of autophagy considered is chaperone-mediated autophagy (CMA) which is
induced by long term amino acid and serum starvation[10]. There are no known
pharmacological inhibitors of CMA, making elimination of a CMA-dependent
mechanism difficult. The hsc73 protein recognizes substrates of CMA through exposure
of a sequence of amino acids typified by the ribonuclease A sequence, KFERQ[97]. The
KFERQ sequence is often degenerate to the point of being unrecognizable, but
examination of the human BHMT sequence failed to find any KFERQ-like sequences.
The inability to identify a KFERQ sequence in human BHMT is consistent with a
published report that KFERQ-like sequences could also not be found in rat BHMT[68].
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Unexpectedly, in a published review of chaperone-mediated autophagy, GST was
included in a list of known CMA substrates with KFERQ-like sequences[10]. Mutation
of the obligate Q or N in KFERQ to an alanine is sufficient to mask recognition by the
chaperone complex. The GSTN43ABHMT mutation did not change BHMT fragmentation
in response to starvation of serum and essential amino acids, or to any of the
macroautophagy inhibitors, suggesting that CMA was not a mechanism responsible for
BHMT lysosomal import. A recent study found that vinblastine, 3MA, and wortmannin
did not inhibit CMA[71] and all were effective in blocking the accumulation of BHMT
fragment 1. The pharmacological data of vinblastine, 3MA, and wortmannin support the
idea that CMA is not a mechanism of lysosomal import for BHMT.
A third argument against import by CMA can be made from the data on higher
order structure. Multimerization of BHMT is necessary for cleavage of the L2 loop to
produce fragment 1. The need for oligomerization suggests that BHMT must be
imported into the lysosome with quaternary structure intact. During CMA, proteins in
the chaperone complex bind LAMP2a at the lysosome membrane and then unfold so that
the protein can be threaded through the lysosomal membrane and enter the luminal space.
It seems extraordinarily unlikely that BHMT could regain its quaternary structure in the
lysosome after entering by the CMA mechanism and be cleaved to generate fragment 1.
In addition, in the course of this study, siRNA targeting LAMP2 successfully
reduced expression of LAMP2 protein by approximately 90%. Of the two shRNAs
tested, one did not effect BHMT processing and one slightly enhanced BHMT
fragmentation (data not shown). The latter result is consistent with a report with selective
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knock-down of LAMP2a causes a compensatory increase in macroautophagy[12].
Together, these data support the hypothesis that BHMT is not a substrate for CMA.
Microautophagy is a third mechanism that could import GST-BHMT directly into
the lysosome. There is very little published information available about lysosomal
invagination and import, although it is generally considered to be a constitutive process,
with one exception. In yeast there is a report that TOR positively regulates
microautophagy as a mechanism to reduce vacuole size after rapamycin treatment and
macroautophagy-induced swelling of the vacuole[9]. The protein complex at the vacuole
membrane that mediates this process is conserved in mammals, although the existence of
a similar mechanism in mammals is not known. However, in this scenario, rapamycin
would be expected to inhibit, not induce degradation. To eliminate microautophagy as a
mechanism of BHMT lysosomal import, it was necessary to knock out a
macroautophagy-specific gene.
Beclin1, the human Atg6 ortholog, is a good candidate for specific targeting by
shRNA because its role in macroautophagy is widely accepted in the autophagy field, its
silencing is often cited as validation of macroautophagy, and available antibodies are
sensitive enough to demonstrate changes in levels of endogenous protein. Low levels of
Beclin1 have been linked to decreased autophagy in MCF7 cells, while over-expression
of Beclin1 in MCF7 cells Beclin1 has been shown to induce autophagy and reduce
tumorigenicity[38]. It should be noted that in this study, ectopic expression of HABeclin1-myc in the cells tested is not sufficient to increase autophagy, as determined by
either the LC3 or BHMT assays (data not shown). There could be cell-specific
differences between the MCF7 cells in the cited work and the cells used in this study.
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Another possibility is that overexpressed Beclin1 in HEK293 cells forms substoichiometric complexes that are not autophagy competent. One study found that
overexpessed Beclin1 required the coexpression of a mutant associating protein, PIST, to
induce autophagy[98]. Alternatively, the epitope tags fused to Beclin1 may interfere with
any autophagy-promoting function. Ectopic expression of Beclin1 without epitope tags
should help resolve the latter issue. The data show that shRNA targeting three distinct
regions of the Beclin1 mRNA decreased expression of Beclin1 protein. Significantly,
depletion of Beclin1 is sufficient to decrease accumulated levels of BHMT fragment 1 in
starved cells, establishing unambiguously that the BHMT assay is reading
macroautophagy.
The second autophagy-specific target chosen to validate the BHMT assay is the
serine-threonine kinase orthologous to yeast Atg1, hULK1. In humans, hULK1
expression has been linked to the trafficking of Atg9 between the trans-Golgi network
(TGN) and late endosomes[52]. The link between hULK1 and mAtg9 is consistent with
impaired trafficking of Atg9 in yeast ∆atg1 mutants between the pre-autophagosomal
structure (PAS) and non-PAS structures[47]. Two separate shRNAs targeting hULK1
effectively decreased levels of accumulated BHMT fragment 1 in amino acid starved
cells, validating that the BHMT assay is measuring macroautophagy by depletion of a
second autophagy gene.
Regarding autophagy, the ability of shRNA targeting ULK1 to inhibit BHMT
fragmentation indicates that hULK1 and its isoform hULK2 do not seem to have
overlapping functions. hULK1 and hULK2 share the same basic domain structure with
an amino terminal kinase domain, a central proline-serine rich domain, and a carboxy-
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terminal domain. The catalytic and carboxy-terminal domains are well conserved
between the two isoforms, with little conservation noted in the central proline-serine (PS)
rich domain[50]. It has been suggested that the human Atg8 orthologs GATE-16,
GABARAP, and to limited degree LC3, bind the middle PS domain of hULK1[99].
Future experiments that exchange domains between these two kinases will help
determine what regions of the kinase are essential for autophagy.
The above data indicate that hULK1 is important for autophagy and should be
studied regarding its role in regulating autophagy. This study attempted to answer three
questions regarding hULK1 and autophagy: 1) Is hULK1 specific activity effected when
autophagy is induced by amino acid starvation or rapamycin or when cells are treated
with autophagy inhibitors? 2) Do levels of hULK1 change in response to the induction of
autophagy and is this a mechanism of regulation? 3) Is hULK1 activity required for
autophagy?
In yeast, there are two theories regarding Atg1 activity and macroautophagy.
Kamada et al. reported that activity was necessary for autophagy while Abeliovich et al.
found that Atg1 protein was necessary for macroautophagy and the related Cvt pathway,
but its activity was only required for the Cvt pathway[45, 46]. Both studies suggest that
Atg1 functions in a complex of proteins and that phosphorylation of Atg13 and Atg1
regulate Atg1 activity. The data in this study show that the catalytically inactive
hULK1KD inhibits the generation of fragment 1, suggesting that hULK1 activity may be
necessary for mammalian autophagy. However, levels of over-expressed hULK1KD are
likely greater than endogenous hULK1, making the formation of sub-stoichiometric
complexes possible which could interfere with parallel pathways.
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This led to the study of hULK1 specific activity in conditions known to induce or
inhibit autophagy. Kamada et al showed that two well known inhibitors of TOR,
starvation or rapamycin, increase yeast Atg1 specific activity[45]. In contrast to the yeast
data, the results here show that the specific activity of HA-ULK1-myc does not change in
response to starvation or rapamycin, and is not affected by inhibitors of autophagy such
as 3MA, wortmannin or chloroquine. What might explain this? An obvious explanation
would be that yeast Atg1 and human hULK1 are not regulated in the same manner.
Some kinases are regulated by levels of expression and there is one report that levels of
ULK1 mRNA increase with viral infection in neurons[100]. Since hULK1 mRNA
increased in the case of viral infection, and because viral invasion is one way to induce
autophagy, it seemed possible that hULK1 levels might increase with amino acid
starvation. The data with qPCR show that levels of hULK1 mRNA remain essentially
unchanged after 6 hours of amino acid starvation. It does not appear that amino acid
starvation regulates hULK1 at the transcriptional level.
How else might hULK1 be regulated? Yeast Atg1 is regulated by the posttranslation modification of associating proteins. Atg13 must be de-phosphorylated for
Atg1 to be active which suggests that an active phosphatase is required to regulate Atg1
activity. It may be that hULK1 requires the association and/or modification of other
proteins for regulated activity that is not reflected in an in-vitro assay. It is also possible
that the amino or carboxy termini of hULK1 may be important for regulation of its
activity. The epitope tags fused to hULK1 may interfere with the regulation of its
activity. Little is known about the importance of domains, post-translational
modifications, or regulatory proteins for either of the hULKs. Potential issues of
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interference caused by the fusion of epitope tags to the hULK1 protein are currently
being addressed by making a non-tagged construct for ectopic expression.
It may be that hULK1 is constitutively active and regulated by localization,
expression or other mechanism. Autophagy is a membrane trafficking process, and it is
possible that hULK1 re-localizes to or from membrane structures in autophagystimulating conditions. This is consistent with its role in mAtg9 trafficking. Preliminary
studies with the epitope tagged hULK1 have failed to demonstrate differences in
distribution between cytosolic, nuclear, or membrane fractions of cell extracts (data not
shown). This issue will be revisited with a non-epitope-tagged version of the kinase.
In-vitro kinase assays demonstrate that hULK1 can autophosphorylate, and
metabolic labeling with 32PO4 shows that hULK1 is phosphorylated in-vivo. This
suggests that phosphorylation is a mechanism of regulation of hULK1. The activation
loop (T-loop) in subdomain VIII of hULK1 contains a cysteine-glycine pair of amino
acids that is highly conserved in members of the AGC and CaM kinase families. Kinases
that belong to these family groups are phosphorylated on a conserved threonine in the Tloop by an upstream kinase. Mutation of this conserved threonine to an alanine in
hULK1 renders hULK1 catalytically inactive (data not shown) suggesting importance of
T-loop phosphorylation in the activation of hULK1. In the structurally related hULK2, a
priming phosphorylation event is apparently necessary for autophosphorylation and
activity, as prolonged treatment with calf intestinal treatment renders hULK2 inactive
(data not shown). This phosphorylation event is likely T-loop phosphorylation. The
inability of hULK2 to reactivate after prolonged CIP treatment makes it unlikely that
hULK2 phosphorylates its own T-loop, although it cannot be ruled out if another priming
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phosphorylation is required. hULK2 also shows a high preference for serine over
threonine, providing additional evidence that T-loop auto-phosphorylation is unlikely.
Interestingly, in the yeast genetic screens, no potential up-stream kinase was identified
for Atg1. The failure to identify an up-stream kinase in the autophagy screens supports
the yeast model which suggests Atg1 activity is not required for autophagy.
Phosphorylation by other kinases may also be important for activity of hULK1 as it has
been suggested that PKA may phosphorylate yeast Atg1[101]. Future studies are planned
to purify and identify the hULK1 upstream T-loop kinase.
There are no known endogenous substrates of either Atg1 or hULK1. Pull-down
experiments and proteomic analysis can be used to identify potential substrates of
hULK1. Many of the Atg proteins are phospho-proteins, and hULK1 can phosphorylate
some of them in-vitro (data not shown). With the tools developed in this study, changes
in metabolic labeling of Atg proteins in cells depleted of hULK1 will be used to study
effects of hULK1 on Atg post-translational modifications. Regarding activity of hULK1
and autophagy, future experiments are planned that will attempt to rescue the autophagy
defect caused by the shRNA-mediated decrease of hULK1 with expression of either the
catalytically active or kinase dead alleles of hULK1. If successful, these types of
experiments will validate the importance of hULK1 in autophagy and will help determine
if catalytic activity is important for autophagy.
In physiology, there are times when circulating amino levels are low, such as after
prolonged fasting or in postnatal infancy. Amino acid levels are an important part of the
regulation of macroautophagy based on what is reported in the literature[73] and on the
response of the BHMT assay. The data show that the BHMT assay is not sensitive to
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high levels of essential amino acids. Most of the studies with the BHMT reporter have
been done in transformed HEK293 cells that are cultured in DMEM with high amino acid
levels. Do transformed cells adapt to high levels of amino acids, or is the cellular sensing
mechanism for amino acids unaffected. A linear response of BHMT fragment 1
accumulation to extra-cellular levels of amino acids is only seen when levels of DMEM
essential amino acids fall below 10%. This was surprising until levels of the amino acids
in DMEM were compared to the normal adult reference ranges. The response of cells in
culture is within the physiological range. It appears that cells do not adapt to high levels
of amino acids, but maintain sensitivity at more physiological levels. The BHMT assay
responds appropriately to physiological levels of essential amino acids, especially when
one considers that it is measuring the endpoint of a biological process.
Interestingly, the BHMT assay does not respond equally to the individual
essential amino acids. It is possible that the intracellular levels of the essential amino
acids may not reflect the extracellular environment within the time frame of the
experiment. Bloomaart et al. demonstrated that not all amino acids are in equilibrium
with the extracellular environment[73]. However, he also showed that the intracellular
levels of a select group of amino acids reflect extracellular concentrations in a linear
fashion. His findings included leucine, isoleucine, lysine, phenylalanine and tyrosine,
some or all of which were suggested to be amino acids that regulate autophagy[73]. In
support of this, the BHMT assay shows sensitivity to leucine, phenylalanine, lysine, and
tyrosine. The BHMT assay is also sensitive to arginine, which was not tested in the
Bloomaart study.
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It is possible that the mechanisms that sense amino acids levels may have
selective sensitivity for individual amino acids. How does the cell sense and respond to
these particular amino acids? There are two kinases that sense amino acids and both have
been implicated in autophagy: mTOR and the eIF2alpha kinase, GCN2[54, 102]. Amino
acids, particularly leucine, strongly activate p70S6 kinase through mTOR[103]. How
does mTOR sense amino acids? Recent studies suggest that amino acids increase Vps34
activity which in turn activates mTOR[36, 37]. This is counter to reports that amino acid
starvation activates Vps34[33], however it is likely that Vps34 functions in distinct
complexes that may affect mTOR in opposing ways. How does Vps34 sense amino
acids? This mechanism is not yet known and may involve internal and external signals.
One report suggests that amino acids may act as a first messenger and signal through
plasma membrane receptors[104].
GCN2 responds to levels of intracellular amino acids. GCN2 is an eIF2α kinase
that is activated by the deacylation of tRNA. Once activated, it phosphorylates the
eukaryote initiation factor 2 alpha (eIF2α) at S51 causing a general translation arrest, but
facilitating the translation of GCN4, a transcription factor that has been shown to regulate
several autophagy genes[105]. In yeast, amino acid starvation induces autophagy
through GCN2; however rapamycin can induce autophagy in the ∆gcn2 mutant[102].
One explanation for this could be that GCN2 and TOR activate autophagy through
parallel pathways. The BHMT assay indicates that full autophagy activation requires the
additive effects of multiple amino acids, supporting the idea that mTOR and GCN2 might
respond independently to the same nutrient stress. If true, there could be distinct levels of
autophagy activation. Intracellular levels of leucine and the other branched chain amino
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acids decrease by as much as 90% within 30 minutes of amino acid withdrawal without
affecting the acylation of their respective tRNAs[74]. Thirty minute starvation is
sufficient to inactivate mTOR which may activate autophagy initially, followed by a
second tier of activation by GCN2. Interestingly, both GCN2 and mTOR regulate
translation at the level of initiation, suggesting that translation initiation is an important
part of the regulation of autophagy.
Lysosomes are dynamic organelles that differ between cell types in their
complement of hydrolytic enzymes. It was tested to see if the BHMT would generate an
identifiable fragment in starved cells of other types and species. Cell tested include
T98G cells, MCF7 cells, H1299 cells, NIH3T3 cells and C2C12 cells. T98G cells are
human glioblastoma cells that are negative for expression of PTEN. Loss of PTEN
results in sustained signaling through the PI3 Kinase/Akt pathway, a growth signaling
pathway that activates mTOR and is generally thought to suppress macroautophagy[57].
Despite the loss of PTEN, T98G cells were capable of a robust, macroautophagic
response to amino acid deprivation. MCF7 cells are human, breast carcinoma cells that
are reported to have depleted levels of the autophagy-specific protein, Beclin 1. It has
been shown that MCF7 cells have decreased levels of macroautophagy, which could be
increased by overexpression of exogenous Beclin 1[38]. The MCF7 cells tested with the
BHMT assay were capable responding to amino acid starvation, although the percent
increase of accumulated fragment in starved cells compared to control was less than in
T98Gs.
H1299 cells are human lung cancer cells that are devoid of the tumor suppressor
p53. The induction of p53 has been linked to increased autophagy through several
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mechanisms, including negative effects on mTOR and through the lysosomal protein,
damage-regulated autophagy modulator DRAM[106, 107]. The dramatic accumulation
of BHMT fragment in starved H1299 cells demonstrates that macroautophagy can
respond to amino acid starvation in a p53-independent manner. It may be the p53 is
required for an autophagic response to genotoxic stress, but is not necessary for a
response to amino acid starvation. NIH3T3 cells are immortalized mouse fibroblast and
C2C12 cells are immortalized mouse myoblasts. Both mouse cell lines generated a
fragment of the same size as fragment 1 in human cells, implicating a similar lysosomal
cathepsin. The C2C12 cells did not transfect to a very high efficiency and consequently
the level of fragment 1 was low, but fragmentation with starvation still occurred that was
sensitive to both 3MA and chloroquine. In conclusion, the lysosomal protease that
cleaves BHMT to generate fragment 1 is generally distributed between various cell types
and species, broadening the possible applications of the BHMT assay.
4.2. BHMT and higher order structure
The BHMT data suggest that quaternary structure is maintained within the
autophagosome. This conclusion is supported by the data that fragment 1 is only
generated from BHMT subunits that can form multimers. While it is possible that the
cathepsin that cleaves L2 requires an intact carboxy-terminus to bind and cleave, the
resistance of the GST-BHMTW352A mutant to generate fragment 1 argues against this
possibility.
Second, monomeric and multimeric BHMT molecules are both substrates for
macroautophagy. This conclusion is supported by the protection assay and by the
generation of fragment 2′ in the GST∆TBHMT and GST∆TBHMT∆C51 reporters.
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Quaternary structure of BHMT is not important for the proteolytic cleavage in the region
of GST to produce fragment 2′. Although this was not the expected result, it raises an
interesting question. Why is BHMT degraded through macroautophagy and not by
another mechanism? The BHMT truncation mutants and W352A point mutant all appear
to make stable proteins. More severe truncations, however, result in unstable protein that
is likely proteasomally degraded soon after translation. An attractive hypothesis is that
macroautophagy is a preferred mechanism to remove enzymes or organelles
(mitochondria) that contain metal ions, to sequester the oxidizing Zn2+, Cu2+ or Fe2+ ions
that could be harmful to the cytoplasmic environment. In support of this, a rare
autosomal recessive disease, mitochondrial myopathy and sideroblastic anemia (MSA), is
caused by an unknown gene mutation that maps to the chromosomal region of
hULK1[108]. As the name suggests, the disease is marked by excessive accumulation of
iron stores, which could be caused by a defect in macroautophagy. The crystal structure
of BHMT predicts that although ∆C51 and W352A BHMT mutants cannot oligomerize,
they likely assemble into normal (α/β)8 barrel subunits, with the Zn2+ intact, making
them both macroautophagy substrates.
Third, the data of GST∆TBHMT and GST∆TBHMT∆C51 on sucrose gradients
provide evidence of a 3MA-sensitive and 3MA-resistant macroautophagy. GST∆TBHMT
is a substrate of the first and GST∆TBHMT∆C51 is a substrate of both. This result is
surprising because the autophagy field defines macroautophagy almost exclusively in
terms of sensitivity to 3MA.
Does macroautophagy proceed in cells treated with 3MA? 3MA’s inhibition of
Vps34 is likely partial inhibition. Strong inhibition of PI3K activity with wortmannin is

204

sufficient to inhibit fragmentation of both forms of BHMT and macroautophagy, which
suggests that in cell treated with 3MA, some PI3P is still made. Is it enough to support
autophagy? The data of the HA-LC3B reporter show that in the presence of 3MA, LC3II is produced and lysosomally degraded. Is this LC3-II part of a cargo vesicle?
The data of GST∆TBHMT∆C51 fragment 2′ on the sucrose gradient argue that the
LC3-II produced in the presence of 3MA is actively sequestering and delivering
GST∆TBHMT∆C51 to the lysosome. What is the difference between the light (5/ 6)
fractions and the dense fraction (8) on the sucrose gradient? The dense fractions are
sensitive to 3MA and the lighter are resistant. From the sum of the date, the following
characterization of fractions 6 and 8 could be made (Table 5). The more buoyant fraction
6 contains autophagosomes, newly formed autolysosomes, and pure lysosomes. Fraction
8 contains denser autolysosomes/amphisomes.
In 3MA treated cells, LAMP1 in fraction 8 is decreased. The decrease of LAMP1
in fraction 8 in 3MA-treated cells suggests that PI3P is required for the fusion events
necessary to generate dense autolysosomes/amphisomes. The density shift of LAMP1
from fraction 8 to fraction 6 is consistent with sucrose gradient data from wortmannin
treated cells (data not shown). Does the LAMP1 in fraction 5/6 represent lysosomes or
more boyant autolysosomes? The co-fractionation of GST∆TBHMT∆C51 fragment 2′ and
LC3-II with LAMP1 in 5/6 suggests that autolysosomes form in fractions 5/6 when levels
of PI3P are limiting.
Why is GST∆TBHMT∆C51, but not BHMT degraded in 3MA-treated cells? What
is the relationship between PI3P and the different abilities of these two mutants to
oligomerize? It could be through a mechanism that involves proteins that are regulated
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by binding to PI3P. Downstream effectors of hVps34 signaling bind to PI3P through a
FYVE domain (first described in proteins Fab1, YOTB/ZK632.12, Vac1, and EEA1) or
in some instances through a Phox homology (PX) domain. Despite the importance of
PI3P in autophagy, there are very few Atg proteins that actually bind PI3P. The few Atg
proteins that have FYVE or PX domains are involved in cargo recognition of the Cvt
pathway. Could this type of cargo recognition be involved in mammalian autophagy and
in the selection of BHMT? A model of this type of recognition proposes the existence of
a FYVE-domain adapter protein that would recognize oligomeric but not monomeric
BHMT to bring it to the autophagosome (Fig. 51). Or perhaps BHMT normally forms
complexes FYVE-like proteins, as BHMT reportedly associates with both autolysosomes
and mitochondria, even though it does not itself have a FYVE domain, PX domain, or
other membrane tethering modifications. Thus, when PI3P is available and autophagy is
induced, its association with autophagosomes is through a PI3P-dependent mechanism.
If a FYVE adapter-like protein recognizes only BHMT, how does
GST∆TBHMT∆C51 become sequestered in autophagosomes? GST∆TBHMT∆C51 is a
BHMT monomer in a non-functional conformation. Is there a mechanism that cells use
to target misfolded, non-essential, or aggregated proteins for macroautophagy? Reports
show that p62/SQSTM1 can function as an adapter-like protein that physically links
aggregates of mutant huntingtin protein with LC3 and autophagosomes for
degradation[109]. The association between p62 and the mutant huntingtin protein
requires p62’s ubiquitin-association (UBA) domain. Is this a cellular mechanism that
cells use to recognize and remove misfolded proteins by macroautophagy? It is proposed
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Figure 51. Proposed model for 3MA-sensitive and 3MA-insensitive
macroautophagy. In the proposed model, production of PI3P enriches autophagosomes
with its normal cargo through FYVE or PX-containing adapter molecules. When PI3P
levels are limiting, this cargo is no longer favored. Abnormal protein structure is
recognized by adapter proteins that directly interact with Atg8-orthologs at the
autophagosome membrane. These complexes are modeled after p62s proposed role in
clearing mutant huntingtin protein.
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that this type of mechanism explains the degradation of the GST∆TBHMT∆C51 monomer,
and that when PI3P is limiting, degradation of these aggregates continues.
The p62-like adapter mechanism involves direct targeting of aggregates to LC3.
Could other Atg8 orthologs have similar roles? And does this explain one of the
unanswered questions in autophagy of why there are so many mammalian Atg8
orthologs? When LC3-II was first described as being specific for autophagosomes, the
data did not suggest that LC3-II was on all autophagosomes. This suggests that the other
Atg8 isoforms may have functions similar to LC3, and indeed, all have been found
onautophagosomes. The data that links p62 and LC3 is significant. The plethora of the
other Atg8 orthologs suggests that there may be multiple adapters and autophagosome
receptors for the clearance of cellular ‘garbage’ like GST∆TBHMT∆C51.
It is proposed that there are two types of macroautophagy, a signaling autophagy
and a structural autophagy (Fig. 51). Both require some PI3P. The signaling autophagy
requires sufficient levels of PI3P for recognition of normal cargo such as BHMT. The
structural autophagy requires less PI3P and the coordinate activity of the Atg proteins
that participate in autophagosome formation. Under starvation conditions with readily
available PI3P, both BHMT and GST∆TBHMT∆C51 are degraded. When PI3P is limiting,
cargo recognition is limited, but the structural, basal autophagy continues to degrade
abnormal cargo, such as GST∆TBHMT∆C51.
In mammalian cells, Vps34 plays a role in trafficking decisions that control the
destination of internal vesicles. The proposed model suggests that substrates of the
signal-dependent autophagy are more regulated than random. It makes energetic sense to
be selective in the process of degradation of proteins that require new synthesis when the
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crisis has past. There are other stressors that induce autophagy such as viral or pathogen
invasion, where non-specific wholesale degradation of cellular protein might not be
desired. However, there are no conditions where accumulated, misfolded, or aggregated
protein is desirable. It is this second, structural autophagy that is valuable for the health
of the cell and organism.
4.3. Regulation of autophagy and p70S6 Kinase
The protein kinase mTOR plays a central role in the ability of cells to sense
growth signals, amino acid levels, and energy in order to make decisions that effect the
translation of new proteins, cell growth and proliferation. The signals through mTOR to
its downstream effectors p70S6K and 4E-BP1 regulate events involved in the initiation of
translation and regulate events in macroautophagy (Fig. 5). If nutrients are readily
available from the extracellular milleau, mTOR signals for the cell to grow. When
extracellular nutrients are scarce, down-regulation of mTOR signaling increases
autophagy to degrade internal proteins for the energy and raw materials necessary for
survival.
What is the relationship between p70S6 kinase and autophagy? There is strong
correlative evidence of an inverse relationship between phosphorylation of the ribosomal
subunit S6 and autophagy in a mammalian setting. The negative correlation between
phosphorylated S6 and autophagy has led to a proposed model that places phosphorylated
S6 at the endoplasmic reticulum. In the proposed model, the inhibition of mTOR causes
de-phosphorylation of S6 and its release from the rough ER. The smooth ER created by
the loss of ribosomes is proposed to be one source of the autophagosome membrane[54].
This mechanism directly links mTOR, p70S6 kinase and S6 with autophagy.
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In Drosophila, it has been proposed that p70S6 kinase must be active for efficient
autophagy[58]. How is p70S6 kinase active if TOR is inactive? It has been suggested
that residual activity of p70S6 kinase remains when TOR is first inactivated. This
activity is both sufficient and required for autophagy. Without TOR activity, it is also
self-limiting, preventing uninhibited autophagy from progressing to the point of cell
death.
In the current study, using the BHMT assay as a measure of macroautophagy,
there is no correlation between the phosphorylation of S6 and autophagy. Both the
constitutively active allele of S6K and RHEB increase the signal to S6 in the absence of
amino acids. However RHEB inhibits autophagy and active S6K does not inhibit
autophagy, suggesting that the inhibitory signal to autophagy is through mTOR, but does
not go through the p70S6K arm of the pathway.
The constitutively active S6K does cause a slight increase in levels of BHMT
fragment 1. If the model from Scott et al. in Drosophila is correct, then S6K activity may
be pushing a maximum signal to autophagy. An alternate explanation is that the overexpressed allele may have a dominant interfering effect by sequestering mTOR. Others
have shown that this can have a negative effect on mTOR’s other substrate, 4E-BP1.
However, the phosphorylation data with 4E-BP1 suggest that in this instance that
activated S6K did not inhibit mTOR signaling to 4E-BP1.
Interestingly, the RHEB-mediated sustained positive signal through the mTOR
pathway caused hyperphosphorylation of 4E-BP1 and decreased total 4E-BP1 protein.
Decreased levels of a negative regulator of eIF-4E cause unregulated translation, which
may lead to tumorigenesis. The RHEB-induced decrease of 4E-BP1 could be a
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mechanism that explains how a strong positive signal through the mTOR pathway might
lead to cancer. Does the mTOR signal to autophagy go through 4E-BP1? The hypothesis
is attractive because it links the signal to autophagy with a signal for the initiation of
translation. It is also consistent with the role of the eIF2α kinases, which also inhibit
translation initiation and promote autophagy[102]. Future studies will explore the
potential relationship between eIF4E and autophagy. In conclusion, the above data
confirm that the signal to autophagy is through mTOR, but that it does not go through
p70S6 kinase.
The re-addition of amino acids to cells increases Vps34 activity and activates
mTOR signaling, thereby inhibiting autophagy. However autophagy also requires Vps34
activity. Autophagy’s need for Vps34 activity is supported by the data that fragmentation
of both BHMT mutants is completely inhibited by wortmannin. How is it that both
mTOR and autophagy require Vps34 activity and both are inhibited by wortmannin, but
active mTOR inhibits autophagy? It could be explained in terms of levels of PI3P.
Vps34 activity increases levels of PI3P, a well known way to modulate signaling
pathways through the recruitment of proteins with FYVE and PX domains. It is likely
that the Vps34 activation of mTOR may involve these types of PI3P-dependent
molecules with a low affinity for PI3P. Thus high levels of PI3P would activate mTOR.
Amino acid starvation would drop PI3P to levels that are high enough to support
autophagy, but too low to activate mTOR. A decrease in mTOR signaling would then
increase autophagy.
The 3MA treatment of cells expressing the two types of BHMT cargo suggests
that modulating levels of PI3P during starvation that might effect the selection of cargo.
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Figure 52. Proposed model for Vps34, PI3P, and mTOR regulation of autophagy.
In nutrient rich conditions, PI3P levels are high, mTOR is active and autophagy is at
basal levels. With amino acid starvation, PI3P levels decrease, mTOR signaling is
decreased and the inhibition on autophagy is relieved. In ischemia, Vps34 activity
decreases and PI3P levels fall. In these conditions, autophagy of normal cargo ceases,
but autophagy continues that targets misfolded proteins that are likely to accumulate in
ischemic conditions.
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A model has been proposed in which adapter proteins facilitate the selection and
degradation of cytoplasmic proteins. Regulated cargo requires the recognition of PI3P by
FYVE or PX proteins. However, structurally abnormal protein continues to be degraded
when PI3P levels are low. However, if Vps34 activity is completely inhibited, as
happens with wortmannin treatment, autophagy cannot proceed.
This suggests that there are levels of PI3P in the cell that effect the progression of
autophagy (Fig. 52). At high levels, mTOR is active and autophagy is inhibited. At low
levels, mTOR is inactive and autophagy is active. If PI3P levels continue to decrease,
autophagy also becomes inhibited. Under what physiological condition might this occur?
The data show that ischemia is one situation where both mTOR and autophagy are
inhibited.mTOR signaling is down-regulated in response to decreased levels of amino
acids and ATP. The ischemia experiment was designed to determine how these cellular
stressors affect autophagy. It has been suggested in the literature that cells subjected to
conditions of ischemia induce autophagy as a means of survival[110]. This mechanism is
proposed to explain how apoptosis-defective (i.e. Bax-/-/Bak-/-) solid tumors survive in a
nutrient-poor environment, until an adequate blood supply can be established to supply
nutrients[110]. Is autophagy induced in ischemia? In an in-vitro model of ischemia,
Degenhardt et al, concluded ischemia induced autophagy, based on GFP-LC3
localization[110]. The data here, using a similar model of ischemia, show that autophagy
as measured by BHMT was inhibited in ischemic conditions, and was slightly inhibited
by loss amino acids and glucose. It is likely that the limited response was due to
decreased levels of ATP. Autophagy is very energy dependent. Multiple steps of the
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autophagic process require ATP and even small changes of ATP levels have been shown
to slow autophagic proteolysis[84].
In ischemic conditions, defined as loss of nutrients, serum, glucose and low
oxygen, both LC3-II processing and BHMT fragmentation were strongly inhibited.
Down-regulation of mTOR does not necessarily mean that the cell has increased
autophagy. It is likely that inactive mTOR relieves an inhibitor signal that allows
autophagy to proceed as long as sufficient ATP is available for the events required for
autophagy. However, even in full ischemia, a small increase of BHMT fragment is
observed under amino acid starvation conditions, suggesting that some autophagy was
induced. But the severe decrease in LC3-II suggests that as ATP levels drop, the ATPdependent step of LC3 processing is likely negatively affected.
Together, the data suggest that Vps34 activity and levels of PI3P determine if
mTOR is active or inactive (Fig. 52). If mTOR signaling is down-regulated and
autophagy is active, modulation of PI3P levels can determine the type of cargo that will
be degraded. A severe decrease in PI3P will inhibit autophagy. Ischemia is a situation
where mTOR is off and there is only a small autophagy response. Could this be an
example of PI3P levels dropping below a threshold necessary to support autophagy? It is
likely that the glucose starvation and ischemia conditions also decrease PI3P. This is
consistent with the published report that glucose starvation or AICAR, an activator of
AMPK decreases Vps34 activity[37]. In addition, conditions of glucose deprivation and
hypoxia are two potential stressors that cells face in a physiological situation. Decreased
ATP and oxygen can ultimately lead to the production of misfolded proteins. Under
these conditions, clearance of unfolded proteins would be a priority, and the proposed
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mechanism might explain how cells are able to mount a response to selectively remove
this population of aggregate-prone protein. This model predicts that BHMT∆C51 under the
same stress conditions would continue to generate fragment 2´. Future experiments are
planned to test ∆C51 in this cell culture model of ischemia.
Diseases of aging such as Alzheimer’s, Parkinson’s, Huntington’s, and Inclusion
Body Myositis are all major neurological and muscular diseases associated with the
accumulation of aggregated proteins. Therapeutic strategies that increase autophagy can
help alleviate the cellular stress of abnormal protein accumulation. Rapamycin, a
negative inhibitor of mTOR, has already shown promise as a drug of choice by increasing
the degradation of mutant huntingtin protein. The studies here predict that in times of
nutrient stress, the cell has adapted macroautophagy such that misfolded proteins are
preferentially degraded for the benefit of the cell.
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